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Summary 
 
The three research projects presented in this thesis apply organic synthesis as the main tool to 
answer interdisciplinary scientific questions. In the first project, organic synthesis is the key to 
tailor molecules for direct interaction with living organisms. The second project comprises a new 
method for the preparation of biologically relevant lead structures. The last project examines the 
synthesis of bifunctional pyrrolizidine diamines and their application in the capture of carbon 
dioxide.  
Chapter 1 starts with a general introduction to the field of chemical surface engineering on 
living cells. The different functionalization approaches are briefly introduced and selected illus-
trative examples are presented.  
Chapter 2 describes the surface functionalization of the green alga Chlamydomonas reinhard-
tii with the antibiotic vancomycin. We used a peptide-anchor adhering to the surface glycopep-
tides of the algae. By synthetic means, we linked this anchor to vancomycin to give a conjugate 
with good antimicrobial activity. The conjugate adhered to the cell wall of C. reinhardtii, as veri-
fied by confocal fluorescent microscopy. Bacterial assays showed that the modified algae inhib-
ited the growth of bacteria and led to complete inhibition of bacterial growth, after optimization. 
Delivery of the vancomycin-conjugate from the surface of the algae to the cell wall of the bacte-
ria was mainly driven by diffusion. 
 
 
Illustration of vancomycin-modified algae with bacteria. 
  
  
vi 
In Chapter 3 we report on a method for the preparation of 7a-substituted pyrrolizidine car-
boxamides. These compounds can be prepared by reaction of isonitriles with pyrrolines. Using a 
variety of isonitriles with different electronic and steric properties, we gained access to a diverse 
range of pyrrolizidine derivatives. An extension of this method by further functionalization of 
the pyrrolizidines as well as mechanistic studies are presented.  
 
 
In Chapter 4 our investigations of pyrrolizidines as scavengers for CO2 are described. We 
quantified the efficiency of CO2 uptake and elucidated the nature of the CO2 adducts as well as 
the reversibility of the overall process. 
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Zusammenfassung 
 
Die drei Forschungsprojekte dieser Dissertation führen die herausragende Bedeutung orga-
nisch synthetischer Methoden für interdisziplinäre Fragestellungen vor Augen. Im ersten Projekt 
wird gezeigt, wie synthetische Methoden zur Herstellung maßgeschneiderter organischer Mole-
küle angewandt werden können, die direkt mit lebenden Organismen interagieren können. Das 
zweite Projekt ist eine neue Methode zur Synthese biologisch relevanter Moleküle. Im letzten 
Projekt haben wir bifunktionelle Pyrrolizidin Diamine in ihren Eigenschaften untersucht CO2 zu 
binden.  
Kapitel 1 gibt eine generelle Einführung in das Gebiet der chemischen Oberflächenmodifika-
tion an lebenden Zellen. Die bekannten Verfahren werden kurz vorgestellt und anhand ausge-
wählter Beispiele veranschaulicht. 
Kapitel 2 beschreibt unsere Resultate zur Oberflächenfunktionalisierung der Grünalge 
Chlamydomonas reinhardtii mit dem Antibiotikum Vancomycin. Hierzu haben wir einen Peptid-
Anker benutzt, der Affinität zu den Oberflächenglykopeptiden der Zellwand aufweist. Der Pep-
tid-Anker wurde über Festphasenpeptidsynthese hergestellt und anschließend mit Vancomycin 
verknüpft. Das resultierende Vancomycin-Konjugat zeigte weiterhin zufriedenstellende antimik-
robielle Wirkung. Außerdem zeichnete es sich durch sehr gute Bindungseigenschaften an die 
Oberfläche der Algen aus, was mit Hilfe konfokaler Fluoreszenzmikroskopie nachgewiesen 
werden konnte. Wachstumsexperimente mit Bakterien und Algen zeigten, dass die zuvor modifi-
zierten Algen das Bakterienwachstum hemmen und nach weiterer Optimierung sogar ganz un-
terbinden. Das Vancomycin-Konjugat wurde primär durch Diffusion von der Oberfläche der 
Algen auf die Zellwand der Bakterien übertragen.  
 
 
Illustration von Vancomycin-modifizierten Algen in Gegenwart von Bakterien.  
  
  
viii 
In Kapitel 3 beschreiben wir eine Methode zur Synthese 7a-substituierter Pyrrolizidin-
Carboxamide. Diese Substanzen sind durch direkte Reaktion von Isonitrilen mit Pyrrolinen zu-
gänglich. Isonitrile mit verschiedenen sterischen und elektronischen Eigenschaften wurden er-
folgreich als Startmaterialien eingesetzt und ermöglichten somit den effizienten Zugang zu einer 
Vielzahl von Pyrrolizidin-Derivaten. Darüber hinaus stellt dieses Kapitel mechanistische Studien 
zu dieser Reaktion und weitere Modifizierungen der Produkte vor.  
 
In Kapitel 4 sind unsere Untersuchungen von Pyrrolizidinen als CO2-bindende Moleküle be-
schrieben. Unsere Ergebnisse liefern Erkenntnisse zur Natur der CO2-Addukte sowie der Effizi-
enz und Reversibilität des Prozesses. 
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1 Introduction to Cell Surface Engineering 
1.1 Cell surface engineering as a tool for the introduction of phenotypes 
Cell therapy is the treatment of diseases by injection, transplantation or infusion of live cells. 
The cells can originate from the same patient (autologous) or from a different donor (allogen-
eic)[1] and cell therapies have emerged as standardized treatments in clinical use. Stem cell ther-
apy is a fundamental technique for the treatment of leukemia with bone marrow transplants 
(hematopoietic stem cell transplants), but also non-hematopoietic stem cells are undergoing clin-
ical evaluation. Among those are mesenchymal stem cells (MSCs) for the treatment of a number 
of diseases such as the Hurler syndrome[2], skeletal[3] and neurological disorders[4] or they can be 
used for the regeneration of bones[5], cartilage[6] or myocardia[7] tissue. Further cell treatments, 
such as neural stem cell therapy are still under investigation for the treatment of neurological 
disorders or human embryonic stem cells for the treatment of diabetes or Parkinson’s disease, 
although the latter is highly controversial from an ethical standpoint of view.  
Living cells can be engineered to improve their properties and function, enhancing cell surviv-
al, proliferation or differentiated function.[1] A traditional approach for this engineering is the 
preconditioning of cells ex vivo to later show enhanced effector function, self-renewal or longev-
ity in vivo.[8] Further, the cell function can be modulated by appropriate drug treatment in addi-
tion to cell therapy, or the cells can be genetically engineered using synthetic biology to obtain 
genetically reprogrammed cells.[9]  
More recently, another approach for the modification of living cells has emerged using the 
tools of molecular biology and chemistry to alter cell surfaces.1 This approach directly remodels 
the cell itself for a very defined introduction of new phenotypes using techniques from chemis-
try, materials science or molecular biology. The cell surface plays the key role in all interactions 
of the cell with its environment and by manipulating it, properties such as adhesion, migration, 
tissue homing and cell-cell interactions can be altered.[1] Chemical surface engineering provides 
the opportunity to introduce functionality to the cell wall using synthetic materials, which are not 
accessible by genetic engineering. This is a vast advantage because it does not restrict the modi-
fication to originate from nature. In addition, it can be well defined where and at which time the 
cell is modified.  
A major challenge of cell surface engineering is the loss of the cells’ viability during the mod-
ification procedure or afterwards due to the modification. The experimental modification proto-
col needs to be carefully adapted to the cells needs because physical stress, change of pH, or 
                                                
1 For a review on the surface engineering of bacteria see: [10] 
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composition of the incubation solution can have severe effects on the well-being of the cell. The 
surface molecules for functionalization should be selected such that the cell can still exert its 
biological function and, for instance, essential surface proteins should remain intact. Another 
challenge is the internalization of the performed modification by cellular uptake mechanisms. 
And finally, the modified surface needs to be resistant to potential mechanical forces such as 
sheering, and the biochemical environment. There are several different techniques and approach-
es that have been used to modify the surface of living cells while addressing these challenges. 
The following sections will shortly introduce different cell surface engineering techniques from a 
chemical perspective.  
 
 
1.2 Covalent modifications on naturally occurring functional groups 
The most direct functionalization of a cell surface is the reaction of a functional material with 
the reactive groups of the cell surface (Figure 1). These groups usually are amine or thiol groups 
present on a cell membrane protein. The functional material contains reactive groups such as a 
succinimidyl ester or a maleimide group (Scheme 1). 
 
 
Figure 1: Direct functionalization by covalent attachment of naturally occurring functional groups.2 
 
As an example Lee et al. modified pancreatic islets on the surface with a polyethylene glycol 
(PEG) chain using a succinimidyl ester functionalized PEG.[11] As a consequence, the cells were 
coated by a layer of PEG molecules. When injected into rats, the cells were tolerated by the im-
                                                
2 Illustrations in this chapter were inspired by: [1] 
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mune system of the animals much longer as compared to the unmodified cells due to the coating. 
This example shows the potential application as immunogenic surface antigens.  
Using the same attachment technique Francis and co-workers attached DNA strands to vari-
ous cells including red blood cells and T-cells.[12] A bifunctional PEG chain was attached to the 
amine groups of the cell surface by reaction with a succinimidyl ester. On the other end, DNA 
was attached to a maleimide group via a thiol-decorated linker.  
The reactivity of maleimides can also be used for the attachment to cells by reaction with free 
thiols of cysteines present in proteins on the surface. In their work, Irvine et al. used maleimide 
groups to link polymer nanoparticles to the surface of cells.[13]  
 
 
Scheme 1: Amines and thiols on the cell surface can be reacted with succinimidyl esters or maleimides. 
  
Another technique for the attachment of a functional material is by reaction of a succinimidyl 
ester-functionalized biotin with the amine groups on the cell surface. This offers an advantage 
due to the wide range of biotinylated molecules that can be bound to a biotinylated cell surface 
via a streptavidin bridge (Figure 2). This technique has been used for the functionalization of 
MSC cells with Sialyl LewisX, a tetrasaccharide carbohydrate which drastically improved the 
rolling, adhesion and finally overall “homing“ of the cells in a foreign environment.[14]  
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Figure 2: Direct functionalization of cell surfaces by biotin allows for the attachment of an array of bioti-
nylated materials via a streptavidin bridge. 
 
 
1.3 Modifications by hydrophobic insertion into the cell membrane 
Membrane proteins function as receptors and play key roles in cellular signaling or nutrient 
uptake of the cell. Smaller membrane proteins control processes such as endocytosis or adhesion. 
They are either made up of protein alpha helices and span the plasma membrane, or are com-
prised of covalently linked lipids, which insert and interact with the lipid bilayer.[15] The latter 
binding principle has been used to engineer cells with artificial receptors. Molecules or nanopar-
ticles can be decorated with hydrophobic chains and are able to spontaneously insert into the 
lipid bilayer in the presence of cells (Figure 3). Functional anchors such as glycoinositol phos-
pholipids (GPIs) can be combined with virtually any protein by heterologous expression to give 
a recombinant protein. This protein is then isolated and used for surface engineering of target 
cells.[16,17] 
 
Figure 3: Recombinant proteins produced by heterologous expression can insert into the lipid bilayer of 
target cells.  
HN
Functional material
Biotin
Streptavidin
Membrane protein
Cell membrane
Cell membrane
Recombinant protein
 Introduction to Cell Surface Engineering 
5  
A variation of this approach is the use of palmitated protein A or protein B, which can be pre-
pared by reaction of the proteins with the N-hydroxy-succinimid ester of palmitic acid (Figure 
4).[18] These proteins bind immunoglobins through their Fc region and allow for the fixation of 
antibodies on cell surfaces thereby broadening the functionalization possibilities with only one 
anchoring system. 
 
 
Figure 4: Inserted palmitated proteins can be functionalized with a variety of antibodies binding to their 
epitope. 
 
In addition to the previously mentioned protein functionalization, hydrophobic insertion has 
also been done with chemically synthesized analogues. This allows for the functionalization of 
the surface with small molecules and even the delivery of otherwise cell-impermeable mole-
cules.[1,15] Bertozzi and co-workers synthesized functionalized glycopolymers such as 1.1 that 
inserted into the lipid bilayer with a hydrophobic chain to mimic cell surface mucins (Figure 5).3 
Once in the cell membrane, the artificial compounds showed analogous behavior to natural mu-
cins.[19]  
 
Figure 5: Chemically synthesized mucin-mimic polymer. 
  
                                                
3 Mucins are highly glycosylated proteins. 
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1.4 Surface modification by adsorption 
The surface of mammalian cells is charged due to biomolecules such as phospholipids carry-
ing phosphate groups or proteins and glycoproteins with carboxylate groups that contribute to an 
overall net negative charge. This charge is not able to form stable complexes to monovalent 
partners, but nanomaterials with multiple cationic sides can bind relatively strongly to such sur-
faces via multivalent electrostatic interactions (Figure 6).[1] Using this principle, Chaikof et al. 
engineered islets with various biocompatible reactive groups such as a biotin tag, an azide or a 
hydrazine (Figure 7).[20] A key feature of this study is a positively charged polylysine peptide 1.2 
adhering to cell surfaces. Special feature of the peptide is that 40% of the lysine groups are  
PEGylated. The introduction of the PEG groups was necessary to decrease the cytotoxicity of the 
compound.4 
 
 
Figure 6: Surface modification by adsorption triggered by positively charges functional materials. 
 
 
 
                                                
4 Polycations can induce the formation of pores in the plasma membrane. These pores allow for the transport of 
small molecules through the plasma membrane into the cell that can lead to cell death.[21-23] 
Cell membrane
Functional material
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Figure 7: Positively charged polylysine 1.2 attaches to negatively charged cell membranes via electro-
static interactions. Reactive groups such as biotin, azide or hydrazine are attached to the peptide and can 
be used for further functionalization.  
 
 
1.5 Modifications by attachment to naturally occurring receptors 
Another technique for the functionalization of living cells is the attachment of modified lig-
ands to naturally occurring receptors on the cell surface (Figure 8). A challenge to use this ap-
proach is the often-transient nature of these ligand-receptor interactions, as the ligand can disso-
ciate from its receptor leading to a less stable attachment. 
However, there are a number of examples using multivalent ligand binding and thereby exem-
plifying the utility of this approach. Rubner and co-workers used CD44 receptors and its natural 
ligand (hyaluronic acid) for the attachment of magnetic nanoparticles.[24] Notably, the cells could 
be functionalized only on one side of the cell, due to prior attachment of the cells to a polyelec-
trolyte multilayer patch. In another example, Bertozzi et al. used a hexavalent lectin termed Helix 
pomatia agglutinin (HPA) for the binding of carbon nanotubes to cell surfaces.[25] The carbon 
nanotubes were functionalized with α-GalNAc residues that are specific receptors for HPA. In 
addition, HPA is also capable of binding to cells and cross-linking glycoproteins, so that the car-
bon-nanotube-HPA complex could be fixed to the cell. 
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Figure 8: Naturally present membrane receptors can bind to modified ligands for surface engineering.  
 
1.6 Metabolic introduction of functional groups for further modification 
The metabolic introduction of bioorthogonal groups5 to the cell surface represents a very ele-
gant way for the functionalization of living cells. This approach uses biosynthetic precursors that 
carry bioorthogonal groups such as alkynes, azides, ketones or aldehydes and are incorporated 
into the living organism using its own biochemical machinery. After incorporation, the products 
carry the artificial tag that was previously installed on the precursor (Figure 9). These biosyn-
thetic precursors can be amino acids for the functionalization of proteins,[27-30] sugars for the 
functionalization of cell surface glycans[31,32] or farnesyl and farnesol pyrophosphates to be used 
for lipid modification.[33] A precondition for this approach is that the enzymes involved in the 
biosynthetic processes tolerate the modifications on the precursors. After the modified precursor 
has been implemented into the cell it can be reacted in a mild way using bioorthogonal chemical 
reactions.[26] For example, azides can be reacted with phosphines in a Staudinger ligation[32,34] or 
by “Click”-reaction with alkynes.[35] Aldehydes or ketones can be reacted with hydrazines to 
hydrazones.[31] This approach offers the possibility to introduce functional molecules to the cell 
surface such as fluorescent probes[32] or viral receptors.[36] 
                                                
5 Bioorthogonal groups are non-native, non-perturbing chemical handles that are unreactive with groups present in 
biological systems. Bioorthogonal groups can later be modified with exogenously delivered probes.[26] 
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Figure 9: Metabolic incorporation of modified biosynthetic precursors that are later used to engineer cell 
surfaces.  
 
An example closer related to the research in this thesis is the metabolic functionalization of a 
living diatom with thiol moieties (Figure 10).[37] Diatoms are unicellular algae with a cell wall 
comprised of silica.[38] Although the exact mechanisms of biomineralization are unknown Finn 
and co-workers were able to use thiol-functionalized silanes for the introduction of the functional 
group. The artificial building blocks are first hydrolyzed in the medium and then implemented in 
the silica framework of the organism. The utilization of the altered building block led to an over-
all similar morphology of the algae. However, differences in pore size were observed leading to 
a decreased density of the organism. Further functionalization of the modified diatom is not re-
ported. 
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Figure 10: Metabolic introduction of thiol groups to diatoms.[37] 
 
1.7 Conclusion 
This introduction into cell surface engineering spotlighted the different classes of the chemical 
modification of living cell surfaces. We showed that there are a number of approaches to engi-
neer these surfaces including covalent and non-covalent binding, the use of natural receptors or 
the introduction of non-natural binding sites on the surface. Most of the approaches are still in 
the early stage of development and to become more relevant to real clinical applications, they 
need to be implemented for a concrete therapeutic benefit. There are situations where chemical 
modification approaches are clearly beneficial over other techniques. For instance, chemical en-
gineering is much less severe and non-permanent than the sometimes-unpredictable consequenc-
es of genetic engineering. There are also cases in which genetic engineering is very difficult or 
even impossible and in these situations, chemical surface engineering can serve as a useful tool. 
Overall, chemical surface engineering has emerged as a vibrant field of research in the interface 
of chemistry, biology and nanotechnology with the potential to solve fundamental problems in 
an interdisciplinary way.  
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2 Surface Engineering of Algae 
2.1 The green alga Chlamydomonas reinhardtii 
The unicellular green alga Chlamydomonas is one of the most frequently used model organ-
isms in laboratory research, offering a simple platform to study fundamental processes in life 
with an easy life cycle and cellular features such as phototaxis and photosynthesis.[39] Figure 11 
shows a light microscopy image of a C. reinhardtii culture. The genus consists of 459 species 
with Chlamydomonas reinhardtii being its most prominent representative.[40] The ellipsoid alga 
consists of a single basal chloroplast surrounding a nucleus that is located in center and contains 
a prominent nucleolus (Figure 12). The cell is encased by a cell wall in close proximity to the 
plasma membrane. Notably, the cell features two anterior flagella with which the cell is able to 
move and turn in aqueous environment triggered by phototaxis response. 
 
 
 
Figure 11: Light microscopy image of a C. reinhardtii culture. 
 
 
CHAPTER 2 
 
12 
 
Figure 12: Cellular architecture of C. reinhardtii. The cell comprises the central nucleus (N) with the 
nucleolus (Nu), two isoform flagella (F), the cup-shaped chloroplast (C) including an eyespot (E), the 
starch-containing pyrenoid (P) and the mitochondria (M). It also contains the Golgi vesicle (G), starch 
grains (S), and vacuoles (V).[40,41] 
 
2.1.1 Cell wall architecture 
The cell wall of C. reinhardtii has been identified to consist of a dense arrangement of hy-
droxyproline-rich glycopeptides with arabinose, mannose, galactose and glucose showing the 
highest abundance of the sugars.[40] These glycoproteins show similarities to those of higher 
plant species but are also clearly distinctive in their sugar composition and molecular organiza-
tion.[40,42-45] The cell wall is divided into seven sub-compartments showing different morphology 
(Figure 13).[46,47] The innermost layer (W1) consists of an irregular network of fibers with differ-
ing thickness that radiate outwards the cell. The thickness of this layer has been identified to 
vary from 30 to 200 nm. The next layer (W2) shows a very similar composition as W6, both 
consisting of a dense network of fibers. For the W2 layer the fibers lie mostly parallel to the cell 
surface, whereas a more crystalline arrangement of thick fibers is observed for W6, flanked by 
thin crossfibrils and an open-weave lattice. The layer in between (W4) is of granular consistency. 
Layers W2, W4 and W6 are often termed as the ‘central triplet’ and show high consistency inde-
pendent from culture conditions or fixation techniques. The electron-transparent layers W3 and 
W5 are assumed to be spaces instead of true wall components.[40,47] The outer layer W7 is com-
posed of granular fibers resembling layer W1. 
CHAPTER 1 : The Genus Chlamydomonas2
suggested it may have been C. pulvisculus, but since the published descrip-
tion and illustration could apply to several of the species recognized today, 
Ettl considered the type genus to be C. reinhardtii, which was not described 
until 1888 but by the 1960s had become the most widely used species in 
laboratory work. Pröschold et al. (2001; Pröschold and Silva, 2007) have pro-
posed that the genus be redefi ned based on the laboratory wild-type strain 
of C. reinhardtii isolated in 1945 in Massachusetts. The essential features 
of the genus are two anterior fl agella of equal length, whose points of emer-
gence from the cell body are not widely separated; a cell wall; and a single 
chloroplast or chromatophore containing one or more pyrenoids ( Figure 1.1 ). 
 Dill (1895) listed 15 species of Chlamydomonas, of which six were new 
descriptions. By 1927 the list had grown to 146 species found in central 
Europe. Pascher (1927) delineated six subgenera based on chloroplast shape 
and number and position of the pyrenoid(s), and Gerloff (1940) provided 
a new key to these and described additional species, bringing the total 
to 321. Ettl’s comprehensive monograph Die Gattung Chlamydomonas 
FIGURE 1.1  Cell structure of  Chlamydomonas reinhardtii , showing the central nucleus (N) with the 
nucleolus (Nu), the two isoform fl agella (F), the cup-shaped chloroplast (C) with the eyespot (E) and 
the starch-containing pyrenoid (P) and the mitochondria (M). In addition, one may distinguish the Golgi 
vesicle (G), starch grains (S), and vacuoles (V). From Nickelsen and Kück (2000). 
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Figure 13: Cell wall of detergent-treated C. reinhardtii. Courtesy of U. W. Goodenough and J. E. Heu-
ser.[40] 
 
2.1.2 Chloroplast 
Chloroplasts are organelles present in plants and algal cells and mainly provide the cell with 
energy through the process of photosynthesis. The photosynthetic dye is chlorophyll that also 
gives the cell the characteristic green color.6 In C. reinhardtii, the chloroplast takes a cup-shape 
configuration, which appears like a U-shaped structure surrounding the nucleus (Figure 14, a). 
The pyrenoid is embedded in the chloroplast and is acting as the central unit for CO2-fixation, 
providing sufficient supply for photosynthesis.[48,49] Besides a strong UV/VIS absorption chloro-
phyll also shows strong fluorescence in the red region. This is a useful tool in fluorescence mi-
croscopy for the identification and location of the algae (Figure 14, b). 
 
  
                                                
6 The green color results from strong UV/VIS absorption in the UV and blue region and in the yellow and red region 
of the visible light spectrum.  
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FIGURE 2.4 Cell wall of detergent-treated, wild-type  C. reinhardtii gamete after tangential fracture of 
quick-freeze, deep-etch specimen. Layers are as defi ned in Figure 2.3. Bar ! 0.5 µm. Courtesy of U.W. 
Goodenough and J.E. Heuser.
FIGURE 2.3 Diagram of the cell wall of  C. reinhardtii . Adapted from an original color fi gure courtesy 
of Sabine Waffenschmidt.
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a 
 
b 
 
Figure 14: Chloroplast of C. reinhardtii. a) Arrangement of the chloroplast inside the cell. b) Fluorescent 
single confocal image of the chloroplast. Scale bar equals 10 µm. 
 
2.1.3 Phototaxis 
Phototaxis is the movement of an organism towards or away from a stimulus of light. Photo-
taxis can be positive, when the organism is moving in the direction of the light source or nega-
tive, when it is moving in the opposite direction. For organisms conducting photosynthesis, this 
is a highly advantageous stimulus because the organism can arrange itself most efficiently to 
receive energy.[50] The green alga C. reinhardtii moves using the two flagella. The phototactic 
behavior of C. reinhardtii is very complex and is influenced by a variety of factors. First, it 
strongly depends on the strength of the light source whether the algae react with positive or 
negative phototaxis. With low to moderate light intensities (<103 ergs/cm2) the algae accumulate 
in a light beam, with high light intensities they avoid light.[51] Further, the cells behave different-
ly depending on environmental influences such as culture medium, temperature and stage of life 
cycle.[52,53] The algae strain used for the experiments, as well as the age of the culture, have sig-
nificant influence on the phototactic response. Cells of freshly inoculated algae cultures show 
negative phototaxis, whereas cells from older cultures are positively phototactic.[54] Further, pho-
totactic behavior is maximal in the exponential growth phase and decreases in the stationary 
phase.[55] Overall, it can be concluded that a variety of factors need to be considered when strate-
gically utilizing the phototaxis of the algae. 
  
N
P
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2.1.4 Surface functionalization of C. reinhardtii 
The algae C. reinhardtii displays an interesting target for synthetic biology. Due to its easy 
life cycle, simple growth conditions and attractive features like phototaxis, it has been the objec-
tive on many genetic engineering approaches in the past.[56,57] However, to the best of our 
knowledge, only one example has been reported that documented surface functionalization of the 
green alga by non-genetic means. The report published by Whitesides and co-workers describes 
the surface modification of C. reinhardtii with a polystyrene bead.[58] The polystyrene bead was 
irreversibly attached to the surface, and the alga was able to cover distances of up to 20 cm with 
velocities of 100-200 µm·sec-1. For the attachment of the bead to the surface, a 10-mer of 4-
hydroxyproline was utilized that was connected to the polystyrene bead via a photocleavable 
linker (Figure 15). In first experiments, the authors demonstrated that the alga could transport the 
polystyrene bead through a microfluidic channel guided by LEDs that were alternately turned on 
(Figure 16). This served as a nice demonstration that the algae can function as a micro-bio-
robot[59,60] controlled by the use of light. Later, the authors cleaved the polystyrene bead from the 
anchor with a 20 s light irradiation at 365 nm. 
 
 
 
Figure 15: System used by Whitesides and co-workers for the immobilization of a polystyrene bead on 
the surface of C. reinhardtii. 
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Figure 16: Transport of microloads by C. reinhardtii through a microfluidic channel triggered by a light 
stimulus.[58] Copyright (2005) National Academy of Sciences. 
 
2.2 Bacillus subtilis 
The Gram-positive bacterial strain Bacillus subtilis is a widely used model organism. The cells 
are 2.3 µm in length and 0.6 µm thick and the surface of the cells is fully flagellated allowing the 
bacteria to move quickly at velocities of up to 4 µm/sec (Figure 17).[61] The appearance of the 
cells during cell cultivation is not homogenous. Depending on the age of the culture single rod 
shapes or long chains composed of single cells are observed. The cell appearance of the bacteria 
depends strongly on the growth stage and on the bacterial strain[62-64]; we have observed the bac-
teria to appear mostly in single or double rods during the exponential phase and in chains during 
the stationary phase (see section 7.2.2, Figure 57 in the experimental part). 
B. subtilis can be isolated from many environments, both of terrestrial and aquatic nature. The 
biofilm forming bacterium grows on plant roots[65,66] or can be isolated from the rhizosphere 
from a variety of plants.[67-69] In these environments it is often subjected to harsh conditions such 
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as nutrient deprivation, desiccation, heat, UV-light and pressure making it necessary for the or-
ganism to be flexible to survive.[70] As a response, it forms highly resistant dormant endospores 
that can spread through the air.[71,72] Once formed, the dormant cells can persist for long periods 
of time.  
 
Figure 17: Bright field image of B. subtilis taken with a confocal microscope. 
 
Bacterial cells consist of a cell wall surrounding inner components such as nucleoid (DNA) 
and ribosomes embedded in the cytoplasm. The cell wall in Gram-positive bacteria functions as 
protection from mechanical influences and allows them to live in hypotonic environments.7 The 
cell wall consists of a relatively thick (20-80 nm) peptidoglycan or murein (Lat.: murus, wall) 
layer that lies on top of the cell membrane (Figure 18). Starting at the cell membrane, lipo-
teichoic acids pierce the peptidoglycan layer to the outside of the cell wall. In contrast, Gram-
negative bacteria contain a thin peptidoglycan layer, which is covered by an outer membrane. 
Due to the second outer membrane and the thinner peptidoglycan, Gram-negative bacteria are 
not stained by Gram-stain, a chemical cocktail (crystal violet and iodine) for the detection of the 
peptidoglycan.  
 
Figure 18: Comparison of the cell walls of Gram-positive bacteria and Gram-negative bacteria. 
  
                                                
7 Hypotonic: The salt concentration of the environment is lower than the intracellular salt concentration. 
Peptidoglycan
Lipoteichoic acid
Liposaccaride
Outer membrane
Peptidoglycan
Plasma membrane
Gram-positive Gram-negative
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The life cycle of B. subtilis involves two mechanisms. The first one is the vegetative cycle, 
which occurs under normal growth conditions and serves the reproduction of bacteria. The se-
cond is the sporulation cycle that takes place under starvation conditions and ends in the for-
mation of dormant endospores (Scheme 2).[73] The vegetative cycle starts with segregation of the 
chromosome inside the bacterial cell, which proceeds to the formation of a binucleate. Further, 
the cell wall of the bacteria starts to form a cross-wall initiating the separation of the cells; and 
further proceeds by segregation to finally release a second cell.[74] This cycle takes 120 min for 
B. subtilis, while it only takes 20 min for the Gram-negative bacteria Escherichia Coli. Opposed 
to this, the process of sporulation is mainly initiated by starvation, when the cell sees the need to 
transform into a highly resistant version. The stimulus of starvation triggers a complex cascade 
of biochemical reactions that involve the synthesis of the transcriptional regulator Spo0A that 
activates the transcription of several key sporulation-specific genes.[75] Based on this, the cell 
divides asymmetrically and a smaller cell, the prespore, is engulfed. This process involves the 
segregation of chromosome in the prespore and the mother cell. Next, the prespore is encapsulat-
ed by formation of the cortex, cell membrane and cell wall. At the same time the cell is dehy-
drated and mineralized. Finally, a multilayered coat of proteins is assembled around the cortex. 
During this process, the ability of the spore to respond to suitable environments for vegetative 
growth is included. Lysis of the mother cell releases the dormant endospore that is able to react 
to specific germinants to shed its protective layers and rehydrate. 
 
Scheme 2: Simplified schematic representation of the vegetative and sporulation cycle of B. subtilis. 
Chromosome segregation is not shown for the sporulation cycle. 
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2.3 Vancomycin – a glycopeptide antibiotic 
Vancomycin is a glycopeptide antibiotic isolated from a soil sample in the mid 1950s by Eli 
Lilly in the USA and first used clinically in 1959 (Figure 19).[76] It is produced by the Gram-
positive bacteria Amycolatopsis orientalis. At the beginning, the clinical use of the isolate caused 
a number of side effects, which hampered its application.[77] Later, it was recognized that the side 
effects were mainly caused by impurities present in the isolates, which could be removed by an 
improved purification procedure. Vancomycin and its relatives ristocetin A and teicoplanin have 
been the antibiotics of last resort against methicillin-resistant Staphylococcus aureus and other 
pathogens for a long time.[78] Unfortunately, the frequent prescription of vancomycin has led to a 
wide-spread resistance of bacterial strains in hospital.[79] 
 
 
Figure 19: Structure of vancomycin. 
 
The molecular structure of vancomycin involves a peptide backbone constituted from seven 
amino acids. Other characteristic features are the chlorine atoms attached to the aromatic rings of 
the side chains and the atropisomeric biaryl ring-system. The structural elucidation has first been 
investigated by NMR spectroscopy[80-83] and finally by X-Ray crystal structure analysis.[84,85]  
Vancomycin is a potent antibiotic against Gram-positive bacteria and used for treatment of pa-
tients that are allergic to β-lactam antibiotics. Its mode of action is the complexation to the pepti-
doglycan precursor and thereby inhibiting the maturation of the cell wall.[86] As a consequence 
the bacteria lyse.[87] The complex formed between the cell wall fragment D-Ala-D-Ala and the 
peptide backbone of the antibiotic is stabilized by an array of van der Waals interactions and five 
key H-bonds (Figure 20).[88] 
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Figure 20: Complex between vancomycin and the peptidoglycan precursor. 
 
Drug-resistant bacteria such as enterococci have developed mutations that defend themselves 
against vancomycin. The structural basis for the resistance lies in the exchange of the D-Ala-D-
Ala terminus to D-Ala-D-Lac. This simple substitution (N→O) results in a 1000-fold decrease in 
binding of vancomycin to the cell wall fragment.[89] Basis for this is the loss of the central H-
bond present in the D-Ala-D-Ala complex (Figure 21). In contrast, the new complex contains a 
repulsive lone-pair interaction between the carbonyl of vancomycin and the ester oxygen of lac-
tic acid that mainly contributes to the loss of activity. Overall, this mutation leads to an increase 
of the MIC of vancomycin by a three-fold of magnitude.[90]  
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Figure 21: Interactions of vancomycin with the modified cell wall fragment. 
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2.4 Project outline 
The objective of this project was the surface functionalization of the green algae C. reinhardtii 
with the antibiotic vancomycin. In a first step, a system had to be designed which allows for at-
tachment of the antibiotic to the surface (Scheme 3). In a second step, the algae were tested on 
their antimicrobial activity against the Gram-positive bacteria Bacillus subtilis.  
 
 
Scheme 3: Schematic representation of surface modification of C. reinhardtii with vancomycin followed 
by antimicrobial tests against B. subtilis. 
 
Several challenges are addressed here: First, the coating needs to be sufficiently adhesive to 
remain on the surface after removal of the incubation solution and wash of the algae. Second, the 
properties of the algae in terms of general appearance and motility should not be severely im-
paired. Third, the operational procedure should be easy and practical. Finally, the amount of sub-
stance on the surface needs to be sufficiently high to exert an antimicrobial effect.  
  
Incubation Wash B. subtilis
 Surface Engineering of Algae 
23  
2.5 Preliminary work  
Earlier work was carried out in our group by a former postdoc, Prof. Dr. Chandan Kumar Ja-
na. He investigated a 4-hydroxyproline oligomer, which was fluorescently labeled by reaction 
with fluorescein isothiocyanate to give compound 2.01.  
The attachment of the substance to the algae was tested by incubation of the algae with 2.01. 
The algae were washed and examined under a fluorescence microscope using different filters.8 
The images show the autofluorescence of C. reinhardtii in a and a’ in green color; and the fluo-
rescence of substance 2.01 in b and b’ in red color (Figure 22).9 The bright field images c and c’ 
show the sample with transmitted light. The irregularities, especially visible in c, result from salt 
residues, which remain after the sample has dried out. The overlay images d and d’ show that the 
red and green fluorescence is localized on the same position and from this we conclude, that 
compound 2.01 is localized on the alga.10  
 
 
 Figure 22: Algae C. reinhardtii modified with 2.01. a) Autofluorescence of algae. b) Immobilized sub-
stance. c) Bright-field image. d) Merged image of a, b and c. Pictures indicated with ‘ are magnified im-
ages of the same samples. Images were taken by Chandan Kumar Jana. 
 
 
  
                                                
8 Imaging was performed on a widefield microscope (Leica DMI 4000), not listed in the instrumental part. 
9 The convention to choose the color of the fluorescent signal according to the emission wavelength of the fluoro-
phore, was not followed in this case. For the upcoming images the convention was implemented. 
10 The overlay of red and green results in yellow color in the merged image.  
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2.6 Synthesis of 4-hydroxyproline oligomer derivatives and their interaction with C. 
reinhardtii 
For the immobilization of vancomycin on the surface of the algae, 4-hydroxyproline oligomer 
was utilized as the anchor for attachment to the cell surface.[58] On the 4-hydroxyproline oligo-
mer, a linker was installed which carried the fluorescent tag. The primary amine of the linker 
was used for the attachment of the antibiotic. Vancomycin offers several functional groups suita-
ble for modification, for instance a carboxylic acid, a primary or a secondary amine.[91] The car-
boxylic acid group has been proven earlier to be a suitable site for functionalization[92,93] because 
it is not directly involved in the hydrogen bonding complex with the precursor peptidoglycan 
peptide terminus N-acyl-D-Ala-D-Ala (see section 2.3).  
 
Scheme 4: Schematic representation of the 4-hydroxyproline oligomer-vancomycin conjugate. 
 
We started with the reproduction of the results obtained earlier (see 2.5 Preliminary work), 
which involved the synthesis of the 4-hydroxyproline oligomer. In addition to fluorescently la-
beled 9-mer (compound 1), we also decided to prepare the corresponding 10-mer. First, the 4-
hydroxyproline oligomer was synthesized by solid phase peptide synthesis using Fmoc-protected 
amino acids, which were coupled on the C-terminus to a Rink amide resin. The resin had a rela-
tively high loading of 0.59 mmol/g, which means a close proximity of the reactive groups on the 
polystyrene bead. The synthesis was performed with a solid phase peptide synthesizer that per-
formed the following steps in nine cycles: (1) coupling, (2) Fmoc deprotection and (3) capping.  
The peptide (2.03) was cleaved from the resin using a cocktail consisting of TFA, TIS and wa-
ter. Due to the polarity of the compound, HPLC purification was not possible. Instead, the solid 
was dissolved in water and filtered over a SPE column previously equilibrated with water. Re-
maining components from the resin11 could be removed in this way. 
 
 
                                                
11 One component was identified as this diphenyl ketone:  
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Figure 23: Synthesis of the 4-hydroxyproline oligomer 2.03 by solid phase peptide synthesis. 
 
 
Scheme 5: Synthesis of fluorescently labeled 4-hydroxyproline oligomer connected by thiourea-bridge. 
 
 
The fluorescent label was installed by addition of the 9-mer or the 10-mer to fluorescein 
isothiocyanate in a mixture of buffer and THF. At this stage, the 4-hydroxyproline oligomer was 
dissolved in water and THF was added to dissolve the fluorescent reagent. 
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LC-MS analysis of the crude mixtures revealed that the products partially had reacted accord-
ing to a reaction named Edman degradation to release a fluoresceinthiohydantoin 2.08 as well as 
the peptide shortened by one amino acid unit 2.07 (Scheme 6). This reactivity of peptides that 
are α-substituted with a thiourea is well known and commonly used for the determination of 
amino acid sequences of peptides.[94,95] In our case, the fluoresceinthiohydantoin could be sepa-
rated from the product by HPLC purification, but overall this side reaction shows that the com-
pounds are not entirely stable in aqueous media.  
 
Scheme 6: Thiourea substituted peptides such as 2.01 can decompose according to the Edman degrada-
tion. 
 
Next, we incubated the algae with compounds 2.01 and 2.04 for 48 h at a concentration of 
4.67·10-3 mmol/mL.12 The algae were first concentrated by centrifugation and the medium was 
removed, such that the algae density was about 10x higher than in the culture they have been 
raised in. Then the substances were added as a solution in the culture medium of the algae. After 
48 h, the algae were washed with medium and imaged on a confocal microscope (Scheme 7). 
The fluorescence images revealed that both compounds 2.01 and 2.04 were attached to the algae. 
The images taken are single layers of the center of the algae, so that the distribution of the com-
pound inside the algae is visualized. Both compounds were clearly internalized by the algae, so 
that attachment solely to the surface can be excluded. Additionally, there was no significant dif-
ference in adherence between 2.01 and 2.04, both substances attached equally well to the algae.  
 
                                                
12 The attachment of the compound to the algae was strongly dependent on the concentration. The concentration 
used was adapted from earlier protocols. 
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Scheme 7: Single layer confocal microscopy images of algae incubated with 2.01 or 2.04. a) and b) Al-
gae incubated with 2.01. c) and d) Algae incubated with 2.04. Scale bars equal 10 µm. 
 
Encouraged by these results, we proceeded with the syntheses of anchor systems according to 
Scheme 4. Scheme 8 shows the two anchor systems that contain a fluorescent marker and allow 
for functionalization on the free amine. Anchor 2.09 includes a lysine unit as a linker that allows 
for attachment of fluorescein on the N-terminus and connection of vancomycin to the free amine 
on the side chain. Fluorescein is connected through an amide bond to ensure a chemically stable 
connection, in contrast to compounds 2.01 and 2.04. Additionally, we also prepared compound 
2.10, which contains an additional spacer group.13  
 
                                                
13 In case that the space between oligoproline and fluorophore in compound 2.09 would be insufficient and would 
lead to a decreased binding ability of the anchor to the algae.  
a b
c d
fluorescein chloroplast
9mer 9mer
10mer 10mer
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Scheme 8: Anchors 2.09 and 2.10 for functionalization. 
 
The synthesis of the anchors 2.09 and 2.10 required the preparation of the 4-hydroxyproline 
oligomer fragment and the additional couplings of the linkers and the fluorophore. Instead of 
performing the linker and fluorophore couplings with 4-hydroxyproline oligomer in solution, we 
decided to perform the entire synthesis on the solid phase, which has the advantage that only one 
final HPLC purification is necessary. In a first approach, we used a conventional Rink amide 
resin with a loading of 0.59 mmol/g and performed a lysine coupling at room temperature fol-
lowed by deprotection (Scheme 9). As a next step, we tried to couple 5-carboxyfluorescein to the 
free amine group of the lysine. Unfortunately, the coupling could not be brought to full comple-
tion, even after a second, new set of reagents was added. Finally, we succeeded to bring the reac-
tion to full completion only by heating to 110 °C for 30 min in the microwave. Cleavage from 
the resin under acidic conditions delivered 2.09 in 10% yield after HPLC purification.  
The synthesis of anchor 2.10 started with coupling of Fmoc-6-AHX, followed by capping, 
deprotection and coupling to lysine (Scheme 10). For both couplings, elevated temperatures un-
der microwave irradiation were necessary to achieve full completion. The same was true for 
coupling of 2.13 with 5-carboxyfluorescein whose reaction progress was monitored by TNBS14 
and Kaiser15 test of the peptide resin.  
                                                
14 Incomplete reaction: red beads. Complete reaction: colorless beads. 
15 Incomplete reaction: blue beads and solution. Complete reaction: colorless beads and solution. 
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The explanation for the required elevated temperatures presumably has two reasons. First, oli-
goprolines arrange in helices and are highly rigid, sterically demanding peptides.[96] This proper-
ty is even enhanced by the tert-Butyl groups of the 4-hydroxyproline units. Second, the addition-
al Fmoc-6-AHX linker of 2.13, provides flexibility to the linker chain that can entangle and 
make the free amine inaccessible for reaction. 
The accelerating effect of microwave irradiation in peptide synthesis is believed to be based 
on the direct interaction with the amide dipole moments of peptides thereby leading to more effi-
cient heating.[97] Although the reactions were complete and product was isolated, elevated tem-
peratures are not ideal with regard to the thermal lability of fluorescein and its bioconjugates. 
Therefore, we were aiming for conditions that were milder for the peptide and that delivered the 
product in higher yield. 
 
Scheme 9: Synthesis of anchor 2.09. 
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Scheme 10: Synthesis of anchor 2.10 and reaction progress of 5-carboxyfluorescein coupling using 
TNBS (top) and Kaiser (bottom) test. 
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For improvement of the synthesis we switched to a resin that provides more space for the pep-
tide on the solid phase. In contrast to the previously used resin with a loading of 0.59 mmol/g the 
Rink Amide NovaPEG resin provides significantly more space for the peptide because it com-
prises a PEG chain between the polystyrene bead and the Rink Amide group (Scheme 11). 
Thereby this resin provides an environment during the synthesis almost like in solution. In addi-
tion, the loading of the resin (0.39 mmol/g) is significantly lower than for the previously used 
resin. Indeed, using this resin and slightly modified coupling conditions for the fluorescein cou-
pling, the product was obtained in higher yield and purity. The couplings were all carried out at 
room temperature, especially important for the fluorescein coupling to maintain of the fluores-
cent brightness. 
 
Scheme 11: Improved synthesis of anchor 2.09 using a Rink amide NovaPEG resin. 
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Next, we measured the fluorescent properties of compound 2.09 (Figure 24) and compared 
them to the fluorescence of a suspension of C. reinhardtii originating from the chlorophyll of the 
chloroplast (Figure 25). Compound 2.09 shows an excitation maxium at 486 nm and an emission 
maximum at 523 nm. C. reinhardtii shows an excitation maximum of 489 nm and an emission 
maximum at 689 nm. Importantly, the emissions of both, compound 2.09 and the algae, lie at 
different wavelengths. There is only minor emission of C. reinhardtii from 500-600 nm, so that 
both algae and 2.09 can be monitored without strong interference in fluorescence. In addition, 
both can be excited with a 488 nm argon laser, which makes a parallel acquisition possible.  
 
 
Figure 24: Fluorescence spectrum of 2.09. 
 
 
Figure 25: Fluorescence spectrum of C. reinhardtii. 
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With compounds 2.09 and 2.10 in hand, we investigated the immobilization of both conju-
gates on C. reinhardtii. The algae were incubated at a concentration of 4.67·10-3 mmol/mL for 
48 h under shaking. The cells were washed and investigated with a confocal microscope 
(Scheme 12). Both anchors 2.09 and 2.10 were attached to the algae and in both cases, the com-
pounds penetrated inside the cell. However, the amount of substance appeared to be much less, 
than for anchors 2.01 and 2.04 (see Scheme 7). The apparent fluorescence was rather weak and 
dead cells appeared to be even stronger labeled than cells that were still alive (indicated by white 
arrows).16 We were wondering whether the strong labeling for compounds 2.01 and 2.04 was 
caused by the fluoresceinthiohydantoin formed by Edman degradation during the incubation 
procedure. Fluoresceinthiohydantoin is a small molecule and might be able to penetrate inside 
the algae or react with the cell’s components. As an alternative explanation, the presence of a 
primary amine in compounds 2.09 and 2.10 possibly caused the weak labeling by an increased 
water solubility of the substances.  
 
Scheme 12: Incubation of algae with compounds 2.09 and 2.10. a)-c) Algae with compound 2.09. d)-f) 
Algae with compound 2.10. Scale bars equal 10 µm. 
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fluorescein chloroplast
e
a b
d
overlay
c
f
CHAPTER 2 
 
34 
To investigate an increased labeling by the possible decomposition products of 2.01 and 2.04, 
we prepared compound 2.18 by coupling of 2.03 with 5-carboxyfluorescein in solution (Scheme 
13). Compound 2.18 connects the fluorescein unit by an amide group, but should display very 
similar polarity to 2.01 and 2.04. Incubation of the algae with 2.18 under the previous conditions 
showed similar labeling as anchor 2.09 and 2.10, and much weaker attachment to the algae than 
2.01. This leads to the assumption that strong labeling of compound 2.01 is based on the for-
mation of its degradation product fluoresceinthiohydantoin. In control experiments we did not 
see any attachment of the fluorescent reagents 5-carboxyfluorescein or fluorescein isothiocya-
nate to the algae. However, the structurally similar fluorescein diacetate is a common cell per-
meation agent used for the staining of live cells.17 In this respect, it is clearly possible that fluo-
resceinthiohydantoin also permeates cells. 
 
 
 
Scheme 13: Synthesis of 2.18 and incubation of algae. a) and b) Incubation with 2.18. c) Algae incubated 
with compound 2.01 for comparison. Scale bars equal 10 µm. 
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2.7 Synthesis of vancomycin conjugate 
Vancomycin was coupled to anchor 2.09 in solution. The conditions tested for the coupling of 
vancomycin to anchor 2.09 are summarized in Table 1. 
 
 
Table 1: Conditions for the coupling of vancomycin to anchor 2.09.  
Entry Coupling reagent Vancomycin/coupling reagent Time SM : product Isolated 
yield 
1 HATU 1.5/1.4 19 h 4.7 : 1 n. d. 
2 HATU 1.5/1.4 5 d 4.4 : 1  n. d. 
3 PyBOP 3/3 5 d 0.67 : 1 n. d. 
4 PyBOP 6/6 4 h 0 : 1  n. d. 
5 HATU 6/6 16 h 0.63 : 1 n. d. 
6 PyBOP 3/3 14 h 2 : 1  n. d. 
7 PyBOP 3/6 2.5 h 0 : 1 19% 
8 PyBOP 3/3 + 3 equiv. HOBt 2 h 0 : 1  44% 
9 PyBOP 1.2/1.2 + 1.2 equiv. HOBt 1.5 1.8 : 1 n. d.  
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The challenge of the coupling between vancomycin and compound 2.09 resided in incomplete 
conversions of 2.09. This was often observed with HATU as the coupling reagent. When the 
coupling reagent was changed to PyBOP, this could be improved. However, care had to be taken 
as over-coupling was observed when using large excess of vancomycin resulting in the coupling 
of two vancomycin molecules to each other (Table 1, entry 4). With short activation time of van-
comycin and excess of coupling reagent, the reaction was brought to completion without signifi-
cant over-coupling (Table 1, entry 7). This could be further improved by use of HOBt as an addi-
tive resulting in cleaner reaction mixtures and higher isolated yield (Table 1, entry 8). At least 2 
equiv. of vancomycin, coupling reagent and HOBt were required to bring the reaction to comple-
tion.  
The fluorescence spectrum of compound 2.19 shows an excitation maximum at 497 nm and an 
emission maximum at 525 nm (Figure 26). This makes compound 2.19 suitable for simultaneous 
imaging with C. reinhardtii (for the fluorescence spectrum of C. reinhardtii see Figure 25). 
 
 
Figure 26: Fluorescence spectrum of 2.19. 
 
In addition to the fluorescently labeled vancomycin derivative, we also prepared a derivative 
without fluorophore, which we wanted to utilize later in the bacterial growth experiments. For 
this, we applied the chemistry used towards the synthesis of compound 2.13 by preparation of 
linker 2.20 on the resin followed by cleavage from the resin. The anchor 2.20 was dissolved in 
water, purified by filtration over a SPE column, and lyophilized. The lyophilized product was of 
sufficient purity to be coupled to vancomycin with the same conditions as for the synthesis of 
compound 2.19 (Scheme 14). 
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Scheme 14: Synthesis of vancomycin conjugate 2.21. 
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2.8 Immobilization of vancomycin conjugate on algae 
The immobilization of conjugate 2.19 was realized by incubation of the algae in a solution of 
2.19 with mild shaking followed by a simple washing protocol. Time and concentration of the 
incubation solution determined the extent of loading on the algae. With high concentrations of 
2.19 (4.5·10-3 mmol/mL) very strong labeling was observed within 3 h (Scheme 15, a-e). How-
ever, these conditions strongly affected the behavior of the algae in that the algal motility com-
pletely stopped even after seconds of exposure. On the other hand, the autofluorescence was still 
maintained, which indicates that the cells were still living. Dead cell material showed almost no 
autofluorescence of the chloroplast, but strong adhesion of compound 2.19 (indicated by arrow). 
By lowering the incubation concentration (1·10-3 mmol/mL), the motility of the algae could be 
maintained compared to the control algae that was incubated under the same conditions but with 
algae medium instead of a solution of 2.19 (Scheme 15, f-j). At this concentration, the algae 
were clearly covered with compound 2.19 after 12 h of incubation time, as visible in the confocal 
z-stack image (Scheme 15, i) and in the merged image with the autofluorescence of the chloro-
plast (Scheme 15, h). A single confocal layer reveals that the substance has been mainly deposit-
ed on the cell wall. However, also a considerable amount of substance penetrated the cell, with a 
concentration enhancement especially at the side of the flagellar collar. 
The motility of the algae could be increased drastically by lowering the concentration of the 
incubation solution from 4.5·10-3 mmol/mL to 1·10-3 mmol/mL. However, the mobility was still 
decreased compared to fresh algae from the culture bottles. We, therefore, postulated that not 
only the concentration of the substance, but also the algae density in comparison to the incuba-
tion solution had an influence on the motility. Indeed, by lowering the algae amount in relation 
to incubation solution, the algae completely maintained their motility as in a fresh culture 
(Scheme 15, k-o). Conjugate 2.19 showed strong adhesion to the flagella, making the presence 
of the flagella easily observed (for enlarged images see Scheme 15, p-t). The concentration of 
the conjugate could be lowered even further (c = 1.5·10-4 mmol/mL) with an incubation time of 
24 h, but the substance loading was not sufficiently high for the antibacterial assay application 
performed later (Figure 27). 
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Scheme 15: Fluorescence microscopy images of C. reinhardtii treated with 2.19.  
a)-e) C. reinhardtii, treated with 2.19 at 4.5･10-3 mmol/mL for 3 h. f)-j) C. reinhardtii, treated with 2.19 
at 1·10-3 mmol/mL for 12 h. k)-o) C. reinhardtii incubated with 2.19 at lower algae concentration in com-
parison to solution (c = 1·10-3 mmol/mL). p)-t) Enlarged image of C. reinhardtii incubated with 2.19 at 
lower algae concentration in comparison to solution (c = 1·10-3 mmol/mL). Scale bars equal 10 µm. 
 
 
 
Figure 27: Incubation at 1.5·10-4 mmol/mL for 24 h. Scale bar equals 10 µm. 
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2.9 Investigations on the binding affinity of vancomycin to C. reinhardtii 
Overall the binding affinity of conjugate 2.19 was clearly higher than for anchor 2.09. Our 
first presumption was that vancomycin itself also binds to the surface of the algae thereby in-
creasing the overall binding affinity of conjugate 2.19. To investigate the binding of vancomycin 
to C. reinhardtii we performed two different experiments. In the first experiment we labeled 
vancomycin with a fluorescent tag, to trace the behavior of the conjugate on the algae. In the 
second experiment we performed immunofluorescence for the detection of vancomycin. 
 
2.9.1 Fluorescently-labeled vancomycin 
The attempt to directly attach a fluorophore to vancomycin by reaction with 6-
aminofluorescein failed because a very complex mixture was obtained. Therefore, we decided to 
use the fluorescent linker 2.22 instead. The linker was attached under similar conditions as used 
before for the synthesis of the oligoproline vancomycin conjugate 2.19 (Scheme 16). 
 
Scheme 16: Synthesis of fluorescently labeled vancomycin. 
 
Unfortunately, 2.23 displayed drastically reduced water solubility in comparison to vancomy-
cin. The substance was well soluble in DMSO but could not be dissolved in the algae culture 
medium even when 20% DMSO was added. The concentration of the substance was chosen as in 
the incubation conditions, but even by lowering the concentration, the substance did not dissolve. 
Similar results were obtained with a commercially available BODIPY-vancomycin conjugate 
(Thermo Fischer Scientific, Molecular Probes). Overall, the poor water solubility of the sub-
stances prevented this approach to be a suitable study for the adhesion of vancomycin to C. rein-
hardtii. 
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2.9.2 Immunolabeling of vancomycin 
A second possibility to trace vancomycin with fluorescence is by immunolabeling. In this ap-
proach, an antibody is used that specifically binds to vancomycin. There are two general tech-
niques: direct and indirect immunofluorescence. In direct immunofluorescence the specific pri-
mary antibody (1° antibody) is covalently linked to a fluorochrome and allows for direct visuali-
zation of the substance. In indirect immunofluorescence a two-step incubation is performed. 
First, a 1° antibody is used that specifically binds to the target structure. Secondly, a fluoro-
chrome-coupled secondary antibody (2° antibody) is applied that specifically binds to the 1° an-
tibody. The specificity results from direct binding of the 2° antibody to the species in which the 
1° antibody was raised. Indirect immunofluorescence offers two main advantages over direct 
immunofluorescence: 1) More flexibility is obtained regarding the choice of fluorophore because 
the primary antibody is not necessarily produced with a range of different fluorochromes. The 
secondary antibody is usually available with several fluorophores and like this the right fluoro-
chrome can be chosen for the individual experiment. 2) A signal amplification is obtained be-
cause multiple 2° antibodies can bind to one primary antibody. This leads to an increase in fluo-
rescence, requiring less primary antibody and overall increases the sensitivity of the method. The 
drawback of indirect immunofluorescence lies in the extended working procedure requiring a 
second antibody incubation and more wash cycles. However, because of the flexible combina-
tions of the 1° with 2° antibodies it is often preferred over direct immunolabeling. Indirect im-
munofluorescence was therefore chosen for the detection of vancomycin on C. reinhardtii, 
schematically illustrated in Scheme 17. 
 
Scheme 17: Indirect immunolabeling of vancomycin with a 1° and 2° antibody on C. reinhardtii. 
 
The algae were incubated overnight with vancomycin at a concentration of 1·10-3 mmol/mL. 
The cells were washed, immobilized and fixed/permeabilized on cover slips for microscopy.[98] 
The algae cells were blocked with goat serum to minimize unspecific binding of the 1° antibody 
with the cell. 
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The immunolabeling was carried out with a 1° antibody binding specifically to vancomycin, 
which was raised in mouse (IgM). For the 2° antibody we used a goat anti-mouse IgM heavy 
chain antibody Alexa Fluor® 350 conjugate. Table 2 summarizes the working conditions used as 
well as those that are recommended by the supplier or the standard conditions. Incubation exper-
iments involving vancomycin were carried out in duplicates. However, staining of the duplicates 
was performed in one batch. 
 
Table 2: Comparison of applied conditions with standard/recommended conditions. 
Antibody Conditions used Standard/recommended conditions 
1° antibody 1:250 dilution 
3 h 37 °C 
1:250:1:500 dilution 
1-4 h 37 °C 
2° antibody 5 µg/mL 
2 h 37 °C 
1-10 µg/mL 
1-2 h 37 °C 
 
The experiments performed are summarized in Table 3. To allow for reasonable interpretation, 
a number of control experiments were necessary. The first control experiment (a) was the deter-
mination of the cellular autofluorescence, by refrain from using any antibody treatment in this 
sample. The second control experiment (b) is the use of only the 2° antibody for visualization of 
unspecific binding of the 2° antibody to cellular structures. The binding specificity of the 1° an-
tibody can be controlled by using algae that have not been incubated with vancomycin (c). Un-
specific binding of the 1° antibody would result in a signal in this control. As a positive control 
we chose to incubate the algae with conjugate 2.19, whose presence on the algae can be identi-
fied by observation of green fluorescence (d). In addition to this, the algae were incubated with 
2.21, to visualize a potential attachment of this conjugate to the algae (e). Finally, the algae were 
incubated with vancomycin (f).  
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Table 3: Control experiments and samples prepared for immunofluorescence. 
Experiment Sample preparation Purpose 
a   Autofluorescence 
Incubated with vancomycin 
12 h, 1·10-3 mmol/mL 
 
· Fixation/Permeabilization 
· Blocking 
Control for visualization of 
cellular autofluorescence 
b   2° Antibody 
Incubated with vancomycin 
12 h, 1·10-3 mmol/mL 
 
· Fixation/Permeabilization 
· Blocking 
· 2° Antibody 
Control for unspecific binding 
of 2° antibody 
c   Untreated algae 
 
· Fixation/Permeabilization 
· Blocking 
· 1° Antibody 
· 2° Antibody 
Control for binding specificity 
of 1° antibody 
d   2.19 
Incubated with 2.19 
12 h, 1·10-3 mmol/mL 
· Fixation/Permeabilization 
· Blocking 
· 1° Antibody 
· 2° Antibody 
Sample to visualize attachment 
of 2.19 to C. reinhardtii 
e   2.21 
Incubated with 2.21 
12 h, 1·10-3 mmol/mL 
· Fixation/Permeabilization 
· Blocking 
· 1° Antibody 
· 2° Antibody 
Sample to visualize attachment 
of 2.21 to C. reinhardtii 
f   Vancomycin 
Incubated with vancomycin 
12 h, 1·10-3 mmol/mL 
· Fixation/Permeabilization 
· Blocking 
· 1° Antibody 
· 2° Antibody 
Sample to visualize attachment 
of vancomycin to C. reinhardtii 
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Scheme 18: Immunolabeling of C. reinhardtii. a) Algae incubated with vancomycin but not stained with 
antibodies. b) Algae incubated with vancomycin but only stained with 2° antibody. c) Algae that have not 
been modified but stained with 1° and 2° antibody. d) Algae incubated with 2.19 and stained with 1° and 
2° antibody. e) Algae incubated with 2.21 and stained with 1° and 2° antibody. f) Algae incubated with 
vancomycin and stained with 1° and 2° antibody. Scale bars equal 10 µm. 
 
fluoresceinchloroplast Alexa Fluor® 350
A A A A
B B B B
C C C C
D D D D
E E E E
F F F F
bright field
 Surface Engineering of Algae 
45  
The results obtained from the immunolabeling of C. reinhardtii are shown in Scheme 18. The 
images represent single layers of the algae, taken with a confocal laser scanning microscope. The 
images were recorded in a sequential mode with the bright field, chloroplast and fluorescein be-
ing taken in one sequence using the 488 nm laser. The Alexa Fluor® 350 antibody was excited 
with a 355 nm UV laser and detected in the second sequence. The intensity for the UV laser had 
to be set to high intensity (65%, 76 mV) to observe any signal for the blue fluorescent dye. All 
images shown were acquired using the same settings on the microscope and the same parameters 
during the image processing. This allows for direct comparison between the different experi-
ments. 
In the autofluorescence control (a) neither green nor blue fluorescence were observed as ex-
pected because the sample has been incubated with non-fluorescent vancomycin and no antibody 
treatment was performed. Image series b represents the sample that has been incubated with 
vancomycin followed by staining only with the 2° antibody. The sample shows no fluorescence 
in the green channel, but shows some signal in the blue channel. The signal observed is a faint 
blue background with some labeling of the algae. The signal observed is mainly localized in the 
area of the flagellar collar of the algae. This sample has not been treated with the anti-
vancomycin 1° antibody, therefore the signal observed is the unspecific binding of the 2° anti-
body. Usually the acquisition parameters are adjusted so that there is no signal visible in this 
control. In this case we decided to maintain the parameters to visualize possible differences in 
the signal distribution.  
The algae that have not been incubated with any compound overnight, but have been subject-
ed to the immunofluorescence protocol (c), showed the same distribution of signal in the blue 
channel as in experiment b. This indicates that the signal observed is indeed resulting from un-
specific binding of the 2° antibody with the sample. In addition to this, the 2° antibody may bind 
to the coating of the cover slip (background signal). The next sample (d) were algae, which have 
been incubated with the fluorescently tagged vancomycin conjugate 2.19. We expected that 
sample d, algae that have been incubated with the fluorescently tagged vancomycin conjugate 
2.19, would act as positive control as we can trace the presence of the compound on the algae in 
the green channel. Against our expectations, the compound showed no significant signal en-
hancement compared to the control samples. This might be due to the fact that the antibody lost 
its affinity towards vancomycin when the oligoproline anchor was covalently attached to the 
antibiotic. Another possibility might be the internalization of the compound to the surface of the 
organism. A similar result was observed for sample e, where the algae have been incubated with 
vancomycin conjugate 2.21. We also expected an increased signal, although we had not proved 
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the adherence of the sample to the surface in advance. The algae that have been incubated with 
vancomycin and subjected to the complete immunolabeling protocol are shown in series f. Com-
pared to b, d and e, a slight enhancement of the signal at the surface of the algae is noticeable. 
Compared to control experiment c the difference is less pronounced. Therefore, it is difficult to 
formulate a clear statement regarding the binding of vancomycin to the surface of the algae. The 
method seems to be not very sensitive, resulting in harsh parameters18 necessary for the imaging 
of the samples. In addition, the absence of a reliable positive control complicates the interpreta-
tion of the results. Immunolabeling often involves extensive optimization to find the optimal 
conditions for the specimen with the applied antibodies. For future experiments we could also 
investigate the effect of different incubation concentrations and times. An alternative would be 
the use of a 1° vancomycin antibody covalently attached to a microbead which has been shown 
to effectively trace the presence of vancomycin on magnetic nanoparticles.[99] This would allow 
a better quantification of traced vancomycin molecules; on the other hand difficulties could arise 
by non-specific interactions of the nanoparticle-antibody with the surface of the algae.  
 
2.10 Antimicrobial activity of vancomycin conjugates 
To confirm, that the synthesized vancomycin conjugates still possess antimicrobial activity, 
we tested their inhibitory activity against the Gram-positive bacteria Bacillus subtilis. First, we 
performed disk diffusion tests (Kirby Bauer) on agar plates previously inoculated with B. subtilis 
(Figure 28). The compounds were applied on paper disks and the agar plates were incubated 
overnight at 37 °C. As can be seen from the inhibition zones, the antibacterial potency of the 
conjugates clearly decreased in comparison to vancomycin itself. This result is also reflected in 
the MIC (Minimal Inhibitory Concentration) of the compounds. The MIC values of the vanco-
mycin conjugates 2.19 (MIC = 8-4 µg mL-1) and 2.21 (MIC = 4 µg mL-1) was reduced in com-
parison to vancomycin (MIC = 0.125-0.06 µg mL-1), but still displayed acceptable activity.19 
This decrease in activity is likely due to the decreased binding potential to the N-acyl-D-Ala-D-
Ala fragment of the target bacterial cell wall because of the 4-hydroxyproline oligomer anchors. 
We found that the 4-hydroxyproline oligomer anchor alone displayed no antibacterial activity 
(see experimental part). 
 
                                                
18 High laser intensity. 
19 MIC values were determined by Myriam Gwerder. 
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Figure 28: Antimicrobial activity of conjugates 2.19 and 2.21 against B. subtilis. 
 
 
2.11 Antimicrobial activity of modified C. reinhardtii against B. subtilis 
To evaluate the concept of chemical surface engineering as a possibility to introduce new phe-
notypes to an organism, we had to show that the modified algae are able to kill bacteria. In the 
following section, our investigations on the antimicrobial activity of C. reinhardtii modified with 
vancomycin conjugates are presented.  
The antibacterial tests were performed in liquid culture to ensure homogeneous distribution 
and free diffusion of the modified algae and bacteria and to allow for easy contact. Bacterial 
growth was quantified by measuring the optical density at 600 nm (OD600).[100] The determina-
tion of the optical density is a sensitive and established quantification method for bacterial 
growth. We grew the cultures in a 1:1 mixture of B. subtilis medium and algae medium in coni-
cal tubes that were shaken in an incubator at 37 °C and 200 r/min. Samples from the cultures 
were taken every hour and optical density was determined. For each experiment we established a 
reference growth curve by measuring the bacterial growth in the presence of unmodified algae. 
Experiments were performed at least in triplicates. 
We started our experiments by incubating the algae for 3 h and 12 h at a concentration of 
4.5·10-3 mmol/mL in solutions of the respective compounds. For the compounds we chose parent 
vancomycin and both vancomycin conjugates 2.19 and 2.21. The algae were washed with Kuhl 
medium (5x), diluted in fresh medium and inoculated with B. subtilis. The resulting growth 
curves are depicted in Scheme 19. 
MIC values (μg mL-1)
vancomycin
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conjugate 2.21
4
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CHAPTER 2 
 
48 
Figure a shows that for algae previously incubated with vancomycin (3h and 12h), the bacteri-
al growth is not inhibited compared to the control of unmodified algae. For compound 2.21 a 
slight inhibition of bacterial growth is obtained (b). Surprisingly, for compound 2.19, the bacte-
rial growth is completely inhibited only after 3 h incubation time (c). After 1 h of incubation 
time, the growth was initially inhibited, but evolved later. This result showed, that C. reinhardtii 
could indeed be turned into an antimicrobial killer cell and that compound 2.19 was much more 
effective for this purpose than conjugate 2.21. As already pointed out in section 2.8, at high in-
cubation concentration the algae have the tendency to loose their flagella. During the preparation 
of the algae samples we observed, that for both compounds 2.19 and 2.21 the algae showed no 
motility at all. In contrast to this, algae incubated with vancomycin showed comparable motility 
to the untreated algae. A possible reason for this might be that vancomycin is not able to cross 
the algal cell wall. With the attached 4-hydroxyproline oligomer vancomycin is transported in-
side the cell. Another explanation is that the flagella apparatus reacts sensitive upon coating of 
the surface and sheds the flagella. This appears not be the case for vancomycin. 
a 
 
b  
 
c 
 
Conditions 
Culture density:  1.25·106 cells/mL  
Culture volume:  6 mL  
Incubation conc.:  4.5·10-3 mmol/mL 
Wash cycles:  5  
Scheme 19: Growth curves for B. subtilis in the presence of algae modified with vancomycin, 2.21 and 
2.19. Data points show individual replicates.  
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Next, we investigated different incubation concentrations of compound 2.19. As can be seen 
from Scheme 20, the bacterial growth increased with decreasing incubation concentration. This 
is in alignment with the conception that the higher the incubation concentration, the more sub-
stance is deposited on the algae. The motility of the algae was completely suppressed for incuba-
tion concentrations of 3·10-3 mmol/mL and 2·10-3 mmol/mL. At 1·10-3 mmol/mL the algae be-
haved like the untreated algae. Therefore we decided to continue our investigations at a concen-
tration of 1·10-3 mmol/mL. 
a 
 
b  
 
c 
 
Conditions 
Culture density:  1.25·106 cells/mL  
Culture volume:  6 mL  
Incubation time:  3 h 
Wash cycles:  5  
Scheme 20: Growth curves for B. subtilis in the presence of algae incubated at different concentrations. 
Data points show individual replicates. 
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The adhesion of the compounds to the surface of the algae might be a reversible process that 
can also be influenced by the extent of washing after the incubation. Therefore, we next investi-
gated the effect of washing on the bacterial growth by reducing the number of wash cycles, at the 
same time increasing the amount of algae.20 Changing the washing protocol to 1x (Scheme 21, a) 
instead of 5x (Scheme 20, a) resulted in complete inhibition of the bacterial growth. The same 
conditions but two wash cycles did not significantly inhibit the growth anymore, (Scheme 21, b) 
indicating that one wash cycle is not enough for removal of the compound from solution. As a 
control experiment, algae incubated with vancomycin and washed 2x, did not inhibit growth, 
showing that two wash cycles were enough to remove excess antibiotic. 
 
a 
 
b  
 
c 
 
Conditions 
Culture density:  3.35·106 cells/mL  
Culture volume:  6 mL  
Incubation conc.:  1·10-3 mmol/mL 
Incubation time:  3 h 
Scheme 21: Growth curves for B. subtilis in the presence of algae previously washed to different extent. 
Data points show individual replicates. 
                                                
20 Concerning the washing protocol is has to be mentioned that after the incubation, the algae were diluted with 
medium (∼10-fold). The supernatant was removed and then the number of wash cycles started. 
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From the previous experiments we have learned that with 3 h of incubation time and two wash 
cycles, the loading of substance on the algae was not sufficiently high. Therefore, we extended 
the incubation time of the algae from 3 h to 12 h (Scheme 22). Interestingly, after 12 h incuba-
tion, the algae completely inhibited bacterial growth. We also incubated the algae under the same 
conditions with vancomycin as a control. Under these conditions, there was also complete inhibi-
tion of growth with vancomycin. Even after washing three times, the bacteria were completely 
killed. When the algae were incubated for 6 h instead of 12 h, the same result was obtained (data 
not shown). This indicates that there must be some kind of adhesion of vancomycin to the sur-
face of the algae.This effect must evolve with longer incubation times and at higher algae densi-
ties compared to the first experiments.21  
 
a 
 
b  
 
c 
 
Conditions 
Culture density:  3.35·106 cells/mL  
Culture volume:  6 mL  
Incubation conc.:  1·10-3 mmol/mL 
Incubation time:  12 h 
Scheme 22: Growth curves for B. subtilis in the presence of algae incubated for 12 h. Data points show 
individual replicates. 
                                                
21 Increasing from 1.25·106 cells/mL to 3.35·106 cells/mL with respect to earlier experiments. 
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After the finding that vancomycin probably also adheres to the surface of C. reinhardtii, we 
wanted to find conditions at which the difference between 2.19 and vancomycin became appar-
ent. Based on the experiments depicted in Scheme 22, we had to reduce the amount of antibiotic 
present in the culture mixture. As learned from the experiments earlier, this can be done in two 
ways: 1) Reduce the incubation time of the algae so that there is less substance adhered to the 
surface or 2) reduce the amount of algae added to the culture mixture. We had already adjusted 
the incubation conditions for the algae, so that their motility was nicely maintained, so we decid-
ed to adjust the amount of algae in the culture (Scheme 23). Using an algae culture with a densi-
ty of 1.5·106 cells/mL instead of 3.35·106 cells/mL revealed a difference between algae incubated 
with conjugate 2.19 (Scheme 23, a) and vancomycin (Scheme 23, b) by slight inhibition of bac-
terial growth for 2.19-modified algae. 
a 
 
b  
 
 
 
Conditions 
Culture density:  1.5·106 cells/mL  
Culture volume:  6 mL  
Incubation conc.:  1·10-3 mmol/mL 
Incubation time:  12 h 
Wash cycles:  3 
Scheme 23: Growth curves for B. subtilis at an algal culture density of 1.5·106 cells/mL. Data points 
show individual replicates. 
 
0 1 2 3 4 5 6
0.0
0.5
1.0
1.5
2.0
Time (h)
O
D 6
00
unmodified algae
2.19
0 1 2 3 4 5 6
0.0
0.5
1.0
1.5
2.0
Time (h)
O
D 6
00
unmodified algae
vancomycin
 Surface Engineering of Algae 
53  
To further enhance this effect, we used an algae culture with slightly higher density. By utiliz-
ing a culture with 2.5·106 cells/mL, conjugate 2.19 fully inhibited bacterial growth (Scheme 24, 
a). Under these conditions, algae modified with vancomycin showed slight inhibition (Scheme 
24, b). In addition to this, we also were interested in the effect that conjugate 2.21 had under the-
se conditions. Surprisingly, algae previously incubated with 2.21 could not inhibit the growth of 
the bacteria at all. This confirms the results obtained in the initial experiments (see Scheme 19) 
that showed that algae incubated with 2.21 showed drastically less antibacterial potency than 
algae modified with 2.19. This indicates that the fluorophore plays a crucial role for the adhesion 
of the substance to C. reinhardtii. On the other hand, under the earlier conditions, algae modified 
with 2.21 showed a higher inhibition of bacterial growth than vancomycin. This effect was re-
versed with lower concentration of the incubation solution. An explanation for this might be the 
higher potency of vancomycin opposed to 2.21 that has to be taken into account, as the effect 
seen in the growth curve is not only proportional to the adhesion of the substances but also their 
antimicrobial potency. Further, as we have presumed earlier, vancomycin shows some adhesion 
to the algae that becomes more apparent with long incubation times. 
a 
 
b  
 
c 
 
Conditions 
Culture density:  2.5·106 cells/mL  
Culture volume:  6 mL  
Incubation conc.:  1·10-3 mmol/mL 
Incubation time:  12 h 
Wash cycles:  3 
Scheme 24: Growth of B. subtilis at an algal culture density of 2.5·106 cells/mL. Data points show indi-
vidual replicates. 
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2.12 Live/dead staining of bacteria 
As an additional proof to the growth curves, we performed live/dead staining of the bacteria 
with the samples shown in Figure 29, b after 6 h incubation. Viable bacteria are stained by hy-
drolysis of the cell permeable calcein-AM to calcein, which shows green fluorescence. Dead 
bacteria were stained with propidium iodide, which emit red fluorescence. When bacteria were 
grown with unmodified algae, mainly living but also dead cells were observed (Figure 29, a). 
This is because the bacterial growth had already entered a stationary phase. Important, the cells 
either emit green or red fluorescence as indicated by the merged image of the red and green 
channel. The merged image of the bacteria grown with modified algae showed an overlay of red 
and green fluorescence at the same spots (Figure 29, b). Separation of the merged image showed 
that all bacteria emit red fluorescence, which confirmed all cells being dead (Figure 29, c). At the 
same time, compound 2.19 (Figure 29, d) adhered to the surface of the bacteria and is visualized 
on the green channel resulting in an overlay of red and green in the merged image.  
These experiments show, that the substance is transferred from the algae to the bacteria and 
kill them. Attachment of 2.19 to the algae is reversible and binding of the compound to the bac-
terial cell wall is probably stronger than to the algae.  
 
Figure 29: Fluorescence microscopy images of Live/Dead staining of bacteria after exposure to algae for 
6 h. Living bacteria show green fluorescence, dead bacteria show red fluorescence. a) Bacteria in the 
presence of unmodified algae, red and green channel overlay. b) Bacteria in the presence of algae modi-
fied with 2.19, red and green channel overlay. c) Bacteria in the presence of algae modified with 2.19, red 
channel. d) Bacteria in the presence of algae modified with 2.19, green channel.  
a b
c d
Live Dead
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2.13 Mechanistic investigations 
Mechanistically, there are two possibilities how conjugate 2.19 is transferred from the algae to 
the bacteria: (i) by diffusion, where the compound is first released into the medium and then ad-
heres to the bacteria, or (ii) by direct contact of the bacteria with the algae (Scheme 25). In case 
of the first mechanism, the attachment of the substance to the algae must be fully reversible in 
solution. Therefore, we designed an experiment in which we first equilibrated the modified algae 
for a defined period of time under the conditions with which we usually performed the bacterial 
growth curve experiments. Later, we separated the supernatant from the algae and with both, 
algae and supernatant, we investigated bacterial growth. 
The growth curves suggest that both vancomycin and compound 2.19 are removed from the 
algae after 1 h of equilibration in the medium. For compound 2.19, the amount released was suf-
ficiently high enough to fully inhibit the bacterial growth, a), and at the same time, slightly in-
hibited growth by the remaining algae was also observed (Scheme 26, c). For vancomycin alone, 
partial inhibition of bacterial growth was achieved in the supernatant (Scheme 26, b), but no 
inhibition of the remaining algae could be observed (Scheme 26, c). These results indicate an 
overall lower loading of vancomycin and its fully reversible detachment from the algae, as op-
posed to an incomplete release of compound 2.19. Overall, a mechanism proceeding only over 
pathway (ii) can be excluded and, instead, diffusion (i) is likely playing a crucial role in the de-
livery mechanism.  
 
 
Scheme 25: Possible mechanisms for delivery of substances from the algae to the bacteria. 
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c
 
 
 
Scheme 26: Mechanistic investigations on substance delivery. 
 
2.14 Quantification of conjugate 2.19 on C. reinhardtii 
The quantification of substance 2.19 on C. reinhardtii was realized by UV/VIS absorption 
spectroscopy. The UV/VIS absorption spectrum of the alga shows a broad absorption with max-
ima located at 434 nm and 678 nm. The UV/VIS absorption spectrum of compound 2.19 shows 
high absorbance at 497 nm. The alga also shows UV/VIS absorption at 497 nm, so that the 
amount of substance can only be quantified by subtracting the UV/VIS absorption of the unmod-
ified alga at 497 nm. By measuring the increase of UV/VIS absorption at the λmax of 2.19 relative 
to the absorption at this wavelength of the unmodified algae, the amount of substance on the 
modified algae was determined.  
In this context, we also need to determine the algae density or also termed algae concentration 
(in cells/mL). The algae concentration can also be identified by UV/VIS spectroscopy. The algae 
concentration was determined by measuring the absorption at 550 nm. At this wavelength, the 
light is scattered by the algae that is proportional to cell density.[101] Importantly, compound 2.19 
shows no absorption at 550 nm (UV/VIS absorption spectrum of compound 2.19 depicted in 
Figure 31). 
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Figure 30: UV absorption spectrum of C. reinhardtii. 
 
Figure 31: UV/VIS absorption spectrum of 2.19. 
 
When the UV/VIS absorption of unmodified C. reinhardtii at 497 nm and 550 nm was measured 
as a function of algae concentration, a linear relation was obtained for both wavelengths. The 
plots do not cross an absorption of 0 because of scattering of living and dead algae cells.[101]  
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Figure 32: UV/VIS absorptions of unmodified algae at 497 nm and 550 nm at different algae concentra-
tions. 
 
Next, the UV/VIS absorption of the modified algae was measured at 550 nm for the determina-
tion of algae concentration, and at 497 nm for the determination of compound 2.19 in triplicates 
(Table 4).  
 
Table 4: Measured UV/VIS absorption of modified algae at 497 nm and 550 nm. 
Sample 550 nm 497 nm 
1 0.159 0.212 
2 0.159 0.212 
3 0.177 0.243 
 
The measured UV/VIS absorption at 550 nm and the equation obtained from Figure 32 was used 
to calculate the algae concentration (calgae).  
 !!!" = 2.422 ∙ 10!! ∙ !!"#!$ − 0.01821 
 !!"#!$ = !!!!" + 0.018212.422 ∙ 10!!  
 
With the algae concentration, the UV/VIS absorption of the unmodified algae at 497 nm can be 
calculated.  
 !!"# = 2.729 ∙ 10!! ∙ !!"#!$ − 0.01861 
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The UV/VIS absorption at 497 nm resulting from compound 2.19 can be calculated by subtrac-
tion of A497 from the determined value (Amod). 
 Δ! = !!!"# − !!"# 
 
From ΔA the concentration of 2.19 can be calculated using Lambert Beer’s Law.  
Lambert-Beer law: 
 ! = ! !!!! ∙ ! 
 
With the extinction coefficient of ελ = 16300 L·mol-1·cm-1, ΔA can be used to calculate the con-
centration of 2.19 on the modified algae.  
 ! = ! ΔA16300!! ∙ !"#!! ∙ !"!! ∙ 1!!" 
 
The table below shows the values for the intermediate calculation steps and the final concentra-
tion of the substance per volume algae culture in µg·mL-1. 
Table 5: Intermediate calculation values and final concentrations of 2.19 in an algae suspension. 
 calgae (cells/ml) A497 ΔA c (mmol·ml-1) c (µg·ml-1) 
1 7.38·105 0.183 0.0297 1.82·10-6 5.38 
2 7.36·105 0.182 0.0294 1.80·10-6 5.32 
3 8.14·105 0.204 0.0395 2.42·10-6 7.15 
 
The amount of compound attached to the algae lies in the low µg range for culture densities of 
0.7-0.8·106 cells/mL. In initial experiments we found that the minimal inhibitory activity of van-
comycin for our experimental setup is 1 µg/mL (see section 7.2.2).  
With the determined loading of ∼10-20 µg/mL for a culture of 1.5·106 cells/mL,# this lies in 
good agreement. 
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2.15 Cell wall-deficient mutant 
The interaction between anchor 2.19 and C. reinhardtii is of fundamental importance for the 
realization of the surface modification. We were interested in whether the interaction really takes 
place between components present in the cell wall of C. reinhardtii as postulated by Whitesides 
and co-workers,[58] or whether the plant material inside the cell also provides a basis for adhesion 
of the compound. To investigate this, we cultivated a cell wall-deficient mutant of C. reinhardtii 
that lacks the major components of the cell wall (W2-W6) but contains fibers that resemble the 
outer layer of the wild type (Figure 33).  
 
Figure 33: Electron microscopy image of C. reinhardtii prepared by quick-freeze deep-etch technique. 
The cell wall-deficient cw15 mutant lacks the central triplet W2-W6 layers.[40] 
 
The cell wall-deficient mutant was incubated in a 4.5·10-3 mmol/mL solution of 2.19 for 3 h. 
As a control, the cell wall containing algae were incubated under the same conditions. The cells 
were washed, fixed and prepared for microscopy. The difference of the two samples was clearly 
well apparent. After 3 h, the cell wall containing mutant was fully covered with conjugate 2.19 
(Scheme 27). On the contrary, the cell wall-deficient mutant lacked any adhesion of 2.19. As a 
control, we also imaged cell wall-deficient algae that have not been incubated with 2.19. The 
image processing parameters were set the way that we did not see any fluorescence in this con-
trol. The results obtained with this experiment lead to the conclusion that compound 2.19 ad-
heres to components belonging to the cell wall of the algae.  
39
(1986a) compared cw2 and cw15 with wild-type cells in an ultrastructural 
study centered on the endoplasmic reticulum and Golgi. In wild-type cells 
the endoplasmic reticulum adjacent to the cis pole of the Golgi dictyo-
somes swells markedly during the period of cell wall deposition. In cw2,
some swelling is also observed, but it is much less extensive than in wild-
type cells, and in cw15 none is seen. Both cw2 and cw15 appear to release 
the same set of glycoprotein products into the culture medium (Zhang and 
Robinson, 1990; Voigt et al., 1991). Voigt et al. (1997) reported that 18 
mutants representing all three classes formed the same set of intracellular 
wall precursors, although quantities were reduced in some. Most released 
elevated amounts of wall proteins into the culture medium compared to 
wild-type cells. The cw92 mutant, a class C mutant included by Davies 
among those showing aberrant inheritance in crosses, has very little resid-
ual wall material and for this reason has been favored for preparation of 
DNA to be u ed for library construction and sequencing. Additional wall-
defi cient mutants were isolated by Loppes and Deltour (1975, 1978). Some 
FIGURE 2.5 Cell surface of the  cw15 wall-defi cient mutant of  C. reinhardtii , prepared by quick-
freeze, deep-etch technique. A layer of cell wall fi bers extends from the etched cell membrane and 
surrounds the fl agellar bases. The fl agellar collar and dense central layer of wild-type cells are absent. 
The disposition and morphology of the cw15 fi bers most resemble the outer layer of the wild-type wall. 
From Monk et al. (1983); original fi gure by J.E. Heuser.
The Cell Wall
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Scheme 27: Incubation of algae with and without cell wall for 3 h at 4.5·10-3 mmol/mL with 2.19. a) Al-
gae with cell wall (11-32b). b) Cell wall-deficient algae (CC-406 cw15 mt-). c) Untreated cell wall-
deficient algae. Scale bars equal 10 µm. d) Fluorescence of chloroplast of algae with cell wall previously 
treated with 2.19. e) Fluorescence of chloroplast of algae without cell wall previously treated with 2.19. f) 
Fluorescence of chloroplast of algae without cell wall. 
 
2.16 Towards the crystal structure of a 4-hydroxyproline oligomer 
Along with our studies in that the 4-hydroxyproline oligomer played such an important role, 
we were also interested in the architectural arrangement of the 4-hydroxyproline oligomer linker. 
It has been reported that polyprolines can arrange in helical structures,[96] and it has been calcu-
lated that the 4-hydroxy-variant does as well, however,[102] this has never been proven by X-ray 
structure analysis. Knowledge about the secondary structure of our 4-hydroxyproline oligomer 
anchor would provide us with more information, how the anchor might interact with the surface 
of the algae.  
For a more facilitated crystallization we introduced a p-bromobenzoyl group to the 4-
hydroxyproline oligomer, as this group was used in the crystallization of a 6-mer of 4-
hydroxyproline oligomer in earlier reports (Figure 34).[96] The resulting 4-hydroxyproline oligo-
mer 2.24 was hygroscopic and very polar, so that the substance was already hardly soluble in 
MeOH. A number of attempts to obtain crystals from MeOH, MeOH/H2O, EtOH/H2O, Di-
glyme/H2O[103] and other mixtures using various techniques, were unsuccessful because most of 
the time, only oily residues were obtained.  
a bfluorescein
a bcell wall cell wall deficient controlc
chloroplast
d ecell wall cell wall deficient controlf
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Figure 34: 4-Hydroxyproline oligomer functionalized with p-bromobenzoyl group to facilitate crystal-
lization. 
 
We then decided to utilize a method that is used in protein crystallization: the sitting drop meth-
od. A drop of protein solution in water is exposed to a chamber containing a reservoir, which is 
filled with a precipitant solution (mostly salts). From this reservoir a drop is added to the protein 
drop. The concentration difference between the reservoir filled with precipitant and the pro-
tein/precipitant drop causes evaporation of solvent from the drop to the precipitant reservoir, 
resulting in an increase of concentration in the protein drop. This increase of protein and salt 
concentration in the drop, can lead to a crystallization of the protein. Advantage of this method is 
the crystallization from aqueous solutions and the operationally simple screening method be-
cause crystallization sets are commercially available and robots place the drops and reservoir 
solutions in specially designed well plates. Disadvantage is false alarm crystallizations in which 
the salt from the precipitant crystallized instead of the protein.  
We decided to carry out our experimentation at the protein crystallization facilities of the Uni-
versität Zürich. The screens used were general screens with a diverse combination of different 
conditions. We started with a concentration of 10 mg/mL of peptide dissolved in water, but after 
we did not see any precipitation we gradually went up to 60 mg/mL. Although we used several 
screen sets with each contained 96 different conditions, we were not able to get suitable crystals 
for X-ray analysis. Typical results were the precipitation of a solid from the drop (a, Figure 35) 
or a phase separation in the drop, in which the protein separated from the aqueous layer (b). 
Sometimes we also obtained promising crystals such as depicted in c, and the enlargement in 
cross-polarized light in d, but always the crystals were salts resulting from the precipitant and no 
peptide.  
Further attempts for the crystallization should consider modifications on the 4-hydroxyproline 
oligomer anchor such as different rigid groups on the amine or replacement of the amide group 
on the C-terminus by a carboxyl group. 
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Figure 35: Representative images of drops containing 4-hydroxyproline oligomer 2.24. a) 0.1 M NaOAc 
4.5 pH, 0.2 M ZnOAc 10 %w/v PEG 3K. b) 1.6 M Na3Cit. c) 0.17 M (NH4)2SO4, 15 %v/v glycerol, 25.5 
%w/v PEG 4K. d) Enlargement of c) imaged with cross polarized light.  
a b
c d
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2.17 Conclusion  
Our results demonstrate the functionalization the alga C. reinhardtii with the antibiotic van-
comycin. We prepared conjugates between vancomycin and a 4-hydroxyproline oligomer by a 
combination of solid- and solution-phase peptide synthesis. The antimicrobial activity against the 
Gram-positive bacteria B. subtilis decreased in comparison to the parent antibiotic vancomycin, 
but still showed satisfying activities (MIC = 4—8 µg/mL). We immobilized the conjugates on the 
surface of the algae by a simple incubation protocol followed by washing of the cells. Important 
parameters for attachment to the surface were concentration of the incubation solution and incu-
bation time. Both parameters also affected the motility of algae to great extent, so that the pa-
rameters had to be optimized until loading of compound on the surface was sufficient and the 
cells still showed good viability.  
The modified algae were tested in bacterial assays against B. subtilis for their antimicrobial 
properties. It was shown that the modified algae were able to kill the bacteria by transferring the 
substance from the surface of the algae to the cell wall of the bacteria. This process was mainly 
regulated by diffusion, as we observed reversibility for the attachment of the substance to the 
surface. Fluorescently-labeled conjugate 2.19 showed much stronger attachment to the surface 
compared to unlabeled conjugate 2.21, indicating that the 4-hydroxyproline oligomer alone is not 
the main contributor for the attachment of the substances to the cell wall. On the contrary, the 
binding of the conjugates is more complex and the compounds as a whole contribute to this.  
Overall we have shown, that the cell wall of a living cell can be modified by chemical means. 
Our system might be transferred to different cells or viruses resulting in the introduction of dif-
ferent phenotypes. Further research is necessary to better understand the factors that contribute to 
the binding of the conjugates. This could be investigated by the replacement of vancomycin by 
other therapeutic materials or by modification of the 4-hydroxyproline oligomer anchor (intro-
duction of other functional groups to the peptide e.g. free amines).  
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3 Synthesis of Pyrrolizidines 
3.1 Introduction 
3.1.1 Biological relevance of pyrrolizidine alkaloids 
Pyrrolizidine alkaloids are a large class of natural products with about 600 representatives 
known.[104-106] Exclusively produced in plants, these natural products are found in about 6000 
different species, meaning that 3% of all flowering plants contain pyrrolizidine alkaloids. The 
majority of these compounds are isolated from the distantly related angiosperm plant families: 
Asteraceae, Boraginaceae and Fabaceae.[107] Central motif of pyrrolizidine alkaloids is two 
fused cyclopentane rings with a nitrogen atom at the bridgehead (Figure 36). Many of these het-
erocycles occur in oxidized forms such as the N-oxide or the 1,2-unsaturated and a fair amount 
of alkaloids also have a 3H-pyrrolizin-3-one substructure. 
 
 
Figure 36: Pyrrolizidine alkaloids substructures in natural products. 
 
With their isolation source often playing an important role in traditional medicine, pyrrolizidine 
alkaloids are often biologically relevant, exhibiting a variety of activities such as hepatotoxic, 
pulmotoxic, antimitotic, mutagenic or carcinogenic. For example, cremastrine 3.01 has been 
shown to be one of few compounds binding selectively to muscarinic M3 receptors,[108] and it 
has been proposed that selective blockade of M3 receptors might be useful in the treatment of 
respiratory disorders (Figure 37).[109] UCS1025A 3.02 was isolated from the fungus Acremonium 
sp. KY917[110] and showed antiproliferative activity against human tumor cell lines.[111]  
 
Figure 37: Biologically active pyrrolizidines. 
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1,2-Dehydropyrrolizidines such as monocrotaline 3.03 are potent hepatotoxins because they are 
readily oxidized to the corresponding pyrrole intermediates (Scheme 28). This reaction is cata-
lyzed by microsomal cytochrome P450 enzymes mainly localized in the liver and lung tissues. 
The highly reactive intermediates subsequently mediate the interstrand cross-linking of DNA to 
form bis-alkylated adducts such as 3.05 (Scheme 28).[112,113] To protect themselves against these 
toxic alkaloids, arctiids[114] and Zonocerus[115] store pyrrolizidines exclusively in the N-oxide 
state.[116] 
 
Scheme 28: Crosslinking of DNA with formation of reactive pyrrole intermediates. 
 
Another way of preventing this aromatization is the introduction of a substituent on the 7a-
position of the pyrrolizidine ring. Biologically relevant structures with this feature are the musca-
rinic receptor antagonist 3.06 identified by Suzuki et al.[117] or the mixed α7-nicotinic receptor 
antagonist 3.07 prepared and tested by Reymond and co-workers (Figure 38).[118,119] 
 
 
Figure 38: Biologically active 7a-substituted pyrrolizidine alkaloids. 
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3.1.2 Known synthetic methods for the preparation of 7a-substituted carboxamides 
In the course of a study on the synthesis of a natural product, we became interested in struc-
tures such as 3.08, which carry an amide group directly connected to the pyrrolizidine core. The-
se 7a-substituted pyrrolizidine carboxamides, are interesting structural motifs that lack direct 
approaches for their synthesis. 
  
 
There have been indirect syntheses of precursors reported towards 7a-substituted pyrrolizidine 
carboxamides. The first reaction sequence towards the precursors was reported by Suzuki and co-
workers and starts with the synthesis of nitrile-substituted pyrrolizidine 3.10 by condensation 
and reaction of ketone 3.09 with ammonia and potassium cyanide (Scheme 29).[120] For the syn-
thesis of a 7a-substituted carboxamide, the nitrile group of pyrrolizidine 3.10 needs to be hydro-
lyzed to the acid followed by peptide coupling to the corresponding amide.  
 
 
Scheme 29: Synthesis of 7a-substituted pyrrolizidine by Suzuki and co-workers. 
 
Another strategy furnished pyrrolizidines substituted with an ester group at the 7a-position by 
Cordero et al. The reaction sequence started with a 1,3-dipolar cycloadditon of α,β-unsaturated 
amide 3.11 with pyrroline N-oxide 3.12 to furnish the isoxazolidine 3.13 (Scheme 30). These 
compounds are then hydrogenated with a palladium hydroxide catalyst on charcoal to open pyr-
rolidine 3.14, which subsequently cyclized to the pyrrolizidinone 3.15. Hydrolysis of the ester 
group, followed by peptide coupling would give the desired amide functionality as in the previ-
ous example. 
N
NHO
R
7a-substituted 
pyrrolizidine carboxamide
3.08
O
ClCl
NH3, KCN
N
CN
N
NHO
R
3.09 3.10
7a-substituted 
pyrrolizidine carboxamide
3.08
CHAPTER 3 
 
68 
 
Scheme 30: Synthesis of pyrrolizidinone with ester group on the 7a-position. 
 
A third preparation procedure was published by Sansano et al. and utilizes a three component 
reaction involving proline ester 3.16, an α,β-unsaturated aldehyde 3.17 and methyl acrylate 3.19 
(Scheme 31). This reaction involves the in situ preparation of an iminium ion 3.18, which forms 
a 5-membered ring by addition to methyl acrylate. In one step, highly substituted pyrrolizidines 
(3.20) can be obtained with good regio-and diasteroselectivity. An interesting extension of this 
method would be the exchange of the proline ester by an amide-functionalized proline. This 
would provide 7a-substituted pyrrolizidines in a very concise manner.  
 
 
Scheme 31: Three-component reaction for the preparation of 3.20.  
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3.2 Project outline 
The objective of the project was to evaluate the direct preparation of 7a-substituted pyrroliz-
idine alkaloids from simple building blocks. The building blocks we wanted to employ were 
pyrrolines, carrying a hydroxyl group on the side chain and isonitriles as the reaction partner 
(Scheme 32). The primary goal was the investigation of the reaction scope, as it is desirable to 
have direct access to pyrrolizidines with different steric and electronic properties. Furthermore, 
we wanted to investigate the functionalization of the final molecules to access oxidized and re-
duced derivatives at a late stage. Finally, it was desirable to extend the reaction to elaborated 
pyrroline precursors to give access to functionalized derivatives of the pyrrolizidine core. 
  
Scheme 32: Synthesis of 7a-substituted pyrrolizidines from pyrroline imines and isonitriles 
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3.3 Synthesis of the pyrroline building block 
We started with the synthesis of pyrroline 3.21 of which a synthetic route had been reported in 
the literature (Scheme 33).[121,122] Ester 3.24 was hydrolyzed with potassium hydroxide to 3.25, 
which was esterified using sulfuric acid and methanol. Next, N-vinylpyrrolidinone was reacted 
with ester 3.26 in a Claisen condensation to yield N-vinylpyrrolidine-2-one 3.28 in 40% yield 
instead of the reported 96%.[123] This compound was treated with HCl under reflux to hydrolyze 
the vinyl group, decarboxylate, deprotect and form the pyrroline. This reaction has been per-
formed only one time and difficulties occurred with the addition of 3.28 to boiling hydrochloric 
acid with a syringe pump because the needle started to corrode. The reported yield of 95% was 
not reached.  
 
 
Scheme 33: Literature known route to pyrroline 3.21.[123] 
 
Due to the long procedure, difficulties with the last step and low yields for the last two steps, 
we decided to investigate a more direct access to 3.21. We found that when 2-methyl pyrroline 
was deprotonated with LDA and ethylene oxide as a solution in THF was added, imine 3.21 was 
obtained in reasonable yield (Scheme 34). This demonstrates a very direct method for the syn-
thesis of the precursor. 
 
 
Scheme 34: More convenient synthesis of pyrroline 3.21.  
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3.4 Initial cyclization experiments 
For an initial test of the reaction we prepared phenylisonitrile 3.31 by Hofmann carbylamine 
reaction using tetrabutylammonium bromide as a phase transfer catalyst, sodium hydroxide as a 
base and chloroform (Scheme 35). 
 
Scheme 35: Synthesis of phenylisonitrile 3.31 by Hofmann carbylamine reaction. 
 
Next, we reacted pyrroline 3.21 with 3.31 under acidic conditions and elevated temperatures 
(Scheme 36). Fortunately, pyrrolizidine 3.32 could be isolated, but rather in low yield. The struc-
ture of 3.32 was confirmed by a single X-ray crystal structure (Figure 39). 
 
 
Scheme 36: Initial attempt for the synthesis of 7a-substituted pyrrolizidine. 
 
 
 
Figure 39: Single crystal X-ray structure of 3.32. 
 
N
C
NH2
nBu4NBr, NaOH, CHCl3
CH2Cl2
3.30 3.3157%
N
OH
Et3N HCl
toluene, 110°C
N
C
N
NHO
25%3.21 3.31 3.32
CHAPTER 3 
 
72 
To improve the yield, we tried other mild acids such as secondary ammonium salts as well as 
pyridinium chloride. The best yields were obtained with tertiary ammonium salts, with the initial 
triethylamine hydrochloride giving the best results.[124,125] To get the reaction to completion, high 
temperatures were required, but DMF or DMSO gave lower yields than toluene. With an adjust-
ment of the reactant equivalents we were able to improve the yield from 25% to 46% for com-
pound 3.32.  
 
3.5 Synthesis of the isonitrile building block 
To investigate the scope of the pyrrolizidine synthesis we prepared a number of aromatic 
isonitriles by the previously used method. We chose electron withdrawing as well as electron 
rich substituents and those that had different steric effects (Scheme 37). 
 
 
Scheme 37: Aromatic isonitriles prepared by the Hoffman carbylamine synthesis. 
 
Further, we prepared isonitriles from L-amino acids (also isocyanoacetates) in a two-step pro-
cedure (Scheme 38). First, the amino group was formylated using either peptide coupling condi-
tions with formic acid, dicyclohexylcarbodiimide and base[125] or by subjection to trimethyl or-
thoformate.[126] Dehydration of the formylamines was executed with the use of triphosgene at -78 
°C. Phosphoryl chloride can also be used for this transformation, but in the case of chiral sub-
strates led to racemic isonitriles.[127] 
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Scheme 38: Amino acid-based isonitriles. 
 
In addition to the afore mentioned isonitriles, we purchased the commercially available com-
pounds 3.50, 3.51 and 3.52 and prepared the sterically demanding derivative 3.53 according to a 
literature known procedure in three steps and 73% overall yield (Scheme 39).[128] Isonitrile 3.54 
was prepared in two steps and 24% overall yield. 
 
 
Scheme 39: Commercial isonitriles and sterically demanding isonitrile 3.53 and isonitrile 3.54.[128] 
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3.6 Reaction scope22 
With the isonitriles in hand we investigated the scope of the reaction (Scheme 40). The reac-
tion was found to tolerate a variety of isonitriles. For aromatic isonitriles the yield varied from 
good to moderate depending on the electronic properties. The reaction with electron-donating 
isonitriles gave the products 3.55, 3.56, 3.57, and 3.58 in higher yields than electron-poor isoni-
triles, which delivered the products 3.59, 3.60, 3.61, and 3.62. Surprisingly, the sterically de-
manding example 3.63 was observed in higher yield than product 3.32 from the reaction with 
phenyl isonitrile. A reason for this might be the positive inductive effect of the methyl group in 
the para-position, and of the phenyl group in the ortho-position on the aromatic ring. Aliphatic 
isonitriles were also tolerated in this reaction, albeit in lower yield. For example, compound 3.64 
bearing a morpholine ring was obtained in low yield. In contrast, unprotected phenols such as 
3.56 or benzyl-substituted pyrrolizidine carboxamide 3.66 could be obtained in good yield. Fur-
ther, the sterically more demanding α-methylbenzyl isocyanide gave product 3.67 in slightly 
lower yield than benzyl isocyanide indicating that steric factors influence the outcome of the 
reaction to some extent. On average the best yields were obtained using isocyanoacetates. In this 
respect, the highest yield was obtained for the tryptophan related product 3.68 as well as for va-
line derivative 3.73. The reaction towards pyrrolizidine 3.73 could be performed in the presence 
of 10 equivalents of water and product formation was still observed, albeit in lower yield (45%). 
Aromatic (to deliver product 3.70), as well as aliphatic amino acids containing heteroatoms (to 
deliver products 3.71 and 3.72) were also reacted in good yields.  
 
                                                
22 These results were published in I. P. Kerschgens, K. Gademann Synthesis 2015, 47, 3153-3160. 
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Scheme 40: Scope of isonitriles for the construction of 7a-substituted pyrrolizidine carboxamides. 
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Unfortunately, the isocyanoacetates suffered from complete racemization under the reaction 
conditions which is known to be a common issue in other similar transformations such as the Ugi 
reaction.[129] Due to the two electron withdrawing groups, the α-CH has a moderate acidity (pKa 
= 9–11) and can be easily deprotonated by weak bases (Scheme 41). Mechanistically, the race-
mization can occur directly on the isocyanoacetates by enolization (A) or during the reaction (B). 
In the latter, racemization occurs after formation of the nitrilium ion 3.76 by attack of the isoni-
trile on an iminium ion and during oxazole formation 3.77. The oxazole formation is reversible 
so that the racemic isocyanoacetate is obtained in the end. To investigate whether racemization 
potentially takes place before the reaction, we subjected optically pure isonitrile 3.80 to the reac-
tion conditions without pyrroline 3.21 and heated it for 24 h under reflux (Scheme 42). Chiral 
HPLC revealed that complete racemization occurs already on the isonitrile precursors. It can be 
concluded that full racemization occurs even before product formation. Isonitrile 3.52, however, 
is configurationally stable and pyrrolizidine 3.67 is observed in optically pure form.23  
Limitations of the scope displayed isonitriles with strong electron withdrawing substituents 
such as nitro- or CF3-groups.  
 
                                                
23 Isonitrile 3.52 has a drastically reduced α-CH acidity, due to lack of the ester group. 
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Scheme 41: Two mechanisms for the racemization of isocyanoacetates substrates. 
 
 
Scheme 42: Racemization of isocyanoacetate 3.48. Racemization already takes place without addition of 
the pyrroline. 
 
 
3.7 Mechanistic investigations 
Mechanistically, the reaction can proceed via several pathways, of which two are shown in 
Scheme 43. Pathway A starts with protonation of the pyrroline to the corresponding iminium ion 
3.80 and subsequent attack of the isonitrile resulting in nitrilium ion 3.81. This intermediate 
could be intramolecularly trapped by the primary alcohol to give Spiro-intermediate 3.82. To 
proceed to the pyrrolizidine, intermediate 3.82 needs to be opened by the pyrrolidine nitrogen on 
the C-O-bond of the imidate. Another possible mechanistic pathway involves protonation of the 
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alcohol (to 3.83) followed by elimination of water to pyrrolizidinium salt 3.84. The isonitrile can 
then proceed via nucleophilic attack on pyrrolizidinium ions, as has been shown previously with 
cyanide.[130,131] The resulting nitrilium ion 3.85 can be converted to the amide with water that 
was liberated earlier in the sequence. Both mechanisms involve certain unusual transformations. 
Whereas pathway A requires a HOMO-LUMO interaction of the N lone-pair and the σ*-orbital 
of the C-O bond in intermediate 3.82 for a successful outcome of the intramolecular reaction, 
pathway B involves formation of the highly reactive intermediate 3.84 with loss of water. 
 
Scheme 43: Two possible mechanistic pathways for the formation of 7a-substituted pyrrolizidines. 
 
 
To investigate whether one of the two mechanisms applies to our reaction we performed a se-
ries of stable isotope labeling experiments and mass spectrometric detection. Key feature of our 
analysis is the performance of our reaction in presence of excess 18O-labeled water. Following 
pathway B, incorporation of H218O would be obtained by hydrolysis of nitrilium ion 3.83. On the 
other hand, following pathway A, the amide bond is formed intramolecularly thus excluding 
incorporation of external water. The reaction was performed using 10 equiv. of 18O-labeled wa-
ter under the normal reaction conditions. The product was purified and analyzed by HR-MS 
(ESI) (Scheme 44). 
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Scheme 44: Isotope incorporation experiments. 
 
The mass spectra show an enhanced isotope peak of 261.18, which corresponds to a ∼13% in-
creased isotope peak of the 18O-labeled derivative (Scheme 44). This indicates that the reaction 
more likely proceeds via pathway B involving pyrrolizidinium ion formation. This finding is 
supported by earlier reports describing the formation of stable pyrrolizidinium salts, although 
from different precursors.[130-132] 
To further prove this hypothesis, we designed a number of control experiments that primarily 
pursued the goal of isolation of the pyrrolizidine salt 3.84 or its reduced form. In the first exper-
iment, we reacted imine 3.21 under the reaction conditions of our pyrrolizidine formation reac-
tion (Scheme 45). Subsequently, we added lithium aluminum hydride to potentially isolate the 
corresponding pyrrolizidine 3.87. Unfortunately, the reaction only resulted in a complex mixture, 
which indicated towards a decomposition of the starting material under these conditions. 
 
 
Scheme 45: Attempted formation of the pyrrolizidinium salt followed by reduction. 
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Further we attempted to isolate pyrrolizidinium salt 3.88 by subjection to the reaction condi-
tions followed by NMR analysis (Scheme 46). The proton NMR showed exclusively the pres-
ence of starting material and not cyclized product in the mixture. 
 
Scheme 46: Attempted isolation of pyrrolizidinium salt 3.88. 
 
Another experiment to discriminate between pathway A and B is the isotopic labeling of pyr-
roline 3.21 with an 18O-isotope to give pyrroline 3.89 (Scheme 47). Pyrroline 3.89 would be used 
as a normal substrate in the reaction, but the reaction would be carried out in the presence of 
unlabeled water (e.g. 10 equiv.). Following pathway A would result in a 100% incorporation of 
18O into the product, because the oxygen never leaves the substrate. In pathway B, however, wa-
ter is released during the mechanism, which later re-attacks on intermediate 3.85. When the reac-
tion is performed in the presence of unlabeled water we would observe a mixture of isotopes of 
the product.  
 
 
Scheme 47: Isotopic discrimination between pathway A and B with isotopically labeled pyrroline 3.89. 
 
We assumed that the 18O-labeled pyrroline 3.89 could be synthesized by mesylation of pyr-
roline 3.21 in situ, followed by addition of 18O-labeled water. The heavy water could substitute 
the mesylated hydroxyl group to give isotopically labeled 3.89 (Scheme 48). 
 
 
Scheme 48: Planned synthesis of 18O-labeled pyrroline. 
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stirred for 30 min at 0 °C and then warmed the reaction mixture to room temperature. The crude 
NMR of the reaction mixture was very complex, even though no water was added at this point. 
In the next experiment, we lowered the temperature to –20 °C and quenched with water after 
stirring for 30 min. The crude NMR revealed the presence of a pyrrolizidinium salt a and the 
pyrroline b, although it was not clear whether the pyrroline was unreacted starting material or 
resulted from replacement of the mesyl-group by water. Encouraged by this result we wanted to 
increase the product ratio in favor of the pyrroline b. We assumed an improvement would be to 
lower the freezing point of the aqueous solution so that it does not freeze the moment when it is 
added to the reaction mixture. We used a 4 N CaCl2 solution and the more nucleophilic KOH 
(20%) solution. For both cases we observed formation of the pyrrolizidinium salt and only minor 
amounts of the pyrroline. Attempts to isolate the pyrroline were not successful. 
 
Table 6: Initial experiments towards isotope incorporation. 
 
 
 
 
 
 
 
 
 
 
 
3.8 Other related transformations 
3.8.1 Pyrrolidine synthesis 
Extending this method to pyrroline 3.91 carrying a tertiary hydroxy group on the side chain, 
pyrrolidine derivatives 3.92 and 3.93 were obtained as a 2.1:1 mixture of prenylated pyrrolidine 
and its Δ3,4-isomer, respectively, instead of pyrrolizidine formation (Scheme 49).  
N
OH
MsCl, Et3N
N
OMs
3.90
H2O
N
X-
3.21
mostly formation 
of pyrrolizidinium 
salt
N
OH
also formed, but 
could not be 
isolated
a b
CH2Cl2
Entry Conditions a : b 
1 0 °C to RT Complex mixture 
2 -20 °C, quenched with H2O 2.6:1 
3 -20 °C, quenched with CaCl2 (4N)/MeCN, 4 h 2.8:1 
4 -20 °C, quenched with KOH (20%)/MeCN, 2 h Complex mixture 
5 -20 °C, quenched with KOH (20%)/MeCN, 5 min 1:0 
CHAPTER 3 
 
82 
 
Scheme 49: Reaction of pyrroline 3.91 leads to pyrrolidine formation. 
 
Mechanistically, this transformation could proceed similar to the formation of pyrrolizidines 
by an intramolecular mechanism involving an imidate intermediate 3.96 (pathway A), or by 
elimination of water and hydrolysis of nitrilium ions 3.98 and 3.99 (pathway B) (Scheme 50). 
Pathway A would be facilitated by a Thorpe-Ingold effect of intermediate 3.97. To investigate 
the mechanism we applied the previous conditions and performed the reaction with 10 equiva-
lents 18O-labeled water. The 18O-isotope was only enhanced by 0.1%. This strongly indicates for 
pathway A, as for pathway B we would expect a higher 18O-abundance caused hydrolysis in the 
last step. 
 
Scheme 50: Two mechanisms for the formation of pyrrolidines from pyrrolines.  
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Further, we tried to isomerize the double bond of isomer 3.93 to the thermodynamically more 
stable isomer 3.92. We performed NMR-experiments in deuterated solvents using dimethyl ter-
ephthalate as an internal standard. The results are shown in Table 7. First, we attempted the 
isomerization with p-toluene sulfonic acid, a common reagent for the isomerization of double 
bonds.[133,134] At stoichiometric amounts of acid in benzene at 60 °C we observed decomposition 
of isomer 3.93 but no isomerization. In methanol under similar conditions no reaction occurred. 
When the temperature was raised and toluene was used for a longer reaction time, we observed 
decomposition of both isomers. Changing to catalytic amounts of acid only led to decomposition 
of isomer 3.93. Then we changed the isomerization reagent to RhCl3[135] and observed similar 
results as with the p-toluene sulfonic acid, as that no successful isomerization was observed.  
 
Table 7: Isomerization attempts of 3.93 to 3.96. 
 
Entry Reagent Solvent T t Heating Observation 
1 pTSA (4.0 equiv) Benzene-d6 60 1 h Δ 3.93 decomposed 
2 pTSA (4.0 equiv) CD3OD 60 24 h Δ No reaction 
3 pTSA (2.2 equiv) CD3OD 40 24 h Δ No reaction 
4 pTSA (1.0 equiv) Toluene-d8 110 5 d Δ Decomposition 
5 pTSA (0.05 equiv) Toluene-d8 110 3 d Δ 3.93 decomposed 
6 RhCl3 (1.2 equiv.) CD3OD 60 24 h Δ No reaction 
7 RhCl3 (0.5 equiv.) CD3OD 100 1 h µw Decomposition  
8 RhCl3·H2O CD3OD 65 1 d Δ 3.93 decomposed 
 
3.8.2 Indolizidine synthesis 
Next, we attempted an extension of our method to the related indolizidine alkaloids. This 
group of 5/6-fused cyclic alkaloids represents a large class of natural products and biologically 
relevant lead structures.[136,137] 
For their synthesis we first had to prepare the imine precursor. We envisioned the synthesis of 
two precursors: 1) tetrahydropyridine 3.102 with three CH2 units on the side chain and 2) pyr-
roline 3.103 with four CH2 units on the side chain (Scheme 51). For the first precursor we want-
ed to start from 6-methyl-2,3,4,5-tetrahydropyridine by deprotonating and opening of ethylene 
oxide according to the synthesis of 3.21. Under various conditions, using Lewis acids, and dif-
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ferent bases, only very complex reaction mixtures were obtained. We then proceeded to the syn-
thesis of pyrroline 3.103, which was prepared by subjection to LDA, oxetane and boron trifluo-
ride diethyl etherate, albeit in low yield. 
 
Scheme 51: Synthesis of imine precursor. 
 
We then subjected pyrroline 3.103 to isonitrile 3.46 under the reaction conditions previously 
developed (Scheme 52). The indolizidine could be isolated in low yield and with minor contami-
nations.24 Although the desired product was formed, we decided not to proceed further with the 
investigation of indolizidines, because of the low yield and difficulty with the preparation of the 
starting material. 
 
 
Scheme 52: Formation of indolizidine 3.104 with pyrroline 3.103. 
 
3.9 Further transformations 
As an extension of the pyrrolizidine formation reaction, we were able to further functionalize 
pyrrolizidine 3.32 (Scheme 53). The first transformation is the oxidation of the pyrrolizidine core 
at the 3-position according to a procedure developed by Schäfer and co-workers using benzyltri-
ethylammonium permanganate.[138] In this publication, the authors describe the oxidation of sim-
ple long-chain alkyl amines as well as N,N-alkylanilines. A direct oxidation at the 3-position on 
the pyrrolizidine core has not been previously described and makes our report the first of its 
kind. As a mild oxidant, benzyltriethylammonium permanganate delivers the 3H-pyrrolizin-3-
one product 3.105 in good yield, allowing rapid access to these biologically relevant oxidized 
alkaloids.[114,115]  
                                                
24 Analysis by NMR and HR-MS (ESI). 
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Further, the tertiary nitrogen can be oxidized to furnish the corresponding N-oxide 3.106. 
Functionalization based on the N-oxide derivative by Polonovski-Portier or Cope elimination 
protocols showed no reactivity of 3.106. This might be due to the stability of the pyrrolizidine 
core that could have to be transferred to the strained unsaturated form in both reactions. In addi-
tion, in the case of a Cope elimination, the proton on the 2-position might be intramolecularly 
inaccessible for the nitroxide.  
Further, we reduced the amide functionality of 3.32 with Red-Al® to the secondary amine in 
quantitative yield.[111] As highlighted in the introduction of this chapter, these structures have 
been identified to show binding affinities for the central muscarinic cholinergic receptor and 
therefore represent lead structures for the treatment of neurodegenerative diseases.[139] 
 
Scheme 53: Further functionalization of pyrrolizidine 3.32. 
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3.10 The NMR that did not match 
During studies towards the synthesis of 3.107 we discovered a mismatch of the NMR spec-
troscopy data between two different experiments, which actually should result in the same prod-
uct. In one experiment we purified 3.107 by column chromatography using a CH2Cl2/MeOH 
eluent, in the other experiment no chromatographic purification was necessary after extraction 
with NaOH/Et2O. When we compared the analytical data of the two experiments we found that, 
the proton NMR spectrum of the first experiment differed significantly from the second experi-
ment in that the protons next to the amine were shifted downfield by 0.5 ppm. In addition, the 
CH2-protons next to the aniline nitrogen were also shifted. After some experimentation we found 
that when the non-chromatographed sample was subjected to a CO2 stream in deuterated metha-
nol the resulting NMR spectrum corresponded to the sample that had been chromatographed 
(Scheme 55). In the 13C-NMR spectra differences were also visible in the change of some of the 
peaks and the appearance of a new peak at 161.6 ppm (Scheme 56). From this we concluded that 
diamine 3.107 reacts with CO2 (Scheme 54). We also found that this process is reversible be-
cause when the solution previously charged with CO2 was heated to 65 °C for 15 min we ob-
tained back the starting material before CO2 treatment. CO2 binding of amines generally occurs 
in two ways, either as a carbamate 3.108 or by bicarbonate formation (3.109) when water is pre-
sent. The 13C-chemical shift of a carbamate and bicarbonate are very similar, so that from the 
NMR analysis at this stage it cannot be determined in which form CO2 is fixed by 3.107. Our 
investigation on the CO2-binding properties of pyrrolizidine diamines will be described in the 
next chapter.  
 
 
Scheme 54: Pyrrolizidine 3.107 reacts reversibly with CO2. 
N
N
H
CO2
CO2
N
N
OOH
MeOH, rt, 5 min
MeOH, 65°C, 15 min
3.107 3.108
or HN
N
H
HCO3-
3.109
 Synthesis of Pyrrolizidines 
87  
 
Scheme 55: 1H-NMR spectra of pyrroline 3.107. a) Before CO2-treatment. b) After CO2-treatment, with 
the bicarbonate salt form shown. 
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Scheme 56: 13C-NMR spectra of pyrroline 3.107. a) Before CO2-treatment. b) After CO2-treatment, with 
the bicarbonate salt form shown. The additional 13C-signal at 126.3 ppm is CO2 dissolved in CD3OD. 
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3.11 Conclusion 
This chapter described our efforts towards the construction of 7a-substituted pyrrolizidines. 
Due to their broad diversity and their crucial role in plants and animals pyrrolizidine alkaloids 
have been relevant in medicine and biology, and were also an interesting target for chemical syn-
thesis at the same time. However, very few methods for the construction of 7a-substituted pyr-
rolizidines have been reported and there was no previous example that allowed for the direct 
preparation of 7a-substituted pyrrolizidine carboxamides. 
We have demonstrated that these structures can be synthesized in a single step starting from a 
pyrroline and with various isonitriles. The reaction was robust and tolerated a wide scope of 
isonitriles, affording a diverse variety of pyrrolizidine alkaloids within few synthetic operations. 
The products were further functionalized by oxidation and reduction protocols, and were able to 
extend the reaction principle using modified imine precursors for the construction of pyrrolidines 
and indolizidines. And finally, the diamine resulting from reduction of the amide group reacted 
with CO2 in a reversible manner. The binding properties of CO2 for this and related pyrroliz-
idines are investigated in the next chapter. 
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4 Application of Pyrrolizidines in Carbon Dioxide Capture 
4.1 Introduction 
The drastic increase of the global atmospheric and oceanic temperature since the beginning of 
the industrial revolution, will potentially lead to severe consequence for the environment and 
human beings.[140] In the northern hemisphere, the last three decades have been the warmest 
since 1400 years (Figure 40, a). The largest contribution to global warming is caused by atmos-
pheric CO2[140] that increased by almost one third in the last 40 years and shows a clear correla-
tion between CO2 emission and increase in global temperature (Figure 40, b). Major reason for 
the drastically raised CO2 level is the combustion of fossil fuels such as coal, oil and natural 
gas.[141] On the other hand, tropical forests and other woods and green surfaces are cleared,[142] 
which leads to an even stronger imbalance in our atmosphere. The development of sustainable 
alternatives is a strongly developing field, however, many processes and applications still depend 
on the use of fossil fuels.[143] On the other hand, CO2 is an important feedstock, which can be 
used directly in applications such as fire extinguishers, solvent for extraction of substances and 
fragrances or as a cleaner of electronics.[144] These applications only provide a short-term remov-
al of CO2 from the air, but no reduction of the global CO2-levels. More effective in this respect is 
the conversion of CO2 into products with added value thereby utilizing CO2 as a C1-building 
block for chemical synthesis.[145] 
a!
!
b!
!
Figure 40: a) Temperature anomaly in land and ocean (1850-2012) by annual and decadal average.  
b) Increase of atmospheric CO2 over the last three decades. Source: IPCC report 2013.[140] 
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4.1.1 Capture of CO2 
The starting point for all utilization applications is the isolation of CO2 from the atmosphere 
(or a flue gas stream) also termed Carbon Capture and Storage (CCS). Among several techniques 
available for this process,[146] the major industrial technology for the capture of CO2 from gas 
streams is the use of chemical absorbents. The most efficient absorbents are amine solutions that 
can consist of only one component but can also be combined with each other to form mixtures. A 
general flow chart of this process is depicted in Scheme 57. The CO2-enriched gas enters the 
reactor containing the amine solution, most of the time in a solution of water. The CO2 content 
of the gas is captured by the amine absorbent and the remaining gas is released to the atmosphere 
or used for further purposes. The amine solution, now enriched with CO2, is transferred via a 
heat exchanger to the stripper, thereby being warmed to some extent. In the stripper, the amine 
solution is heated up to 120 °C to release the captured CO2 which is cooled down and exits the 
plant for further purposes. Passing the heat exchanger and one further amine cooler lowers the 
temperature of the hot amine solution. The solution is finally transferred back to the amine reac-
tor to reenter the absorption/desorption cycle. 
 
 
Scheme 57: Representation of an amine plant used for the removal of CO2 from gas mixtures or flue 
gas.25  
 
The process is widely established and serves for the purification of flue gas, natural gas or gas 
streams for the chemical industry. Main drawback of this process is the degradation of the amine 
solution resulting in solvent loss, corrosion and generation of volatile degradation com-
                                                
25 http://www.jouleprocessing.com/products/treating/amine-plants (2.12.2016) 
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pounds.[147,148] Further, high temperatures are usually required for removal of CO2 from the 
amine solution leading to immense energy costs and make this system inapplicable for the puri-
fication of flue gas from coal-fired power plants. It has been estimated that a coal plant needs to 
take a 81% increase of its electricity costs to capture 90% of its flue gas CO2 using a standard 
amine absorbent.[149] Thus, the high energy costs prevent this process from being used for the 
removal of CO2 from the flue gas of its biggest producers. 
 
4.1.2 Amines for CO2-capture 
The amines used for the capture of CO2 are usually simple, linear amines such as (methyla-
mino)propylamine (MAPA) or alcoholamines such as aminoethylethanolamine (AEEA), dieth-
anolamine (DEA) or the most common CO2-absorbent monoethanolamine (MEA) (Figure 41). 
Some amines are also branched such as triethanolamine (TEA) or cyclic such as piperazine (PZ). 
Besides the already established absorbents, there have been a number of new compounds with 
different binding concepts developed. These structures involve heterocycles such as melami-
ne[150], ionic liquids including pyridines[151], or the use of amidine bases in combination with 
alcohols.[152] The substances employ different mechanisms for the formation of the CO2-adducts. 
In general, CO2 can be fixed by amines in two ways either as a carbamate or as a bicarbonate salt 
(Scheme 58). For the first binding mode with primary amines, two molecules of amine absorbent 
are required to fix one molecule CO2. This is based on the fact that one amine molecule binds 
CO2 as a carbamate and the other acts as a base, together they form a counterion pair. When CO2 
is fixed as a bicarbonate salt, usually tertiary amines are employed in the presence of water. This 
sort of binding leads to a 1:1 stoichiometry requiring only one molecule of amine absorbent to 
capture one molecule of CO2. However, because the binding is ionic, these absorbents do not 
always reach an equimolar uptake. 
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Figure 41: Industrially used absorbents and other absorbents for the capture of CO2. 
 
 
Scheme 58: CO2-Binding modes by different classes of amine absorbents. 
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4.1.3 Pyrrolizidines for CO2-capture 
In the previous chapter we described the capture of CO2 by pyrrolizidine diamine 3.107. In 
principle, CO2 can be bound by 3.107 in two ways, either as a carbamate or as a bicarbonate salt 
(Scheme 59).  
 
 
Scheme 59: Pyrrolizidine 3.107 can bind CO2 by formation of a carbamate or a bicarbonate. 
 
In the literature, the pyrrolizidine alkaloid temuline, isolated from the plant Lolium temulen-
tum, has been reported to bind CO2 in the carbamate form as has been confirmed by X-ray crys-
tallography (Scheme 60).[153] 
 
 
Scheme 60: Reaction of pyrrolizidine alkaloid temuline leads to carbamate 4.08. 
 
Pyrrolizidines such as the ones reported above provide a nucleophilic nitrogen and a basic 
amine, which both can assist each other in the fixation of CO2. This would lead to a 1:1 stoichi-
ometry by binding of one CO2 unit per equivalent absorbent (Scheme 61). An additional ad-
vantage in comparison to conventional absorbents such as monoethanolamine is the three-
dimensional architecture of the molecule provided by the pyrrolizidine backbone, generating a 
certain rigidity in the molecule. Besides the report on pyrrolizidine temuline, pyrrolizidines are 
completely unexplored for the capture of CO2. 
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Scheme 61: Pyrrolizidines provide bifunctionality and a molecular architecture that might be beneficial 
for the capture of CO2.  
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4.2 Project outline 
This project takes up the finding of the previous chapter, where we discovered that compound 
3.107 reacts with CO2 in a reversible manner. Naturally, the question on the nature of the pyrrol-
izidine-CO2 adduct arises. Further, the efficiency of the CO2 uptake has not been investigated. 
We presumed that the three-dimensional architecture of the pyrrolizidine derivative with its pyr-
rolizidine backbone and the bended side-chain with a second amine could be beneficial for the 
CO2 uptake. An additional feature could be that the two amine groups assist each other in the 
uptake process and may provide advantage compared to linear analogues.  
Our first aim for this project was to synthesize derivatives of pyrrolizidine 3.107 with different 
substituents on the amine and with different CH2-chain lengths. Further, we wanted to investi-
gate to which extent and in which form these derivatives bind CO2. An important parameter in 
this investigation was the reversibility of the CO2-binding and the required energy for this pro-
cess.  
 
Figure 42: Modifications of pyrrolizidine absorbents. 
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4.3 Synthesis26 
For the preparation of pyrrolizidine derivatives we chose to generally prepare compounds with 
one CH2 group and two CH2 groups on the 7a-position. At this stage of the project we did not 
know if the distance between tertiary amine and the amine on the side chain would play any role. 
For this reason we prepared the primary amines 4.13 and 4.15 and the secondary amines 4.14 
and 4.16 (Scheme 62). In addition, we wanted to synthesize anilines 4.17 and 3.107 on larger 
scale, to investigate if there was any difference in CO2 uptake and the nature of binding in com-
parison to the primary and secondary derivatives. As an electron poor variant of 3.107, we chose 
pyrrolizidine 4.18 carrying a strongly electron-deficient substituent on the aniline nitrogen. 
 
 
Scheme 62: Choice of derivatives for the evaluation of the CO2 binding capacity. 
 
For the preparation of the pyrrolizidine derivatives it was important that the synthetic route 
provides sufficient material for the CO2 uptake experiments. In addition it is desirable to include 
as few purification steps as possible to demonstrate the applicability to industrial syntheses. For 
the diversification we decided to perform late-stage modifications on intermediates 4.13 and 4.15 
(Scheme 63). These two intermediates can be prepared from ketone 4.19 by a literature known 
procedure.[117,120] The ketone can be prepared from the bulk chemical γ-butyrolactone.[154]  
  
                                                
26 The substances presented in this chapter were prepared by Jan Hanusch in the course of his master thesis under 
my supervision.  
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Scheme 63: Synthetic strategy for the preparation of pyrrolizidines. 
 
We started with the synthesis of dichloroheptanone 4.19 from γ-butyrolactone after a protocol 
published by Curtis et al. (Scheme 64).[154] The cyclic lactone was subjected to a sodium meth-
anolate solution and heated to 100 °C in a Dean-Stark reaction apparatus. Without isolation and 
purification, condensed product 4.20 is treated with HCl to furnish heptanone 4.19 in an overall 
yield of 68%. The reaction could be carried out at high substrate concentrations for the first step 
and no solvent for the second step, so that the reaction could be scaled up to 200 g with usual 
chemical synthesis equipment. 
 
 
Scheme 64: Synthesis of heptanone 4.19 from γ-butyrolactone. 
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Synthesis of the first pyrrolizidine derivative 4.13 was performed using heptanone 4.19 
(Scheme 65).[120] The ketone was reacted with aqueous ammonium hydroxide, ammonia gas and 
potassium cyanide. The resulting crude mixture was used in the next step without purification.27 
The mixture was reduced using lithium aluminum hydride followed by recrystallization of the 
corresponding hydrochloride salt. Following this procedure the by-product could be fully sepa-
rated from the product.  
 
 
Scheme 65: Synthesis of the pyrrolizidine derivative 4.13. 
 
For the introduction of the methyl group we first formylated 4.13 with ethyl formate under 
basic conditions, followed by reduction of the formyl group using lithium aluminum hydride 
(Scheme 66). 
 
 
Scheme 66: Formylation of 4.13 followed by reduction provides methylated derivative 4.14. 
 
For the introduction of an electron-deficient substituent on the free amine of 4.13 we reacted 
the pyrrolizidine with Sanger reagent 4.23. The reagent is used for peptide sequencing in that it 
is reacted with the amine group of a peptide. The resulting dinitrophenyl peptides are generally 
unstable under acid hydrolysis conditions and the terminal amino acid is released from the pep-
tide.[155] In our case we benefited from the electron poor nature of the reagent, so that 4.13 can 
easily undergo displacement of the fluoride by nucleophilic aromatic substitution (Scheme 67). 
In contrast to the other pyrrolizidine derivatives carrying primary and secondary amines, the 
product could be purified by column chromatography and was isolated in 63% yield. 
                                                
27 The crude mixture contained the product and this pyrroline by-product as a 70:30 (product:by-product) mixture. 
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Scheme 67: Introduction of a 2,4-dinitrophenyl group using the Sanger reagent. 
 
For the synthesis of the pyrrolizidine derivative carrying two CH2-groups, we followed a liter-
ature known protocol starting from heptanone 4.19.[120] The ketone was subjected to ammonia 
gas and treated with α-cyanoacetic acid (Scheme 68). The resulting nitrile 4.24 was reduced 
without purification to the corresponding amine in 25% over two steps. 
 
 
Scheme 68: Synthesis of pyrrolizidine derivative 4.15 from heptanone 4.19.  
 
The methylation of pyrrolizidine 4.15 was carried out analogous to the preparation of 4.14 by 
formylation and reduction (Scheme 69). 
 
Scheme 69: Synthesis of methylated pyrrolizidine derivative 4.16 by formylation and reduction. 
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counter a 5-membered ring. On the other hand, with diamine 4.17 the complexation would in-
volve formation of a 6-membered ring, which is less easily formed than a five membered ring. 
The difficulties obtained in the preparation of 3.107 highlight the power of our method estab-
lished for the synthesis of 7a-substituted pyrrolizidines, with which compound 3.107 was pre-
pared in less steps and higher overall yield.28 
 
 
Scheme 70: Buchwald-Hartwig coupling of primary amines resulting in aniline derivatives 3.107 and 
4.17. 
  
                                                
28 As the amount of 3.107 prepared by Buchwald-Hartwig coupling was not sufficiently high, we used our method 
described in Chapter 3 for the preparation of the material. 
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4.4 CO2-Capture 
In the following section we report our studies on the CO2-binding of the pyrrolizidine deriva-
tives prepared in the previous section of this chapter. The CO2-capture has been approached 
from different perspectives. Initial studies were devoted to NMR-analysis as it can give a prelim-
inary indication if a substance is capable of binding CO2. Further, we attempted the crystalliza-
tion of the CO2-adducts to analyze them by X-ray diffraction. Finally, for the quantification of 
the CO2 uptake, we performed gravimetric experiments. 
 
4.4.1 NMR-studies 
With the first derivative 4.13 we performed NMR studies similar to the ones described in sec-
tion 3.10. The amine was dissolved in CD3OD and subjected to a CO2 stream produced from dry 
ice until the solvent was almost evaporated. The residue was dissolved in CD3OD and 1H-NMR 
and 13C-NMR analysis was performed. As observed earlier for pyrrolizidine 3.107 (section 3.10), 
a clear shift of ∼0.5 ppm towards lower field was obtained for the protons (Figure 43).  
 
Figure 43: 1H-NMR spectra of pyrrolizidine 4.13 before reaction (top) with CO2 and after reaction with 
CO2 (bottom).29  
  
                                                
29 NMR spectra recorded by Jan Hanusch during his master thesis under my supervision. 
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In the carbon 13C-NMR we observed similar peak shifts as for 3.107, and in addition, a new 
peak at 166.8 ppm appeared (Figure 44). This peak was shifted a little to lower field than for 
3.107 with 161.6 ppm. Compared to other CO2-adducts reported in the literature the obtained 
value of 166.8 ppm was slightly shifted to lower field as well. For instance, ionic liquid 4.26 was 
reported to bind CO2 as a carbamic acid and a corresponding 13C-shift of 158 ppm measured in 
deuterated DMSO (Figure 45).[159] Further, Cobalt-complex 4.27 showed a 13C-NMR shift for 
CO2 of 159 ppm in CD2Cl2[160] and amino acid derivative 4.28 was reported to bind CO2 as a 
carbamic acid with a 13C-shift of 161 ppm in CD3OD.[161] For ammonium bicarbonate in CD3OD 
we measured a 13C-NMR shift of 161.5 ppm, indicating that a shift of 166 ppm rather belongs to 
a carbamate than a bicarbonate. Long-range correlations in the HMBC-spectra between the car-
bamate carbon and protons adjacent to the nitrogen were never observed for both 3.107 and 4.13.  
It has to be mentioned, that a shift of the signals in the 1H-NMR is no proof of the CO2-
capture for a compound. For electron poor analogue 4.18 we observe 1H-NMR shifts of the 
peaks towards lower field, but in the 13C-NMR no shifts as well as no newly appearing peak in 
the carbamate region was observed. From this we concluded that 4.18 is most likely too electron-
deficient for CO2-capture. 
 
Figure 44: 13C-NMR spectra of pyrrolizidine 4.13 before reaction (top) with CO2 and after reaction with 
CO2 (bottom).30 
 
                                                
30 NMR spectra recorded by Jan Hanusch during his master thesis under my supervision. 
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Figure 45: Other CO2-adducts and their 13C-NMR shifts. 
 
 
4.4.2 X-ray crystal structure analysis 
During our studies we realized that when the neat primary and secondary amine absorbents 
were treated with CO2, they instantaneously turn into a (usually white) solid. The microscopy 
images in Figure 46 show a drop of absorbent 4.15 placed on a microscopy slide. When the drop 
was subjected to a CO2 stream the drop immediately turned into a solid.31 Dissolving the sub-
stance in methanol and evaporating the solvent by CO2 stream can also generate the solid. For a 
more complete conversion of the amine to the CO2-adduct we prepared the solids from solution 
so that no unreacted material is enclosed in the solid. The growth of crystals for X-ray analysis is 
important because it would clarify the question how CO2 is bound to our compounds. It has to be 
mentioned that attempts to turn anilines 3.107 and 4.18 into solids were not successful.  
 
Before CO2 stream After CO2 stream 
  
Figure 46: Microscopic image of a drop of 4.15 on a microscopy slide before a CO2 stream (left) and 
after a CO2 stream (right).  
  
According to the above-mentioned procedure we prepared solids of the free amines (4.13 and 
4.15) and the methylated compounds (4.14 and 4.16). The difficulty to obtain suitable crystals 
was that by evaporation procedures the CO2 fixed by the amine was released along with evapora-
tion of the solvent. We also had problems using batch-seeding techniques. After some experi-
                                                
31 On the left image it can be noticed that crystallization has already started at the edges of the drop, probably becau-
se of CO2 from the atmosphere. 
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mentation, we succeeded by dissolving the white solid in diisopropyl ether with one drop of 
iPrOH followed by slow evaporation of the solvent at 4 °C. For the compounds 4.13 and 4.16, 
one primary and one methylated derivative, we obtained suitable crystals and from these the cor-
responding single crystal X-ray structures (Scheme 47). The crystal structure for compound 4.13 
revealed that CO2 is bound as a carbamate. The compound crystallized with four molecules of 
the same kind in one space group including water molecules that were placed in between the 
carbamate groups of two pyrrolizidine molecules providing a network of hydrogen bonds. 4.16 
also bound CO2 as a carbamate and crystallized as one molecule in the space group surrounded 
by four water molecules. As apparent from the crystal structures of 4.29 and 4.30 the carbamate 
is not directed towards the ammonium ion. We had expected this orientation as an effect of 
counter ion attraction. However, the supramolecular packing of carbamate 4.29 shows that the 
carbamate is directed towards the ammonium of a second carbamate molecule showing that the 
orientation of the carbamate is strongly influenced by the intermolecular interactions (Figure 48). 
The crystal structure of temuline in the work of Trauner et al. also did not show an orientation of 
the carbamate towards the positively charged nitrogen. Moreover, the authors observed strong 
intermolecular hydrogen bonds in the supramolecular packing.[153] 
 
Figure 47: Single crystal X-ray structures of carbamates 4.29 and 4.30. 
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Figure 48: Unit cell of the single crystal X-ray structure of carbamate 4.29. Carbamate 4.29 crystallized 
with four carbamates and six water molecules in one space group and reveals that the orientation of the 
carbamate is controlled by intermolecular interactions with other carbamate molecules and water.  
 
Interestingly, the architecture of the pyrrolizidine ring of the two carbamates changed com-
pared to pyrrolizidine 3.32. The ring geometry changed from a cis-configuration in 3.32 to a 
trans-configuration of the carbamates 4.29 and 4.30 (Figure 49). Usually, for unsubstituted pyr-
rolizidines mainly the cis-conformer is observed, due to angular strain present in the trans-
isomer, which is absent in the cis-isomer (Figure 50). Substituents on the pyrrolizidine ring, 
however, can strongly influence this equilibrium. The reason for the shift of the equilibrium in 
our case might be the protonation of the tertiary amine in the two carbamates 4.29 and 4.30, as it 
has been reported that protonation can alter the geometry of the pyrrolizidine ring.[162,163] 
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Figure 49: Crystal structures of 4.29, 4.30 and 3.32. The carbamates adopt a trans-orientation of the pyr-
rolizidine core in contrast to 3.32 that show a cis-geometry. 
  
 
Figure 50: The equilibrium between the trans-geometry and the cis-geometry lies on the side of the cis-
form for unsubstituted pyrrolizidines. 
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4.4.3 Gravimetric analysis 
The following section describes the quantification of the CO2 uptake for our pyrrolizidine de-
rivatives. For its determination we chose to use a gravimetric method because a stoichiometric 
uptake results in a weight increase of 34%. A sample size of 3 mmol for the pyrrolizidine deriva-
tives results in a weight increase of 132 mg (Scheme 71). This increase in weight is well measur-
able on an analytical balance. Besides the sufficient sensitivity, this established setup[161,164] does 
not require expensive equipment, such as other methods using calorimetry[159,165] or GC-
analysis[166].  
 
 
 
Scheme 71: Mass increase of pyrrolizidine 4.13 by CO2. 
 
A schematic representation of the setup is depicted in Scheme 72. We decided to build a unit 
that contains both, a CO2- and a N2-stream. This allows for the possibility to apply gas mixtures 
in our experiments, for instance to mimic the composition of flue gas from a power plant, or pure 
N2 to assist in the release of the captured CO2. Two individual flow controllers adjusted the two 
gas flows. Both gas flows can be merged together in a mixing chamber and then delivered to the 
absorbent sample, whose weight is measured on an analytical balance. Before each absorption 
measurement, the apparatus needs to be flooded with CO2 to ensure for a homogeneous gas flow. 
In advance to the absorption measurement, the atmosphere of the sealed tube containing the pyr-
rolizidine absorbent and the solvent, was replace by CO2 to prevent any falsified increase in 
weight caused by CO2 from the atmosphere in the tube.32 Placing the needle with the gas flow 
into the solution started the measurement. As a solvent for the amine absorbents we chose 
PEG200 because auf its high boiling point33 which does not falsify the result by evaporation. In 
addition, PEG200 itself has a very low CO2-absorption. In the beginning of our studies, we placed 
the sealed tube containing the absorbent on the balance and measured the increase in weight con-
                                                
32 Density of air: 1.275 kg/m3. Density of gaseous CO2: 1.977 kg/m3. 
33 >250 °C 
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tinuously using the program Balance Link®. The computer running the program was connected 
to the balance and recorded the weight every minute. The setup was very comfortable because no 
manual data collection was necessary. However, we encountered several problems with this set-
up: 1) The container had to stand freely on the balance and any contact to the needle had to be 
avoided. This made the setup very sensitive to interruptions by the environment. 2) The airflow 
in the room sometimes contributed to fluctuations of weight because the balance could not be 
fully closed as it was attached to the CO2-apparatus. 3) The CO2 flow from the needle was not 
continuous as the needle was placed in the viscous solution. This resulted in strong variations of 
the sample weight and significant fluctuations in the resulting absorbance curves were obtained. 
In addition to this, the starting weight of the measurement was hard to determine, as in the be-
ginning of the measurement it was already strongly fluctuating. As a result of this we obtained 
falsified end values of the overall absorption. Because of these encountered problems, we decid-
ed to determine the increase in weight manually. 
 
Scheme 72: Schematic representation of the CO2-absorption apparatus, which also allows for the use of 
nitrogen gas for the release experiments. 
 
An absorption curve of the absorbents 4.14 and 4.16 is shown in Scheme 73. To our delight, 
the pyrrolizidine absorbents showed a quantitative CO2 uptake with ≥ 1 equiv. CO2 captured by 
1 equiv. amine absorbent. Interestingly, amine 4.14 showed a much faster uptake than 4.16 
showing that the distance between the two amine groups plays an important role in the uptake 
kinetics. The closer proximity of the secondary and the tertiary amine in derivative 4.14 could 
contribute to a more efficient delivery of the proton and thereby leading to a faster uptake 
(Scheme 74). Most likely, CO2 also needs to be activated by hydrogen bonding through solvent 
molecules, as we did not see any uptake in aprotic solvents (toluene-d8, CDCl3) in earlier exper-
N2 CO2
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iments. In comparison to monoethanolamine, the most conventional absorbent in industry, our 
amines showed a clearly improved uptake. 
 
Scheme 73: CO2-absorption curve of pyrrolizidines 4.14, 4.16 and monoethanolamine.34 
 
 
 
Scheme 74: The faster uptake of 4.14 compared to 4.16 could be explained by the closer proximity of the 
secondary and the primary amine.  
  
                                                
34 Absorption curve measured by Jan Hanusch. 
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Table 8: CO2 absorption of pyrrolizidine derivatives and commercially available absorbents  
 
 
 
Absorbent pKa[b] CO2 absorption[d] 
PEG200 - 0.08[e] 
4.13 10.7, 6.2 1.04 
4.14 10.6, 6.6 1.06 
4.15 11.2, 8.4 1.17 
4.16 11.3, 8.6 1.14 
3.107 10.5[c] 0.45 
4.17 11.4 0.42 
4.33 9.6 0.72 
4.34 10.0, 6.1 0.65 
4.35 10.6, 7.8 0.96 
[a] Conditions: PEG200 (12 mmol) and absorbent (3 mmol), 25 °C, CO2 stream 9 mL/min. [b] pKa 
was determined by titration of the aqueous amine solutions with HCl. [c] Amine was dissolved in 
methanol and titrated with aqueous HCl [d] Moles of CO2 per mol of absorbent, absorption by 
PEG200 is included. [e] CO2 absorbed per 4 mmol of PEG200. 
 
Table 8 summarizes the results of the absorption experiments of all our derivatives. The pKa 
values for the substances were also determined to examine on a possible correlation between 
CO2-absorption and basicity. In general, the CO2 uptake for all pyrrolizidines with secondary 
(4.14 and 4.16) and primary amine (4.13 and 4.15) side chains is stoichiometric which means 
that our proposed equimolar uptake is fulfilled. The observed over-stoichiometry of 5-17% is not 
fully clarified yet. Certainly, one part is because the amount of CO2 absorbed by PEG200 is not 
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subtracted from these values. Another part may result from salt formation with water present in 
the solvent. An additional possibility is the formation of undefined pyrrolizidine-CO2 adducts 
such as formation of carbamic acid and bicarbonate salt at the same time. The differences be-
tween the pyrrolizidines with primary and secondary amines are marginal, but the substances 
differ in their absorption kinetics as highlighted earlier in this chapter. On the other hand, aniline 
derivatives 3.107 and 4.17 show a significantly lower absorption compared to the other deriva-
tives.  
Interestingly, for linear diamine 4.34, which shows the same amine connectivity as 4.14, a 
significantly lower absorption was obtained. For this example the three-dimensional architecture 
of the pyrrolizidine might contribute positively to the CO2-absorption. On the other hand for 
linear diamine 4.35 showing the same connectivity as 4.16, this effect is less pronounced. 
For the primary and secondary amine derivatives seems to be a dependency of the basicity on 
the CO2-absorption because the more basic derivatives showed a slightly higher uptake. Howev-
er, a general statement involving all the measured compounds cannot be formulated as has al-
ready been pointed out for other amine absorbents.[167] 
 
4.5 Release 
Next, we investigated the reversibility for the CO2 uptake with compound 4.14 by measuring 
absorption-and-release-cycles. The uptake measurement was not continued until full saturation; 
instead we stopped at a ratio of 0.6-0.7 mmol CO2/mmol amine. Absorption was performed at 
room temperature, desorption was performed at 65 °C and N2-flow (9 mL/min). As can be seen 
from Figure 51 the compound showed full reversibility even after eleven cycles of absorp-
tion/desorption. The application of lower desorption temperatures with different solvents, is cur-
rently under investigation. 
 
Figure 51: Absorption and desorption cycles of pyrrolizidine 4.14 at 9 mL/min CO2 for the uptake and 65 
°C / 9 mL/min N2 for the release.35  
                                                
35 Absorption/Desorption experiments were performed by Jan Hanusch. 
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4.6 Determination of pKa values 
For the pKa values shown in Table 8 we titrated the diamines with aqueous HCl. The methyl-
ated pyrrolizidine 4.14 was well soluble in water, the aniline derivative 3.107 had to be dissolved 
in MeOH and was then titrated with hydrochloric acid. The deviation in the resulting pKa caused 
by the solvent mixture was corrected to a pKa in pure water according to a literature known re-
port.[168] The resulting titration curves are depicted in Figure 52. 
 
 
Figure 52: Titration curves of aniline 3.107 and methylated derivative 4.14. 
 
Interestingly, the aniline shows a typical titration curve of a buffer system with a buffer zone 
in the beginning (0-8 mL HCl) and one equivalent point, indicating that there is only one proto-
nation. From this we can conclude that only the tertiary nitrogen is protonated and that there is 
no second protonation of the aniline nitrogen.36 In contrast, the methylated pyrrolizidine shows 
two distinct protonations, so that both amines are protonated in this case.  
This acid/base behavior of the substances may indicate that aniline 3.107 does not bind CO2 as 
a carbamate. If the aniline nitrogen is not nucleophilic enough to attack a proton, it is most likely 
also not nucleophilic enough to attack a carbon atom (in this case CO2). Further indications are a 
13C-NMR shift of 161 ppm in CD3OD,37 the low CO2 uptake in the absorption measurements and 
the fact that a solid was never obtained for the compound when charged with a CO2 stream. 
  
                                                
36 Because of its higher basicity the tertiary nitrogen is protonated first. 
37 We measured a 13C-NMR shift of 161.5 ppm in CD3OD for ammonium bicarbonate (see section 8.4) 
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4.7 Conclusion 
Our results demonstrate that pyrrolizidine alkaloids can serve as useful agents for the capture 
of CO2. Derivatives functionalized with a primary and a secondary amine bind CO2 as a carba-
mate as shown by single crystal X-ray structure analysis. The uptake of CO2 for these derivatives 
was equimolar and by that exceeded almost twice the capacity of conventional amines. In addi-
tion, the uptake was faster, especially for the derivatives 4.13 and 4.14 with one CH2 group. As 
factors contributing to these properties we identified the proximity of the two amine groups and 
the three-dimensional architecture of the derivatives to be important. In general the low-lying 
pyrrolizidine backbone and the amine side-chain sticking out has been shown to be beneficial for 
the overall uptake of the absorbents. In addition, binding of CO2 has been shown to be reversible 
with up to 11 cycles. The aniline derivatives 3.107 and 4.17 showed a significantly lower uptake 
of CO2 than the other absorbents. Titration of these compounds revealed that the aniline nitrogen 
is not protonated, which leads to the presumption that the aniline is also not nucleophilic enough 
for the formation of a carbamate by nucleophilic attack on CO2. From this we conclude that ani-
lines of this kind most probably bind CO2 as a bicarbonate salt, which seems to occur with lower 
efficiency thereby leading to a lower overall uptake. 
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5 Conclusion 
This thesis entitled “Surface Engineering of Algae and Synthesis of Pyrrolizidines for Carbon 
Dioxide Capture Applications” highlights the utility of organic synthesis as a tool to tackle scien-
tific problems. The investigations presented in this thesis were placed in the areas of chemical 
biology, synthetic method development and the design of molecules for the capture of CO2. 
In the second chapter, we demonstrate engineering of the green alga Chlamydomonas rein-
hardtii with an antibiotic, thereby turning the alga into an antimicrobial killer cell. It was shown 
that attaching the glycopeptide antibiotic vancomycin to the surface induced the new antimicro-
bial phenotype. We found that the compound 2.19, consisting of a 4-hydroxyproline oligomer, a 
fluorophore for visualization and vancomycin was most effective for this purpose.38 The com-
pound was immobilized on the surface during an incubation time of 12 h without affecting the 
motility of the algae. The algae were then tested for their antimicrobial potency against the 
Gram-positive bacteria Bacillus subtilis. By monitoring the bacterial growth over time, we 
showed that 2.19-modified algae are able to kill bacteria, and that the degree of overall culture 
growth can be controlled by variation of the amount of algae. Using laser scanning confocal flu-
orescence microscopy, we visualized the transfer of the substance from the surface of the algae 
to the cell wall of the bacteria. 
 
Our results demonstrate the first functionalization of the cell wall of C. reinhardtii with a ther-
apeutic material. To the best of our knowledge this is also the first example in which a natively 
harmless organism is equipped with the feature to dispatch other organisms by chemical means. 
Our studies might deliver the basis for further functionalization resulting in the introduction of 
different phenotypes e.g. other therapeutic materials or catalysts. Further, this concept could be 
                                                
38 Image: modified from: http://www.pflanzenforschung.de/de/themen/pflanzen-im-fokus/chlamydomonas/ 
(2.12.2016) 
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transferred to different organisms that show similar surface compositions and architecture. Over-
all, we provided an example for the reversible modification of living cells without intervention 
into the organism’s biosynthetic pathways. 
In the third chapter, we describe the synthesis of 7a-substituted pyrrolizidines from simple 
imine and isonitrile precursors. We showed that hydroxyl-functionalized pyrrolines react with 
isonitriles under acidic conditions and elevated temperatures to deliver direct access to these 
bicyclic heterocycles. The reaction tolerates a wide scope of isonitriles with aromatic and ali-
phatic substituents. Mechanistic investigations indicated that the reaction probably proceeds via 
a pyrrolizidinium intermediate. The products could be further functionalized by oxidation and 
reduction protocols. Our method demonstrates the first example for the direct preparation of the-
se heterocycles with few synthetic operations and excellent atom economy. 
 
The last chapter described our investigations on the CO2-binding properties of pyrrolizidines. 
We prepared a number of pyrrolizidine derivatives with different substituents on the side chain 
amine. We found that there were significant differences between amines substituted with aro-
matic groups and primary and secondary amines. Pyrrolizidines containing primary or secondary 
amines were able to bind CO2 quantitatively, whereas the anilines did not reach even half of the 
binding capacity. This finding can be explained by the fact that primary and secondary amines 
bind CO2 as a carbamate, leading to a 1:1 stoichiometry of amine:CO2, on the other hand, ani-
lines probably bind CO2 as a bicarbonate salt. These findings are supported by crystal structures 
for both primary and secondary amines and by NMR studies and titration experiments for the 
anilines. The reversibility of CO2 uptake was demonstrated by absorption-and-release-cycles that 
where repeated multiple times without loss of binding capacity. Overall, CO2-binding pyrroliz-
idines might emerge as a useful alternative to existing CO2-absorbents. Moreover, they might be 
useful tools to assist in the conversion of CO2 to substances with higher value. 
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6 Abbreviations 
 
A absorbance 
Ac acetyl 
AcOH acetic acid 
AHX aminohexanoic acid 
Ala alanyl 
aq. aqueous 
B. Bacillus 
BF bright field 
Boc tert-butyloxycarbonyl 
BODIPY 1,3,5,7-tetramethyl-8-phenyl-4,4-difluoroboradiazaindacene 
BSA bovine serum albumin 
bs broad singlet 
Bu butyl 
°C degrees Celsius 
C. Chlamydomonas 
c concentration 
cat. catalytic 
CCS carbon capture and storage 
CF carboxyfluorescein 
δ chemical shift 
d dublet 
D deuterium 
DBU 1,8-diazabicyclo[5.4.0]undec-7-ene 
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DCC N,N’-dicyclohexylcarbodiimide 
DIC N,N’-diisopropylcarbodiimide 
DiPEA N,N’-diisopropylethylamine 
DMAP 4-dimethylaminopyridine 
DMF dimethylformamide 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
EA elemental analysis 
e.e. enantiomeric excess 
EI electron impact ionization 
e.g.  exempli gratia 
Et ethyl 
equiv. equivalent 
e.r. enantiomeric ratio 
ESI electron spray ionization 
FA formic acid 
FITC fluorescein isothiocyanate 
Fmoc fluorenylmethyloxycarbonyl 
FTIR Fourier transform infrared spectroscopy 
g gram(s) 
Gal galactose 
GC gas chromatography 
GPI glycoinositol phospholipid 
h hour(s) 
HATU 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-
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oxid hexafluorophosphate 
HBTU N,N,N′,N′-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophos-
phate 
HCTU 2-(6-chlor-1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium-
hexafluorophosphat 
HMBC heteronuclear multiple-bond correlation spectroscopy 
HOBt 1-hydroxybenzotriazole hydrate 
HPA Helix pomatia agglutinin 
HPLC high performance liquid chromatography 
HR-MS high resolution mass spectrometry 
HyD Hybrid detector 
Hyp hydroxyl proline 
Hz herz (s-1) 
IC50 50% inhibition concentration 
IgM, IgG immunoglobin mice, immunoglobin goat 
J coupling constant 
Lac lactate 
LDA lithium diisopropylamide 
m multiplet 
L liter(s) 
LC liquid chromatography 
M molarity 
m multiplet 
m-CPBA 3-chloroperbenzoic acid 
Me methyl 
min minute(s) 
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m.p. melting point 
Ms mesyl 
MTBE tert-butyl methyl ether 
mV milli volt 
n.d. not determined 
NMM N-methylmorpholine 
MIC minimum inhibitory concentration 
MS mass spectrometry 
MSC mesenchymal stem cell 
NMR nuclear magnetic resonance 
LED light-emitting diode 
OD optical density 
p para 
p quintet 
PBS phosphate buffered saline 
PEG polyethylene glycol 
Ph phenyl 
ppm parts per million 
Pr propyl 
PyBOP (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate 
q quartet 
quant. quantitative 
Rf retention factor 
RT room temperature 
Rt retention time 
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s singlet 
sat. saturated 
sec second(s) 
SM starting material 
sp. species 
SPE solid phase extraction 
t triplet 
THF tetrahydrofuran 
TIS triisopropyl silane 
TLC thin layer chromatography 
TNBS picrylsulfonic acid 
TFA trifluoroacetic acid 
TSA toluene sulfonic acid 
UHPLC ultra high-performance liquid chromatography 
UV ultraviolet 
ν wavenumber 
VIS visible 
X-Ray X-radiation 
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7 Experimental Part 
7.1 General 
 
Confocal fluorescence microscopy was performed on an inverse confocal laser scanning micro-
scope (CLSM SP5 Mid UV-VIS Leica) equipped with hybrid detectors. The microscope was 
operated using Leica Advanced Fluorescence software and images were processed by adjusting 
the brightness/contrast using Fiji. 
 
Flash chromatography was performed using silica gel 60 (230-240 mesh) from Fluka using a 
forced flow eluent at 0.1-0.3 bar pressure. 
 
GC-MS was measured on a Finnigan Trace GC Ultra (Thermo) equipped with a Finnigan Trace 
DSQ (Thermo) EI MS detector and a Zebron ZB-5MS (30m) column. 
 
Glassware was dried in an oven at 120 °C over at least 24 h and for moisture sensitive reactions 
was heated with a heat gun under inert atmosphere. 
 
Analytical and preparative HPLC was performed on a Shimadzu HPLC system (LC-20AP 
dual pump, CBM-20A Communication Bus Module, SPP-20,A UV/VIS Detector, FRC-10A 
Fraction collector). 
 
IR-spectroscopy was performed on a Varian 800 FT-IR ATR Spectrometer. 
 
Lyophilizations were performed on a Cryst Freeze dryer ALPHA 1- 4 LD plus.  
 
High resolution mass spectra were recorded by the Mass Spectrometric Service of University 
of Basel on a Bruker maXis 4G mass spectrometer using electrospray ionization (HR-MS (ESI)) 
or a Bruker ESQUIRE-LC quadrupole ion trap instrument, equipped with a combined Hewlett-
Packard Atmospheric Pressure Ion (API) source at the University of Zurich. 
 
Melting points were determined using a Büchi B-545 apparatus in open capillaries and are un-
corrected. 
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NMR-spectra were recorded either using a Bruker Avance 400 MHz, a Bruker Avance 250 
MHz or a Bruker Avance DRX 500 MHz spectrometer at room temperature. Chemical shifts (δ-
values) are reported in ppm, spectra were calibrated related to solvent’s residual proton chemical 
shift (CHCl3, δ = 7.26 ppm) or TMS (CDCl3, δ = 0.00 ppm) and solvent’s residual carbon chem-
ical shift (CDCl3, δ = 77.16 ppm). Multiplicity is reported as s = singlet, br. s = broad singlet, d = 
doublet, t = triplet, q = quartet, p = quintet, m = multiplet or unresolved and the coupling con-
stant J in Hz. 19F-NMR spectra were recorded using C6F6 as an internal reference (CDCl3, δ = -
164.9 ppm). 
 
Optical rotations [α]DT
 
were measured at the sodium D line using a 1 mL cell with a 1 dm path 
length on a Jasco P-2000 digital polarimeter, the concentration c is given in g/100 mL. 
 
Reagents were purchased from Sigma-Aldrich, Acros and Fluka and used without further purifi-
cation. 18O-labeled (97%) water was purchased from Eurisotop. 
 
Solid phase peptide synthesis was performed with a Syro I (Biotage) or a CS136XT (CS Bio) 
fully automated peptide synthesizer. 
 
Solvents for work-up and chromatography were technical quality and distilled. Solvents used for 
chemical transformations were either puriss. quality or dried by filtration through activated 
Al2O3 under nitrogen (H2O content < 10 ppm, Karl-Fischer titration). 
 
SPE columns were DSC-18 purchased from Supelco. 
 
Thin layer chromatography was performed on Merck silica gel 60 F254 plates (0.25 mm 
thickness) precoated with fluorescent indicator. 
 
Titration curves were recorded using a Mettler Toledo Seven Easy pH-meter equipped with an 
InLab®409 pH-electrode. 
 
X-ray data collection was performed at low temperature (123 K) using Mo Ka radiation on a 
Bruker KappaAPEX diffractometer. Integration of the frames and data reduction was carried out 
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using APEX2.39
 
The structures were solved by direct methods using SIR92.40
 
All non hydrogen 
atoms were refined using anisotropically by full-matrix least-squares on F using CRYSTALS.41 
Hydrogen atoms were placed in their calculated positions by means of the ‘riding’ model. 
 
7.2 Surface engineering of algae 
7.2.1 Microbiology 
 
Cultivation of algae 
Chlamydomonas reinhardtii (11-32b) was purchased from EPSAG (Experimentelle Phykologie 
und Sammlung von Algenkulturen der Universität Göttingen) and grown in Kuhl medium 
(1011.1 mg L-1 KNO3, 621 mg L-1 NaH2PO4·H2O, 89 mg L-1 Na2HPO4·2 H2O, 246.5 mg L-1 
MgSO4·7 H2O, 14.7 mg L-1 CaCl2·2 H2O, 6.95 mg L-1 FeSO4·7 H2O (Fe-EDTA complex), 1 mL 
L-1 micronutrient solution (61.0 mg L-1 H3BO3, 169.0 mg L-1 MnSO4·H2O, 287.0 mg L-1 ZnSO4·7 
H2O mg L-1, 2.5 mg L-1 CuSO4·5 H2O, 12.5 mg L-1 (NH4)6Mo7O24·4 H2O))42 at 20 °C under me-
dium light (30V). 
 
Cultivation of cell wall-deficient algae 
The cell wall deficient mutant (CC-406 cw15 mt-) was purchased from the Chlamydomonas 
Research Center, University of Minnesota and grown in Tris minimal medium (2.42 g L-1 Triz-
ma® base, 25 mL salt solution (15 g L-1 NH4Cl, 4 g L-1  MgSO4·7H2O, 2 g L-1  CaCl2·2H2O) 
0.375 mL phosphate solution (28.8 g L-1 K2HPO4, 14.4 g L-1 KH2PO4), 1 mL Fe-EDTA complex 
(6.95 mg L-1 FeSO4·7 H2O)) at 20 °C under medium light (30V).  
 
Surface modification of algae: 
Modification of algae with OCV for bacterial growth curves 
6 mL of a C. reinhardtii culture with a cell density of 3.3·106 cells/mL was centrifuged and the 
supernatant removed. The algae were resuspended in fresh Kuhl medium to a volume of 160 µL. 
35 µL of a solution of 2.19 (c = 5.57·10-3 mmol/mL) was added to the algae suspension to reach 
a final overall concentration of 1·10-3 mmol/mL. The algae were shaken for 12 h at room tem-
perature at 350 r/min.  
                                                
39 Bruker Analytical X-ray Systems, Inc., 2006. Apex2, Version 2 User Manual, M86-E01078, Madison, WI. 
40 Altomare, A.; Cascarano, G.; Giacovazzo, C.; Guagliardi, A.; Burla, M. C.; Polidori, G.; Camalli, M. J. Appl. 
Cryst. 1994, 27, 435. 
41 Betteridge, P. W.; Carruthers, J. R.; Cooper, R. I.; Prout, K.; Watkin, D. J. J. Appl. Cryst. 2003, 36, 1487. 
42 Kuhl, A. Lorenzen, H. Handling and culturing of Chlorella. In: D. M. Prescott, ed., Methods in cell physiology, 
Vol. I, p. 152-187, Academic Press, New York and London, 1964. 
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The algae were diluted with 1 mL of Kuhl medium, centrifuged at 2000 r/min for 5 min and the 
supernatant was removed. The algae were washed 3x by addition of 1 mL Kuhl medium, centrif-
ugation and removal of the medium. The algae pellet was resuspended in 2.5 mL Kuhl medium 
for the bacterial growth experiments. 
 
Modification of algae with 2.19 for flagellar preservation 
2 mL of algae culture with a cell density of 3.3·106 cells/mL was centrifuged and the supernatant 
removed. The algae were resuspended in fresh Kuhl medium to a volume of 65 µL. The algae 
suspension was added to 192 µg (6.5·10-5 mmol) of 2.19 and mixed well (final concentration: c = 
1·10-3 mmol/mL). The algae were shaken for 12 h at room temperature at 350 r/min.  
The algae were diluted with 1 mL of Kuhl medium, centrifuged at 2000 r/min for 5 min and the 
supernatant was removed. The algae were washed 3x by addition of 1 mL Kuhl medium, centrif-
ugation and removal of the medium. The algae pellet was resuspended in Kuhl medium for fixa-
tion on microscopy slides. 
 
Preparation of fixed microscopy samples 
Cover slips were coated with 0.1% gelatin solution for 15 min and air-dried. One drop of algae 
suspension was applied on the coverslip and the water was evaporated without the cells being 
dried out. Fixation solution (9% formaldehyde, 3% glutaraldehyde, 0.1% NaCl) was mixed 1:1 
with Kuhl medium, placed on the cells and left for 5 min at room temperature. The fixation solu-
tion was rinsed away with Kuhl medium and the sample was mounted with ProLong® Diamond 
Antifade Mountant. 
 
Bacterial strains and growth conditions 
The bacterial strain used was Bacillus subtilis (ATCC 6633) from DSMZ (Deutsche Sammlung 
von Mikroorganismen und Zellkulturen, Braunschweig Germany). The bacteria were cultivated 
in Medium 1 (5 g l-1 peptone, 3 g l-1 meat extract, 10 mg l-1 MnSO4·7 H2O) at 37 °C (pH = 6). 
 
Antibacterial activity and bacterial growth curves 
Overnight cultures of B. subtilis were grown in a Erlenmeyer flask while vigorous shaking with 
200 r/min at 37 °C. 2% of an overnight culture with OD600 = 6.00 (added volume was adjusted 
according to the OD600 of varying overnight cultures) was added to a 15 mL conical tube con-
taining 2.5 mL of algae suspension and 2.4 mL of Medium 1. Bacteria were grown in an incuba-
tor at 37 °C and 200 r/min and the increase in bacterial growth (600 nm) was measured every 
hour. Graphs were background-corrected by subtracting the OD600 at time 0. 
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Live/Dead staining of bacteria 
1 mL of the bacteria/algae suspension was transferred into an Eppendorf vial and centrifuged at 
2000 r/min for 5 min. The medium was removed and 0.5 mL of PBS was added. To the suspen-
sion was added 100 µL Live/Dead staining solution (previously prepared by adding 10 µL of 
solution A and 5 µL of solution B to 1 mL PBS). The cell suspension was mixed by vortex shak-
ing and incubated at 37 °C for 30 min at 200 r/min. 10 µL of cell suspension was placed on an 
agarose patch (previously prepared from a hot 1% agarose solution) and covered with a cover 
slip. Imaging was performed subsequently. 
 
MIC values 
B. subtilis (ATCC 6633) was inoculated from a fresh agar plate into a 0.9% NaCl aqueous solu-
tion. The turbidity of the bacterial suspension was adjusted to McFarland standard 0.5, and dilut-
ed 1 to 200 in cation-adjusted Mueller-Hinton-II broth. (Note, the MIC values are typically 4-8 
fold lower when the assays are performed in Mueller-Hinton-I broth in the presence of 0.02% 
BSA). The compounds were dissolved in 0.01% acetic acid at a concentration of 1 mg/ml (de-
termined by UV-Vis). In 96 well microtiter plates, two fold serial dilutions of the compounds 
(normally ranging from 64 µg/ml to 0.0005 µg/ml) were prepared in Mueller-Hinton-II broth 
with 0.002% P80 in a final volume of 50 µl. Finally, the bacterial suspension (50 µl) was used to 
inoculate each well on the microtiter plate, corresponding to approximately 5x 105 CFU/ml in a 
final volume of 100 µl. The microtiter plates were covered and incubated overnight at 37 °C with 
shaking at 200 r/min. The MIC was determined by visual inspection and is defined as the mini-
mal concentration of a compound that prevented microbial growth under the conditions de-
scribed. MIC readouts done by Myriam Gwerder. 
 
Kirby-Bauer disk diffusion test 
An overnight culture of B. subtilis was raised in Medium 1 (OD600 = 6.15). On the next day a 
culture was raised using 2% of the overnight culture. The OD600 values were measured every 
hour until OD600∼1.00. Agar plates were prepared using 10% of the bacteria culture. 
Paper disks (6 mm) were incubated with 10 µL of solutions of vancomycin (53 µg), 2.21 (87 µg) 
(shown in Figure 28), 2.19 (100 µg) and 2.09 (50 µg). The paper disks were placed on the agar 
plates and the plates were incubated at 37 °C overnight. Antibacterial activity was evaluated af-
ter 16 h. 
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Figure 53: Kirby-Bauer disk diffusion test using vancomycin, 2.19 and 2.09. 
 
 
7.2.2 Preliminary investigations on bacterial growth  
The following experiments were performed in advance to the growth experiments described in 
Chapter 2. Growth of B. subtilis was investigated in 50 mL conical tubes. The conditions tested 
were: 
B. subtilis medium: B. subtilis grown in 100% Medium 1 
1 µg/mL vancomycin: B. subtilis grown in 100% Medium 1 with 1 µg/mL vancomycin added to 
the medium 
B. subtilis medium/Kuhl medium 1/1: B. subtilis grown in 50% Medium 1 and 50% Kuhl me-
dium 
 
 
Figure 54: Growth of B. subtilis under different conditions. 
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As can be seen from Figure 54, the composition of the medium has a clear influence on the bac-
terial growth. Bacteria grown in a mixture of Medium 1 and Kuhl medium (1:1) stopped growing 
after 4 h. This can be explained by depletion of nutrients in the medium at this point. 
Next, we investigated the effect of the vancomycin concentration in the medium. As can be seen 
in Figure 55, we observed full inhibition of growth with vancomycin in the range of 1 µg/mL–1 
mg/mL 
 
 
Figure 55: Growth of B. subtilis in the presence of vancomycin in the µg/mL range. 
 
In the next set of experiments we lowered the antibiotic concentration to the ng/mL range. As 
can be seen in Figure 56 with these antibiotic concentrations the bacterial growth could not be 
inhibited anymore. 
 
 
Figure 56: Growth of B. subtilis in the presence of vancomycin in the ng/mL range. 
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Figure 57 illustrates the different appearance of B. subtilis at different stages during growth. The 
curve shown in Figure 57 shows the growth of B. subtilis in the presence of unmodified (black 
curve) and with 2.19-modified algae (red curve).43 After 6 h of growth, Live/Dead staining was 
performed and investigated under a fluorescent microscope. The cells present in the beginning of 
the stationary phase (black curve) appeared as long chains that are partly wrapped up in ravels 
(b). On the contrary, the cells during the exponential phase (red curve) are mainly present in sin-
gle or double rods (c). This highlights the different appearance of the cells dependent on the 
stage of growth (mentioned in section 2.2). 
a 
 
 
b 
 
 
 
c 
 
 
Figure 57: a) Growth curve for B. subtilis in the presence of algae both unmodified and modified with 
2.19. b) Live/Dead staining of the culture with unmodified algae after 6 h. The bacterial cells are in the 
beginning of the stationary phase and appear mostly as chains. c) Live/Dead staining of the culture with 
algae modified with 2.19 after 6 h. The bacterial cells were in the exponential phase and appear mostly as 
single and double rods.  
                                                
43 The algae were incubated at a concentration of 1·10-3 mmol/mL for 12 h and washed 3x. 
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7.2.3 Synthesis 
Hyp9-FITC (2.01) 
 
Hyp9-NH2 (8.3 mg, 8 µmol, 1.0 equiv.) and fluorescein isothiocyanate isomer I (4 mg, 10.3 
µmol, 1.35 equiv.) were placed in a vial and 120 µL of Na2CO3/NaHCO3 buffer (pH = 9.5) and 
20 µL THF were added. The reaction mixture was stirred for 48 h at room temperature. The reac-
tion mixture was diluted with 2 mL DMSO:H2O (3:4) and filtered through a SPE column. The 
compound was purified by reversed phase HPLC using H2O/MeCN + 0.1% FA (λ = 210 nm).  
Column: Gemini-NX 10µ C18 110A, 250 mm x 21.2 mm 
Method: 2-2–10–27–100%MeCN_0-6–9–23–25min, 20 mL/min. Rt = 25 min. 
The MeCN was removed by rotary evaporation and the compound was lyophilized from water. 
The compound was obtained as a yellow foam in 83% yield (9.5 mg, 6.7 µmol). 
The purity of the compound was analyzed by analytical reversed phase HPLC using H2O/MeCN 
+ 0.1% FA (λ = 210 nm).  
Column: Gemini-NX 5µ C18 110A, 150 mm x 4.60 mm 
Method: 2–2–10–45–100%MeCN_0–2–4–24–25min, 1 mL/min. Rt = 16.25 min. 
 
 
HR-MS (ESI) C66H79N11O23S2+ [M+2H]2+ calculated: 712.7530, found: 712.7536. 
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Hyp9NH2 (2.03) 
 
The synthesis of 4-hydroxyproline oligomer was performed on the solid phase using an automat-
ed peptide synthesizer (Syro I, Biotage). The synthesis was carried out on a Rink amide resin 
(Merck Millipore) with a loading of 0.59 mmol/g. The reagents used for the synthesis were: 
Fmoc-Hyp(tBu)-OH (4.0 equiv.), HCTU (4.0 equiv.), DiPEA in NMP (4.0 equiv.), Ac2O and 
DiPEA in DMF (50 equiv.), 20% piperidine in DMF. Coupling times were 1.5 h. From 0.1 g of 
the Rink amide resin, 0.25 g of resin was obtained after the synthesis. The peptide was either 
used for further transformations on the resin or cleaved using TFA:TIS:H2O (95:2.5:2.5) (10 
mL/g peptide resin). The cleaved peptide was dropped into MTBE at 0 °C (10 mL/g peptide), 
centrifuged and the MTBE was decanted. The peptide was washed following this sequence 3x. 
The solid was dried under a stream of N2. The solid was dissolved in water and filtered through a 
SPE column using water. The filtrate was lyophilized to yield a white foam.  
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Hyp10-FITC (2.04) 
 
Hyp10-NH2 (9.2 mg, 8 µmol, 1.0 equiv.) and fluorescein isothiocyanate isomer I (4.3 mg, 11 
µmol, 1.37 equiv.) were placed in a vial and 120 µL of Na2CO3/NaHCO3 buffer (pH = 9.5) and 
20 µL THF were added. The reaction mixture was stirred for 48 h at room temperature. The reac-
tion mixture was diluted with 2 mL DMSO:H2O (3:4) and filtered through a SPE column. The 
compound was purified by reversed phase HPLC using H2O/MeCN + 0.1% FA (λ = 210 nm).  
Column: Gemini-NX 10µ C18 110A, 250 mm x 21.2 mm 
Method: 2-2–10–27–100%MeCN_0-6–9–23–25min, 20 mL/min. Rt = 24.75 min.  
The MeCN was removed by rotary evaporation and the compound was lyophilized from water. 
The compound was obtained as a yellow foam in 52% yield (6.4 mg, 4.2 µmol). 
The purity of the compound was analyzed by analytical reversed phase HPLC using H2O/MeCN 
+ 0.1% FA (λ = 210 nm).  
Column: Gemini-NX 5µ C18 110A, 150 mm x 4.60 mm 
Method: 2–2–10–45–100%MeCN_0–2–4–24–25min, 1 mL/min. Rt = 16.25 min. 
 
 
HR-MS (ESI) C71H86N12O25S2+ [M+2H]2+ calculated: 769.2768 found: 769.2764. 
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Hyp9-Lys-CF (2.09) 
 
The synthesis of 4-hydroxyproline oligomer was performed on the solid phase using an automat-
ed peptide synthesizer (CS Bio, CS136XT). The synthesis was carried out on a Rink Amide-
NovaPEG resin (Merck Millipore) with a loading of 0.36 mmol/g. The reagents used for the syn-
thesis were: Fmoc-Hyp(tBu)-OH (4.0 equiv.), HOBt/HBTU (4.0 equiv.), DiPEA in NMP (2.0 
equiv.), 5% Ac2O with 5% 2,6-lutidine in DMF and 20% piperidine in DMF. Each coupling was 
carried out for 1.5 h. From 0.25 g of the Rink-NovaPEG resin, ∼0.4 g of resin was obtained after 
the synthesis. The following steps were performed manually. 
Rink Amide-NovaPEG resin loaded with the 9-mer of 4-hydroxyproline was swelled in CH2Cl2 
for 1 h and the solvent was replaced by DMF. In a separate flask Fmoc-Lys(Boc)-OH (127 mg, 
270 µmol, 3.0 equiv.) was dissolved in 4 mL DMF/CH2Cl2 (1:1) and DiPEA (45 µL, 270 µmol, 
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3.0 equiv.) was added. To the reaction mixture was added HBTU (112 mg, 270 µmol, 3.0 equiv.) 
and the solution was stirred for 8 min at room temperature. The solution was added to the resin 
and the resin was shaken for 1.5 h at room temperature. Completion of the coupling was checked 
using the chloranil test. The resin was washed with DMF (7x). Deprotection was performed us-
ing 4 mL of 20% piperidine in DMF for 3 min and 2x 4 mL for 10 min. The resin was washed 
with DMF (7x). In a separate flask 5-carboxyfluorescein (2.5 equiv., 225 µmol, 85 mg) was dis-
solved in 4 mL DMF and DiPEA (35 µL, 225 µmol, 2.5 equiv.) was added. To the solution was 
added HOBt (33 mg, 225 µmol, 2.5 equiv.) and DIC (28 µL, 225 µmol, 2.5 equiv.) and the solu-
tion was stirred for 15 min at room temperature with exclusion of light. The solution was added 
to the resin and it was shaken for 16 h with the exclusion of light. Completion of the reaction 
was checked using the Kaiser test. The solution was removed and the resin was washed with 
DMF (7x). The beads were treated with 20% piperidine in DMF for 15 min and the beads were 
washed with DMF (5x) and CH2Cl2 (5x).[169] The beads were dried under a stream of N2 until its 
weight remained constant. For cleavage of the peptide, the beads were treated with 8.4 mL of 
cleavage cocktail (8 mL TFA, 0.2 mL TIS, 0.2 mL H2O) for 2 h. The solution was filtered 
through a pad of cotton and TFA was removed by N2 stream. The residue was dissolved in 
MeCN/H2O (1:1) and filtered through a SPE column. The MeCN was removed by rotary evapo-
ration and the compound was purified by reversed phase HPLC using H2O/MeCN + 0.1% FA (λ 
= 492 nm).  
Column: Gemini-NX 10µ C18 110A, 250 mm x 21.2 mm 
Method: 10–10–20–100%MeCN_0–2–25–33min, 20 mL/min. Rt = 14.25 min. 
The MeCN was removed by rotary evaporation and the compound was lyophilized from water. 
The compound was obtained as a yellow foam in 47% yield (65 mg, 31 µmol). 
The purity of the compound was analyzed by analytical reversed phase HPLC using H2O/MeCN 
+ 0.1% FA (λ = 492 nm).  
Column: Gemini-NX 3µ C18 110A, 150 mm x 4.60 mm 
Method: 10–10–20–100%MeCN_0–1–15–20min, 1 mL/min. Rt = 11 min. 
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HR-MS (ESI) C72H91N12O253+ [M+H]3+: calculated: 507.87340 found: 507.87365.  
 
Hyp9-AHX-Lys-CF adduct (2.10) 
 
Rink amide resin loaded with Hyp9-NH2 was swelled in CH2Cl2 for 1 h. The solvent was re-
moved and the beads were washed with DMF (5x). In a separate flask Fmoc-6-AHX-OH (94 
mg, 266 µmol, 3.0 equiv.) was dissolved in 2.5 mL DMF by addition of DiPEA (44 µL, 266 
µmol, 3.0 equiv.) and it was stirred until a clear solution was obtained. HBTU (101 mg, 266 
µmol, 3.0 equiv.) was added and the solution was stirred for 8 min at room temperature. The 
solution was added to the beads and it was shaken at room temperature for 1 h 12 min. The reac-
tion was not complete and the reagents were removed from the resin. The coupling step was re-
peated at room temperature using a new set of reagents and it was shaken at room temperature. 
After 4 h the reaction was still not complete and the beads and the solution were transferred into 
a microwave reaction vial and the mixture irradiated in the microwave for 10 min at 75 °C. Al-
most complete conversion was obtained and the beads were transferred back into a peptide reac-
tion vessel containing a frit. The beads were washed thoroughly with DMF (7x) and capping was 
performed (0.54 mL Ac2O and 0.97 mL DiPEA in 2 mL DMF) for 30 min at room temperature. 
The beads were washed with DMF (7x) and Fmoc deprotection was performed using 20% piper-
idine in DMF for 3 min and 2x 10 min. The beads were washed with DMF (7x). In a separate 
flask, Fmoc-Lys(Boc)-OH (124 mg, 266 µmol, 3.0 equiv.) was dissolved in 2.5 mL DMF, Di-
PEA (44 µL, 266 µmol, 3.0 equiv.) and HBTU (101 mg, 266 µmol, 3.0 equiv.) was added and it 
was stirred for 8 min at room temperature. The beads were transferred in a microwave reactor, 
the solution was added and it was heated to 75 °C for 20 min in the microwave while stirring 
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(entire completion of the reaction by TNBS and Kaiser test). The beads were transferred to a 
peptide reaction vessel and thoroughly washed with DMF (7x). Deprotection was performed 
with 20% piperidine in DMF for 3 min and 2x for 10 min. The beads were washed with DMF 
(7x). 5-Carboxyfluorescein (105 mg, 266 µmol, 3.0 equiv.) was dissolved in 2.5 mL DMF and 
DiPEA (44 µL, 266 µmol, 3.0 equiv.) and HBTU (101 mg, 266 µmol, 3.0 equiv.) was added. It 
was stirred at room temperature for 8 min. The solution was added to the beads that were previ-
ously transferred into a microwave reaction vessel. The mixture was irradiated for 90 min at 75 
°C until the reaction was complete. The beads were washed with DMF (5x) and CH2Cl2 (5x).  
Cleavage of the peptide was performed for 2 h using 1 mL of cleavage cocktail (0.95 mL TFA, 
0.025 mL TIS, 0.025 mL H2O). The solution was filtered and dropped into 30 mL of 0 °C 
MTBE and it was rinsed with 2x 0.2 mL TFA. The mixture was centrifuged (15 min, 3000 
r/min) and the solvent decanted. The solid was washed with 30 mL MTBE (3x). After decanting, 
the residual MTBE was removed by N2 stream and the resulting solid was purified by reversed 
phase HPLC using H2O/MeCN + 0.1% FA (λ = 210 nm).  
Column: Gemini-NX 10µ C18 110A, 250 mm x 21.2 mm 
Method: 2-2–10–27–100%MeCN_0-6–9–23–25min, 20 mL/min. Rt = 20 min. 
The MeCN was removed by rotary evaporation and the compound was lyophilized from water. 
The compound was obtained as a yellow foam in 3.8% yield (5.5 mg, 3.4 µmol). 
The purity of the compound was analyzed by analytical reversed phase HPLC using H2O/MeCN 
+ 0.1% FA (λ = 210 nm).  
Column: Gemini-NX 5µ C18 110A, 150 mm x 4.60 mm 
Method: 2–2–10–45–100%MeCN_0–2–4–24–25min, 1 mL/min. Rt = 13.5 min. 
 
 
HR-MS (ESI) C78H101N13O262+ [M+2H]2+ calculated: 817.8485 found: 817.8495. 
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Hyp9-CF (2.18) 
 
5-Carboxyfluorescein (9.6 mg, 26 µmol, 1.6 equiv.), HBTU (9.1 mg, 24 µmol, 1.5 equiv.) and 
DiPEA (8 µL, 48 µmol, 3.0 equiv.) were dissolved in 80 µL DMF and stirred for 8 min at room 
temperature. The solution was added to Hyp9-NH2 (16.6 mg, 16 µmol, 1.0 equiv.) in 80 µL 
DMSO and the reaction was stirred for 24 with exclusion of light. The reaction mixture was pre-
cipitated in 8 mL MTBE at 0 °C and the mixture was centrifuged, the solvent was decanted and 
the solid resuspended with MTBE (4x). The resulting solid was dried with an N2 stream and pu-
rified by reversed phase HPLC using H2O/MeCN + 0.1% FA (λ = 492 nm).  
Column: Gemini-NX 10µ C18 110A, 250 mm x 21.2 mm 
Method: 10–10–80–100%MeCN_0–1–20–21min, 20 mL/min. Rt = 9.2 min. 
The MeCN was removed by rotary evaporation and the compound was lyophilized. The com-
pound was obtained as a yellow foam in 26% yield (5.8 mg, 4 µmol). 
The purity of the compound was analyzed by analytical reversed phase HPLC using H2O/MeCN 
+ 0.1% FA (λ = 254 nm).  
Column: Gemini-NX 3µ C18 110A, 150 mm x 4.60 mm 
Method: 10–10–80–100%MeCN_0–1–15–15.1min, 1 mL/min. Rt = 6.3 min. 
 
HR-MS (ESI) C66H78N10O242+ [M+H]2+ calculated: 697.25897 found: 697.25890.  
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 IK-466_clean5.lcd 
min
uV
5 10 15 20
0
25000
50000
1Detector A Channel 1 492nm
Method
<<Pump>>
  Mode : Binary gradient
  Pump A : LC-20AP
  Pump B : LC-20AP
  Total Flow : 1.00 mL/min
  B Conc. : 10.0 %
  B Curve : 0
  PressMax : 400 bar
  PressMin : 0 bar
  Pump A Compressibility : 0.45 /GPa
  Pump B Compressibility : 1.20 /GPa
<<Detector A>>
  Model : SPD-20A
  Lamp : D2
  Polarity : +
  Response : 1.0 sec
  Use Cell Temp : Use
  Cell Temp. : 40 C
  Wavelength Ch1 : 492 nm
  Wavelength Ch2 : 371 nm
  Intensity Unit : Volt
  Auxiliary Range : 1.0 AU/V
  Recorder Range : 1.0000
  Synchronize with Auxiliary Range : Off
  Recorder Mode : Ch1 Chromatogram output
  Ratio Range : 10
  Ratio Threshold : 0.0001 AU
<<LC Time Program>>
  Time Module Command Value
1.00 Pumps Pump B Conc. 10
15.00 Pumps Pump B Conc. 80
15.10 Pumps Pump B Conc. 100
20.00 Pumps Pump B Conc. 100
20.10 Pumps Pump B Conc. 10
25.00 Controller Stop
<<Mobile Phase Name>>
  Pump A Mobile Phase A : H2O + 0.1% HCOOH
  Pump B Mobile Phase A : MeCN
Sample Information
Acquired by : System Administrator
Sample Name : IK-466_clean
Sample ID : OHP-CFLUO
Tray# : 1
Vial# : 19
Injection Volume : 10
Data File : IK-466_clean5.lcd
Method File : IK_OHP_CFLUO_Analy10to80in20min.lcm
Batch File : 
Report Format File : DEFAULT.lsr
Date Acquired : 29.10.2015 11:55:59
Date Processed : 30.10.2015 08:53:04
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Hyp9-Lys-CF-Vancomycin (2.19) 
 
Vancomycin (58 mg, 39 µmol, 3.0 equiv.) was dissolved in 0.26 mL DMF:DMSO (1:1) and Di-
PEA (13 µL, 79 µmol, 6.0 equiv.), HOBt (5.3 mg, 39 µmol, 3.0 equiv.) and PyBOP (21 mg, 39 
µmol, 3.0 equiv.) were added and the reaction mixture was stirred for 8 min at room temperature. 
The solution was added to anchor 2.09 (20 mg, 13 µmol, 1.0 equiv.) and the mixture was stirred 
for 2 h at room temperature. The reaction mixture was dissolved in MeCN:H2O (1:3) and filtered 
through a SPE column. The MeCN was evaporated and the compound was purified by reversed 
phase HPLC. 
 
1st purification:  
H2O/MeCN + 0.1% FA (λ = 440 nm).  
Column: Gemini-NX 10µ C18 110A, 250 mm x 21.2 mm 
Method: 2–2–20–60–100%MeCN_0–3–33–41–50min, 20 mL/min. Rt = 26 min. 
2nd purification:  
H2O/MeCN + 0.1% FA (λ = 440 nm).  
Column: Gemini-NX 10µ C18 110A, 250 mm x 21.2 mm 
Method: 13%MeCN_isocratic, 20 mL/min, Rt = 8 min. 
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The MeCN was removed by rotary evaporation and the compound was lyophilized from water. 
The compound was obtained as a yellow foam in 44% yield (17 mg, 6 µmol). 
The purity of the compound was analyzed by analytical reversed phase HPLC using H2O/MeCN 
+ 0.1% FA (λ = 492 nm).  
Column: Gemini-NX 3µ C18 110A, 150 mm x 4.60 mm 
Method: 13%MeCN_isocratic, 1 mL/min. Rt = 7 min. 
 
 
HR-MS (ESI) C138H164N21O48Cl23+ [M+3H]3+ calculated: 984.34661 found: 984.34605. 
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 IK-487_F3_isocratic.lcd 
min
uV
5 10 15 20
0
2500
5000
7500
10000 1Detector A Channel 1 440nm
Method
<<Pump>>
  Mode : Binary gradient
  Pump A : LC-20AP
  Pump B : LC-20AP
  Total Flow : 1.00 mL/min
  B Conc. : 13.0 %
  B Curve : 0
  PressMax : 400 bar
  PressMin : 0 bar
  Pump A Compressibility : 0.45 /GPa
  Pump B Compressibility : 1.20 /GPa
<<Detector A>>
  Model : SPD-20A
  Lamp : D2
  Polarity : +
  Response : 1.0 sec
  Use Cell Temp : Use
  Cell Temp. : 40 C
  Wavelength Ch1 : 440 nm
  Wavelength Ch2 : 492 nm
  Intensity Unit : Volt
  Auxiliary Range : 1.0 AU/V
  Recorder Range : 1.0000
  Synchronize with Auxiliary Range : Off
  Recorder Mode : Ch1 Chromatogram output
  Ratio Range : 10
  Ratio Threshold : 0.0001 AU
<<LC Time Program>>
  Time Module Command Value
20.00 Pumps Pump B Conc. 13
20.10 Pumps Pump B Conc. 100
25.00 Pumps Pump B Conc. 100
25.10 Pumps Pump B Conc. 13
30.10 Controller Stop
<<Mobile Phase Name>>
  Pump A Mobile Phase A : H2O + 0.1% HCOOH
  Pump B Mobile Phase A : MeCN
Sample Information
Acquired by : System Administrator
Sample Name : IK-487_F3_isocratic
Sample ID : 
Tray# : 1
Vial# : 0
Injection Volume : 10
Data File : IK-487_F3_isocratic.lcd
Method File : IK_OHP_CFLUO_isocratic13for20min.lcm
Batch File : 
Report Format File : Analytical Report.lsr
Date Acquired : 03.02.2016 13:07:36
Date Processed : 03.02.2016 13:37:44
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Hyp9-pBrBzOH (2.24) 
 
p-Bromobenzoic acid (9.3 mg, 46 µmol, 1.6 equiv.) DiPEA (14 µL, 87 µmol, 3.0 equiv.) and 
HBTU (17 mg, 44 µmol, 1.5 equiv.) were dissolved in 0.15 mL DMF and stirred for 8 min at 
room temperature. The solution was added to Hyp9-NH2 (30 mg, 29 µmol, 1.0 equiv.) dissolved 
in 0.15 mL DMSO. The mixture was stirred at room temperature for 41 h. The solution was pre-
cipitated in 20 mL 0 °C MTBE and the mixture was centrifuged, the solvent was decanted and 
the solid resuspended with MTBE (3x). The solid was dried with a N2-stream and purified by 
reversed phase HPLC using H2O/MeCN + 0.1% FA (λ = 254 nm).  
Column: Gemini-NX 10µ C18 110A, 250 mm x 21.2 mm 
Method: 10–10–60–100%MeCN_0–3–25–25.1min, 20 mL/min. Rt = 10.8 min. 
The MeCN was removed by rotary evaporation and the compound was lyophilized from water. 
The compound was obtained as a white foam in 40% yield (14 mg, 12 µmol). 
The purity of the compound was analyzed by analytical reversed phase HPLC using H2O/MeCN 
+ 0.1% FA (λ = 254 nm).  
Column: Gemini-NX 3µ C18 110A, 150 mm x 4.60 mm 
Method: 10–10–80–100%MeCN_0–1–15–15.1, 1 mL/min. Rt = 5.4 min. 
 
HR-MS (ESI) C52H71N10O19Br2+ [M+2H]2+ calculated: 609.20347 found: 609.20380. 
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==== IK-469pure1.lcd ====
min
uV
5 10 15 20
0
250000
500000
750000
1Detector A Channel 1 245nm
Method
<<Pump>>
  Mode : Binary gradient
  Pump A : LC-20AP
  Pump B : LC-20AP
  Total Flow : 1.00 mL/min
  B Conc. : 10.0 %
  B Curve : 0
  PressMax : 400 bar
  PressMin : 0 bar
  Pump A Compressibility : 0.45 /GPa
  Pump B Compressibility : 1.20 /GPa
<<Detector A>>
  Model : SPD-20A
  Lamp : D2
  Polarity : +
  Response : 1.0 sec
  Use Cell Temp : Use
  Cell Temp. : 40 C
  Wavelength Ch1 : 245 nm
  Wavelength Ch2 : 225 nm
  Intensity Unit : Volt
  Auxiliary Range : 1.0 AU/V
  Recorder Range : 1.0000
  Synchronize with Auxiliary Range : Off
  Recorder Mode : Ch1 Chromatogram output
  Ratio Range : 10
  Ratio Threshold : 0.0001 AU
<<LC Time Program>>
  Time Module Command Value
1.00 Pumps Pump B Conc. 10
15.00 Pumps Pump B Conc. 80
15.10 Pumps Pump B Conc. 100
20.00 Pumps Pump B Conc. 100
20.10 Pumps Pump B Conc. 10
25.00 Controller Stop
<<Mobile Phase Name>>
  Pump A Mobile Phase A : H2O + 0.1% HCOOH
  Pump B Mobile Phase A : MeCN
Sample Information
Acquired by : System Administrator
Sample Name : IK-469pure
Sample ID : OHP-pBromoBenzOH
Tray# : 1
Vial# : 0
Injection Volume : 10
Data File : IK-469pure1.lcd
Method File : IK_OHP_CFLUO_Analy10to80in20min.lcm
Batch File : 
Report Format File : LSS Data Image.lsr
Date Acquired : 11.11.2015 14:05:25
Date Processed : 11.11.2015 15:41:24
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Hyp9-AHX (2.20) 
 
Hyp10-NH2 was used on Rink amide resin. 0.25 g of Resin was swelled in 2.5 mL CH2Cl2 for 2 h 
and the resin was washed with DMF (4x). Fmoc-6-Ahx-OH (102 mg, 0.29 mmol, 3.0 equiv.), 
HOBt (39 mg, 0.29 mmol, 3.0 equiv.), HBTU (110 mg, 0.29 mmol, 3.0 equiv.) and DiPEA (96 
µL, 0.58 mmol, 6.0 equiv.) were stirred for 8 min at room temperature and then added to the res-
in. The resin was heated under stirring and microwave irradiation at 75 °C for 15 min. Comple-
tion of the reaction was checked using the chloranil test. The beads were transferred in a reaction 
frit and washed thoroughly with DMF and deprotection was performed using 20% piperidine in 
DMF for 3 min and 2x for 10 min. The resin was washed with DMF (5x) and CH2Cl2 (5x) and 
dried with N2-stream. The peptide was cleaved from the resin using 2.5 mL TFA:TIS:H2O 
(95:2.5:2.5) at room temperature for 2 h. The solution was filtered through a Pasteur pipette 
filled with a pad of cotton and dropped into MTBE at 0 °C. The precipitate was centrifuged and 
the solvent decanted (3x). Fresh MTBE was added and centrifugation was repeated (3x). The 
MTBE was removed by N2 stream. The solid was dissolved in water and filtered through a SPE 
column and the column was flushed with water. The water was removed by lyophilization to 
obtain the product as a white foam in 74% yield (82 mg, 71 µmol). The compound was used 
without further purification in the next step. 
HR-MS (ESI) C51H78N11O19+ [M+H]+ calculated: 1148.54700 found: 1148.54679. 
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Hyp9-AHX-vancomycin (2.21) 
 
Vancomycin hydrochloride (30 mg, 20 µmol, 1.0 equiv.) and DiPEA (6.7 µL, 40 µmol, 2.0 
equiv.) were added to 400 µL DMF:DMSO (1:1) and it was stirred until the vancomycin com-
pletely dissolved. HOBt (2.73 mg, 20 µmol, 1.0 equiv.) was added followed by pyBOP (11 mg, 
20 µmol, 1.0 equiv.) and it was stirred for 8 min at room temperature. The solution was added to 
2.20 (46 mg, 40 µmol, 2.0 equiv.) and it was stirred for 3 h at room temperature. Conversion was 
checked by LC-MS and the reaction mixture was dissolved in MeCN:H2O (7:10) and filtered 
through a SPE column. The MeCN was removed by rotary evaporation and the crude mixture 
was purified by reversed phase HPLC. 
1st purification:  
H2O/MeCN + 0.1% FA (λ = 225 nm).  
Column: Gemini-NX 10µ C18 110A, 250 mm x 21.2 mm 
Method: 5–5–100%MeCN_0–5–33min, 20 mL/min, Rt = 9.6 min. 
2nd purification:  
H2O/MeCN + 0.1% FA (λ = 280 nm).  
Column: Gemini-NX 10µ C18 110A, 250 mm x 21.2 mm 
Method: 8%MeCN_isocratic, 20 mL/min, Rt = 6 min. 
The MeCN was removed by rotary evaporation and the compound was lyophilized. The com-
pound was obtained as a white foam in 44% yield (23.1 mg, 9 µmol). 
The purity of the compound was analyzed by analytical reversed phase HPLC using H2O/MeCN 
+ 0.1% FA (λ = 492 nm).  
Column: Gemini-NX 3µ C18 110A, 150 mm x 4.60 mm 
Method: 5–5–100%MeCN_0–2–20min, 1 mL/min. Rt = 5.5 min. 
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HR-MS (ESI) C117H153N20O42Cl23+ [M+H]3+ calculated: 859.99373 found: 859.99435. 
 
CF-vancomycin adduct (2.23) 
 
Vancomycin hydrochloride (15 mg, 10 µmol, 1.0 equiv.) and DiPEA (3.3 µL, 20 µmol, 2 equiv.) 
were added to 200 µL DMF:DMSO (1:1) and it was stirred until the vancomycin completely 
dissolved. HOBt (1.36 mg, 10 µmol, 1.0 equiv.) was added followed by pyBOP (5.26 mg, 10 
µmol, 1.0 equiv.) and it was stirred for 8 min at room temperature. The solution was added to the 
fluorescein linker (9.3 mg, 20 µmol, 2.0 equiv.) and it was stirred for 1 h at room temperature. 
Conversion was checked by LC-MS and the reaction mixture was diluted with 60% MeCN in 
water and filtered through a SPE column. The MeCN was removed by rotary evaporation and the 
crude mixture was purified by reversed phase HPLC. 
H2O/MeCN + 0.1% FA (λ = 280 nm).  
Column: Gemini-NX 10µ C18 110A, 250 mm x 21.2 mm 
Method: 5–5–25–100%MeCN_0–3–33–33.1min, 20 mL/min, Rt = 25.5 min.  
The MeCN was removed by rotary evaporation and the compound was lyophilized. The com-
pound was obtained as a yellow foam in 28% yield (5.36 mg, 3 µmol). 
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 D:\Data\Isabel\OHP_CFLUO\IK-500_pur _3.lcd 
 IK-500_pure_3.lcd 
min
uV
2.5 5.0 7.5 10.0 12.5 15.0 17.5
0
25000
50000
75000
100000
1Detector A Channel 1 280nm
Method
<<Pump>>
  Mode : Binary gradient
  Pump A : LC-20AP
  Pump B : LC-20AP
  Total Flow : 1.00 mL/min
  B Conc. : 5.0 %
  B Curve : 0
  PressMax : 400 bar
  PressMin : 0 bar
  Pump A Compressibility : 0.45 /GPa
  Pump B Compressibility : 1.20 /GPa
<<Detector A>>
  Model : SPD-20A
  Lamp : D2
  Polarity : +
  Response : 1.0 sec
  Use Cell Temp : Use
  Cell Temp. : 40 C
  Wavelength Ch1 : 280 nm
  Wavelength Ch2 : 225 nm
  Intensity Unit : Volt
  Auxiliary Range : 1.0 AU/V
  Recorder Range : 1.0000
  Synchronize with Auxiliary Range : Off
  Recorder Mode : Ch1 Chromatogram output
  Ratio Range : 10
  Ratio Threshold : 0.0001 AU
<<LC Time Program>>
  Time Module Command Value
2.00 Pumps Pump B Conc. 5
20.00 Pumps Pump B Conc. 100
25.00 Pumps Pump B Conc. 100
25.10 Pumps Pump B Conc. 5
30.10 Controller Stop
<<Mobile Phase Name>>
  Pump A Mobile Phase A : H2O + 0.1% HCOOH
  Pump B Mobile Phase A : MeCN
Sample Information
Acquired by : System Administrator
Sample Name : IK-500_pure_3
Sample ID : OHP-L-Vanco
Tray# : 1
Vial# : 0
Injection Volume : 10
Data File : IK-500_pure_3.lcd
Method File : IK-Analytical_5-100-100%_2-20-25min.lcm
Batch File : 
Report Format File : FractColl.lsr
Date Acquired : 13.04.2016 14:09:31
Date Processed : 13.04.2016 14:39:38
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The purity of the compound was analyzed by analytical reversed phase HPLC using H2O/MeCN 
+ 0.1% FA (λ = 280 nm).  
Column: Gemini-NX 3µ C18 110A, 150 mm x 4.60 mm 
Method: 5–5–25–100%MeCN_0–1–20–20.1min, 1 mL/min. Rt = 14.9 min. 
 
 
HR-MS (ESI) C92H100N11O29Cl23+ [M+3H]3+ calculated: 630.86830 found: 630.86989. 
 
7.2.4 Manual crystallization of 2.24 
 
 
 
 
 
 
 
 
 
 
 
  
 20.06.2016 16:47:04  Page 1 / 1 
 D:\Data\Isabel\OHP_CFLUO\IK-502_Prep1_F3.lcd 
 IK-502_Prep1_F3.lcd 
min
uV
0 5 10 15
0
25000
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75000 1Detector A Channel 2 280nm
Method
<<Pump>>
  Mode : Binary gradient
  Pump A : LC-20AP
  Pump B : LC-20AP
  Total Flow : 1.00 mL/min
  B Conc. : 5.0 %
  B Curve : 0
  PressMax : 400 bar
  PressMin : 0 bar
  Pump A Compressibility : 0.45 /GPa
  Pump B Compressibility : 1.20 /GPa
<<Detector A>>
  Model : SPD-20A
  Lamp : D2
  Polarity : +
  Response : 1.0 sec
  Use Cell Temp : Use
  Cell Temp. : 40 C
  Wavelength Ch1 : 225 nm
  Wavelength Ch2 : 280 nm
  Intensity Unit : Volt
  Auxiliary Range : 1.0 AU/V
  Recorder Range : 1.0000
  Synchronize with Auxiliary Range : Off
  Recorder Mode : Ch1 Chromatogram output
  Ratio Range : 10
  Ratio Threshold : 0.0001 AU
<<LC Time Program>>
  Time Module Command Value
1.00 Pumps Pump B Conc. 5
20.00 Pumps Pump B Conc. 25
20.10 Pumps Pump B Conc. 100
25.00 Pumps Pump B Conc. 100
25.10 Pumps Pump B Conc. 5
30.00 Controller Stop
<<Mobile Phase Name>>
  Pump A Mobile Phase A : H2O + 0.1% HCOOH
  Pump B Mobile Phase A : MeCN
Sample Information
Acquired by : System Administrator
Sample Name : IK-502_prep1_F3
Sample ID : CFluo-L-Vanco
Tray# : 1
Vial# : 0
Injection Volume : 20
Data File : IK-502_Prep1_F3.lcd
Method File : IK_OHP_CFLUO_Analy5to25in30min.lcm
Batch File : 
Report Format File : FractColl.lsr
Date Acquired : 25.04.2016 16:56:52
Date Processed : 25.04.2016 17:26:54
No. Substance Method solvent 1 solvent 2 result 
1 3 Vapor diffusion  MeOH - Oil 
3 3 Vapor dialysis MeOH  Et2O  Stiky residue 
3 2.24 Batch, seeding EtOH H2O No evaporation  
4 2.24 Batch, seeding MeCN H2O No evaporation  
5 2.24 Vapor diffusion  H2O Diglyme Amorphous solid 
6 2.24 Batch + seeding MeOH H2O No evaporation  
7 2.24 Vapor diffusion  H2O Dioxane Oil  
8 2.24 Vapor dialysis H2O MeCN Sticky residue 
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7.2.5 Screens used for the automated crystallization of 2.24 
The following screens were used a the Protein Crystallization Facility, Universität Zürich:44 
 
Compound Screen Temperature Concentration 
2.24 GS048 4 °C 10 mg/mL 
2.24 GS048 20 °C 10 mg/mL 
2.03 GS048 4 °C 10 mg/mL 
2.03 GS048 20 °C 10 mg/mL 
2.24 GS027 20 °C 20 mg/mL 
2.24 GS028 20 °C 20 mg/mL 
2.24 GS074 20 °C 20 mg/mL 
2.24 GS075 20 °C 20 mg/mL 
2.03 GS048 20 °C 60 mg/mL 
2.24 GS027 20 °C 60 mg/mL 
 
 
  
                                                
44 The conditions for the individual screens can be downloaded from the website of the Protein Crystallization Cen-
ter UZH: 
https://www.bioc.uzh.ch/de/forschung/core-facilities/protein-crystalization-center/initial-screen/initial-xtal-screens/ 
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7.3 Synthesis of pyrrolizidines 
7.3.1 Synthesis 
3-(3,4-Dihydro-2H-pyrrol-5-yl)propan-1-ol (3.21) 
i-Pr2NH (6.12 mL, 43.0 mmol, 1.2 equiv.) was dissolved in anhydrous THF 
(12 mL) and cooled to –78 °C. n-BuLi (25 mL of 1.6 mol/L solution in hexane, 
40.0 mmol, 1.1 equiv.) was added dropwise and stirred for 40 min at –78 °C. 
2-Methyl-1-pyrroline (3.4 mL, 36.0 mmol, 1.0 equiv.) was added and the reaction mixture was 
stirred for 1 h at –78 °C. Ethylene oxide (16 mL, 40.0 mmol, 2.5 mol/L solution in THF) was 
added at –78 °C and the mixture was stirred for 5 h. The reaction was quenched with sat. aq Na-
HCO3 (20 mL) and the layers were separated. The aqueous layer was extracted with EtOAc (3 × 
20 mL) and the combined organic layers were dried (MgSO4). Evaporation of the solvents gave 
the crude product as a yellow oil. The residue was purified by distillation (bp 55 °C/9.4·10–3 
mbar) to afford a colorless oil, which turned yellow upon standing; yield: 2.44 g (19 mmol, 
53%).  
1H-NMR (250 MHz, CDCl3) δ = 3.87–3.75 (m, 2H), 3.73–3.65 (m, 2H), 2.57–2.38 (m, J = 6.5 
Hz, 4H), 1.96–1.82 (m, 4H) ppm. 13C-NMR (101 MHz, CDCl3) δ = 179.57, 63.10, 60.43, 38.31, 
32.58, 28.62, 22.68 ppm. FTIR (neat) ν = 2965, 2921, 2854, 1619, 1431, 1303, 1267, 1194, 
1113 cm-1. HR-MS (ESI) C7H14NO+ [M+H]+ calculated: 128.1070 found: 128.1070. 
 
General procedure for the synthesis of isonitriles (GP 1):[170]  
Aniline (4.50 mmol, 1.00 equiv.) was dissolved in 20 mL CH2Cl2 and tetrabutylammonium bro-
mide (0.31 mmol, 0.069 equiv.) and aq. 50 w% NaOH (6.5 mL) was added. The mixture was 
stirred vigorously and CHCl3 (6.7 mmol, 1.50 equiv.) was added and stirring was continued 
overnight. The reaction mixture was transferred in a separation funnel, the layers were separated 
and the organic layer was washed with water (2x) and brine (1x). The combined organic layers 
were dried over MgSO4 and the solvent was carefully evaporated. The crude product was puri-
fied by column chromatography.  
 
Isocyanobenzene (3.31) 
Purified by column chromatography on silica gel using Et2O:pentane 1:7 (Rf = 0.8). The 
product was obtained as a greenish oil which darkens upon standing at room temperature 
in 57% yield (1.29 g, 12 mmol). 1H-NMR (400 MHz, CDCl3) δ = 7.45–7.35 (m, 5H) 
ppm. The analytical data were in agreement with the literature.[170] 
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1-Isocyano-4-methoxybenzene (3.35) 
Purified by column chromatography on silica gel using Et2O:pentane 1:2 (Rf = 0.67). 
The product was obtained as a brown oil in 62% yield (0.34 g, 2.5 mmol). 1H-NMR 
(400 MHz, CDCl3) δ = 7.31 (d, J = 8.7 Hz, 2H), 6.90–6.84 (m, 2H), 3.82 (s, 3H) ppm. 
13C-NMR (101 MHz, CDCl3) δ = 160.02, 127.90, 114.71, 55.72 ppm. 
 
1-Fluoro-4-isocyanobenzene (3.36) 
Purified by column chromatography on silica gel using Et2O:pentane 1:1 (Rf = 0.78). The 
product was obtained as a yellow greenish oil which darkens upon standing in 58% yield 
(0.31 g, 2.6 mmol).  
1H-NMR (400 MHz, CDCl3) δ = 7.38 (dd, J = 8.6, 4.7 Hz, 2H), 7.13–7.06 (m, 2H) ppm. 
13C-NMR (101 MHz, CDCl3) δ = 163.73, 161.23 (d, J = 251.79 Hz), 128.58, 128.49, 116.92, 
116.69, 100.13 ppm. 19F-NMR (376 MHz, CDCl3) δ = -111.81 ppm. 
 
1-Bromo-4-isocyanobenzene (3.37) 
Purified by column chromatography on silica gel using Et2O:pentane 1:5 (Rf = 0.83). The 
product was obtained as yellow crystals in 73% yield (0.38 g, 2.1 mmol). 
1H-NMR (400 MHz, CDCl3) δ = 7.54 (d, J = 8.6 Hz, 2H), 7.29–7.22 (m, 2H) ppm. 
 
 
1-Ethynyl-4-isocyanobenzene (3.39) 
The product was purified by column chromatography on silica gel using Et2O:pentane 
1:2 (Rf = 0.8). The Product was obtained as a yellow solid in 44% yield (0.23 g, 1.8 
mmol). 1H-NMR (400 MHz, CDCl3) δ = 7.55–7.47 (m, 2H), 7.34 (d, J = 8.6 Hz, 2H), 
3.20 (s, 1H) ppm. 13C-NMR (101 MHz, CDCl3) δ = 166.14, 133.28, 126.53, 123.68, 
82.03, 80.16 ppm. 
 
2-Isocyano-1,3-dimethoxybenzene (3.40) 
Purified by column chromatography on silica gel using Et2O:pentane 1:2 (Rf 
= 0.32). The product was obtained as a white solid in 78% yield (0.25 g, 1.5 
mmol).  1H-NMR (400 MHz, CDCl3) δ = 7.25 (t, J = 8.5 Hz, 1H), 6.56 (d, J 
= 8.5 Hz, 2H), 3.91 (s, 6H) ppm. 13C-NMR (101 MHz, CDCl3) δ = 156.47, 130.03, 103.88, 
56.39 ppm. FTIR (neat) ν = 3008, 2945, 2841, 1588, 1479, 1264, 1104 cm-1. HRMS (ESI) 
C9H10NO2+ [M+H]+: calculated: 164.0706 found: 164.0704. 
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4-(2-Isocyanoethyl)phenol (3.54) 
Formic acid  (0.690 mL, 18.2 mmol, 5.00 equiv.) and acetic anhydride (0.69 mL, 7.30 
mmol, 2.00 equiv.) were heated at 55 °C for 2 h. 4-(2-Aminoethyl)-phenol (500 mg, 
3.64 mmol, 1.00 equiv.) was dissolved in THF (6.0 mL) and the freshly prepared for-
mic anhydride was added dropwise at room temperature. The reaction mixture was 
stirred at room temperature overnight and quenched with aq. NaHCO3 solution. The 
mixture was transferred to a separation funnel, the layers were separated and the aqueous layer 
was extracted with EtOAc (3x). The combined organic layers were dried over MgSO4 and the 
solvents removed in vacuo.  
The crude formamide mixture 0.321g (1.94 mmol, 1.00 equiv.) was dissolved in dry CH2Cl2 (7.9 
mL) and cooled to -78 °C. Triphosgene (0.202 g, 0.68 mmol, 0.35 equiv.) was dissolved in dry 
CH2Cl2 (2.0 mL) and the solution was given dropwise to the formamide solution. After stirring 
for 5 min, N-methylmorpholine (0.42 mL, 3.80 mmol, 2.00 equiv.) was added slowly over the 
course of 10 min and the reaction mixture was stirred at -78 °C for 2 h. After 2 h the reaction 
conversion was monitored by TLC. The reaction was quenched with water and the heterogene-
ous mixture was allowed to warm to room temperature. The mixture was transferred to a separa-
tion funnel. The two layers were separated and the aqueous layer was extracted with CH2Cl2 
(2x). The organic layers were combined, dried over MgSO4 and the solvent was removed by 
evaporation. The compound was purified by column chromatography using Et2O:pentane 1:1. 
The product was obtained as a brown solid in 24% yield (68.0 mg, 1.94 mmol). 1H-NMR (400 
MHz, CDCl3) δ = 7.14–7.06 (m, 2H), 6.84–6.77 (m, 2H), 4.84 (s, 1H), 3.57 (tt, J = 7.0, 1.8 Hz, 
2H), 2.91 (tt, J = 7.2, 2.1 Hz, 2H) ppm. 13C-NMR (101 MHz, CDCl3) δ = 154.93, 130.07, 
115.78, 43.44, 34.99 ppm. FTIR (neat) ν = 3279, 3020, 2927, 1612, 1595, 1514, 1442, 1349, 
1225 cm-1. HR-MS (ESI) C9H8NO- [M+H]- calculated: 146.0611 found: 146.0612. M.p. = 44 °C. 
 
General procedure for the synthesis of pyrrolizidines (GP 2): 
 
Imine 3.21 (0.47 mmol, 1.0 equiv.) and isonitrile (0.47 mmol, 1.0 equiv.) were dissolved in dry 
toluene (3.6 mL) and Et3N·HCl (0.94 mmol, 2.0 equiv.) was added. The suspension was heated 
under reflux and the reaction was monitored by TLC. The reaction mixture was diluted with wa-
ter, the layers were separated and the aqueous layer was extracted using Et2O (2x 5 mL). The 
combined organic layers were dried over MgSO4. The solvents were removed in vacuo and the 
residue was purified by flash column chromatography on silica gel. 
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N-Phenyltetrahydro-1H-pyrrolizine-7a(5H)-carboxamide (3.32) 
Purification by column chromatography on silica gel using CH2Cl2:MeOH 
40:1 (Rf = 0.41). The product was obtained as a yellow solid in 46% yield 
(50 mg, 0.22 mmol). 1H-NMR (500 MHz, CDCl3) δ = 10.07 (s, 1H), 7.61 
(dd, J = 8.5, 1.0 Hz, 2H), 7.35– 7.28 (m, 2H), 7.11–7.05 (m, 1H), 3.22–3.13 
(m, 2H), 2.71–2.62 (m, 2H), 2.34–2.25 (m, 2H), 1.89–1.78 (m, 4H), 1.78–1.69 (m, 2H) ppm. 
13C-NMR (126 MHz, CDCl3) δ = 176.11, 138.15, 129.06, 123.93, 119.31, 78.47, 56.01, 37.37, 
26.37 ppm. FTIR (neat) ν = 3187, 2961, 2923, 2853, 1670, 1600, 1510, 1440, 1312 cm-1. HR-
MS (ESI) C14H19N2O+ [M+H]+ calculated: 231.1492 found: 231.1494. M.p.: 105–108 °C.  
 
N-(4-Methoxyphenyl)tetrahydro-1H-pyrrolizine-7a(5H)-carboxamide (3.55) 
Purification by column chromatography on silica gel using 
CH2Cl2:MeOH = 40:1 (Rf = 0.19). The product was isolated as a yel-
low solid in 68% yield (83 mg, 0.32 mmol). 1H-NMR (400 MHz, 
CDCl3) δ = 9.94 (s, 1H), 7.62–7.46 (m, 2H), 6.93–6.79 (m, 2H), 3.79 (s, 3H), 3.24–3.11 (m, 2H), 
2.71–2.60 (m, 2H), 2.36–2.24 (m, 2H), 1.91–1.67 (m, 6H) ppm. 13C-NMR (101 MHz, CDCl3) δ 
= 175.65, 156.10, 131.56, 120.81, 114.20, 78.38, 56.01, 55.65, 37.36, 26.39 ppm. FTIR (neat) ν 
= 3256, 2960, 2869, 1678, 1516, 1245 cm-1. HR-MS (ESI) C15H21N2O2+ [M+H]+ calculated: 
261.1598 found: 261.1601. M.p. = 84 °C. 
 
N-(4-(Methylthio)phenyl)tetrahydro-1H-pyrrolizine-7a(5H)-carboxamide (3.56) 
Purification by column chromatography on basic Al2O3 using 
EtOAc:pentane = 1:6 (Rf = 0.32). The product was obtained as a brown 
oil in 47 % yield (61 mg, 0.22 mmol). 1H-NMR (400 MHz, CDCl3) δ 
= 10.05 (s, 1H), 7.60–7.51 (m, 2H), 7.30–7.20 (m, 2H), 3.17 (ddd, J = 
10.3, 6.0, 4.6 Hz, 2H), 2.72–2.60 (m, 2H), 2.45 (s, 3H), 2.33–2.24 (m, 2H), 1.90–1.76 (m, 4H), 
1.76–1.67 (m, 2H) ppm. 13C-NMR (101 MHz, CDCl3) δ = 176.02, 135.99, 132.90, 128.43, 
119.92, 78.47, 56.02, 37.37, 26.38, 17.16 ppm. FTIR (neat) ν = 3245, 2964, 2938, 2868, 1681, 
1505 cm-1. HR-MS (ESI) C15H21N2OS+ [M+H]+ calculated: 277.1369 found: 277.1371. 
 
N-(2,6-Dimethoxyphenyl)tetrahydro-1H-pyrrolizine-7a(5H)-carboxamide (3.57) 
Purification by column chromatography on silica gel using CH2Cl2:MeOH 
= 30:1 (Rf = 0.22). The product was obtained as a yellow oil in 50 % yield 
(69 mg, 0.24 mmol). 1H-NMR (400 MHz, CDCl3) δ = 9.26 (s, 1H), 7.13 (t, 
J = 8.4 Hz, 1H), 6.57 (d, J = 8.4 Hz, 2H), 3.80 (s, 6H), 3.21 (dt, J = 10.2, 5.2 Hz, 2H), 2.64 (dt, J 
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= 9.9, 7.1 Hz, 2H), 2.35 (dt, J = 11.6, 5.4 Hz, 2H), 1.92–1.83 (m, 4H), 1.83–1.73 (m, 2H) ppm. 
13C-NMR (101 MHz, CDCl3) δ = 176.49, 155.70, 127.19, 115.18, 104.75, 100.11, 78.47, 56.27, 
55.97, 37.22, 26.58 ppm. FTIR (neat) ν = 3281, 2959, 2867, 1686, 1593, 1507, 1461, 1256, 
1108 cm-1. HR-MS (ESI) Exact mass calculated for C16H23N2O3+ [M+H]+ calculated: 291.1703 
found: 291.1704. 
 
N-(Benzo[d][1,3]dioxol-5-yl)tetrahydro-1H-pyrrolizine-7a(5H)-carboxamide (3.58) 
Purification by column chromatography on basic Al2O3 using 
EtOAc:pentane = 1:4 (Rf = 0.36). The product was obtained as a brown 
solid in 49 % yield (63 mg, 0.23 mmol). 1H-NMR (400 MHz, CDCl3) δ = 
9.97 (s, 1H), 7.36 (d, J = 2.1 Hz, 1H), 6.89 (dd, J = 8.3, 2.1 Hz, 1H), 6.74 
(d, J = 8.3 Hz, 1H), 5.93 (s, 2H), 3.16 (ddd, J = 10.3, 5.9, 4.5 Hz, 2H), 2.65 (ddd, J = 10.0, 7.8, 
5.6 Hz, 2H), 2.33–2.23 (m, 2H), 1.90–1.76 (m, 5H), 1.76–1.69 (m, 1H) ppm. 13C-NMR (101 
MHz, CDCl3) δ = 175.69, 147.91, 143.87, 132.73, 112.21, 108.14, 101.94, 101.25, 78.41, 56.00, 
37.36, 26.39 ppm. FTIR (neat) ν = 3238, 2963, 2870, 1676, 1504, 1038 cm-1. HR-MS (ESI) 
C15H19N2O3+ [M+H]+ calculated: 275.1390 found: 275.1389. M.p. = 106–108 °C. 
 
N-(Naphthalen-2-yl)tetrahydro-1H-pyrrolizine-7a(5H)-carboxamide (3.59) 
Purification by column chromatography on basic Al2O3 using 
EtOAc:pentane = 1:15 (Rf = 0.28). The product was isolated as a brown 
solid in 41% yield (54 mg, 0.19 mmol). 1H-NMR (400 MHz, CDCl3) δ 
= 10.18 (s, 1H), 8.25 (d, J = 2.1 Hz, 1H), 7.71 (dd, J = 9.8, 7.4 Hz, 3H), 7.48 (dd, J = 8.8, 2.2 
Hz, 1H), 7.37 (ddd, J = 8.2, 6.8, 1.4 Hz, 1H), 7.33–7.28 (m, 1H), 3.19–3.11 (m, 2H), 2.68–2.57 
(m, 2H), 2.32–2.23 (m, 2H), 1.84–1.73 (m, 4H), 1.73–1.66 (m, 2H) ppm. 13C-NMR (101 MHz, 
CDCl3) δ = 176.34, 135.59, 134.12, 130.59, 127.76, 127.65, 126.49, 124.82, 119.75, 115.76, 
78.59, 56.08, 37.43, 26.42 ppm. FTIR (neat) ν = 3237, 3057, 2963, 2867, 1681, 1524, 1496 cm-
1. HR-MS (ESI) C18H21N2O+ [M+H]+ calculated: 281.1648 found: 281.1650.  M.p. = 108–110 
°C. 
 
N-(4-Bromophenyl)tetrahydro-1H-pyrrolizine-7a(5H)-carboxamide (3.60) 
Purification by column chromatography on basic Al2O3 using 
EtOAc:pentane = 1:8 (Rf = 0.19). The product was isolated as a brown 
solid in 30% yield (43 mg, 0.14 mmol). 1H-NMR (400 MHz, CDCl3) δ = 
10.11 (s, 1H), 7.54–7.50 (m, 2H), 7.44–7.40 (m, 2H), 3.17 (ddd, J = 10.3, 6.1, 4.6 Hz, 2H), 2.70–
2.62 (m, 2H), 2.32–2.24 (m, 2H), 1.89–1.78 (m, 4H), 1.77–1.69 (m, 2H) ppm. 
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ppm. 13C-NMR (101 MHz, CDCl3) δ = 176.20, 137.23, 131.97, 120.92, 116.37, 78.51, 56.01, 
37.36, 26.36. FTIR (neat) ν = 3236, 2965, 2869, 1684, 1503, 1396 cm-1. HR-MS (ESI) 
C14H18BrN2O+ [M+H]+ calculated: 309.0597 found: 309.0600. M.p. = 91 °C. 
 
N-(4-Fluorophenyl)tetrahydro-1H-pyrrolizine-7a(5H)-carboxamide (3.61) 
Purification by column chromatography on basic Al2O3 using 
EtOAc:pentane = 1:8 (Rf = 0.5). The product was isolated as a brown 
solid in 41% yield (48 mg, 0.19 mmol). 1H-NMR (400 MHz, CDCl3) δ = 
10.06 (s, 1H), 7.64–7.51 (m, 2H), 7.07–6.95 (m, 2H), 3.17 (ddd, J = 10.3, 6.1, 4.6 Hz, 2H), 2.66 
(ddd, J = 9.9, 7.8, 5.4 Hz, 2H), 2.34–2.24 (m, 2H), 1.91–1.78 (m, 4H), 1.78–1.68 (m, 2H) ppm. 
13C-NMR (101 MHz, CDCl3) δ = 175.97, 159.2 (d, JC,F = 242.7 Hz), 134.29, 120.95, 120.87, 
115.72, 115.50, 78.42, 56.00, 37.35, 26.37 ppm. 19F NMR (376 MHz, CDCl3) δ =  –122.03 ppm. 
FTIR (neat) ν = 3230, 2965, 2870, 1680, 1513, 1407, 1211 cm-1. HR-MS (ESI) C14H18FN2O+ 
[M+H]+ calculated: 249.1398 found: 249.1399. M.p. = 133-135 °C 
 
N-(4-Ethynylphenyl)tetrahydro-1H-pyrrolizine-7a(5H)-carboxamide (3.62) 
Purification by column chromatography on basic Al2O3 using 
Et2O:pentane = 1:3 (Rf = 0.21). The product was obtained as a brown 
oil in 18 % yield (22 mg, 0.086 mmol). 1H-NMR (400 MHz, CDCl3) δ 
= 10.17 (s, 1H), 7.63–7.54 (m, 2H), 7.49–7.40 (m, 2H), 3.24–3.12 (m, 2H), 3.03 (s, 1H), 2.71–
2.62 (m, 2H), 2.33–2.24 (m, 2H), 1.90–1.78 (m, 4H), 1.78–1.67 (m, 2H) ppm. 13C-NMR (101 
MHz, CDCl3) δ = 176.25, 138.58, 133.03, 118.95, 117.22, 83.77, 78.53, 76.62, 56.01, 37.38, 
26.36 ppm. FTIR (neat) ν = 3236, 2931, 2869, 1680, 1513 cm-1. HR-MS (ESI) C16H19N2O+ 
[M+H]+ calculated: 255.1492 found: 255.1494. 
 
N-(5-Methyl-[1,1'-biphenyl]-2-yl)tetrahydro-1H-pyrrolizine-7a(5H)-carboxamide (3.63) 
Purification by column chromatography on silica gel using 
CH2Cl2:MeOH = 20:1 (Rf = 0.28). The product was obtained as a white 
solid in 63 % yield (88 mg, 0.28 mmol). 1H-NMR (400 MHz, CDCl3) δ 
= 10.24 (s, 1H), 8.27 (d, J = 8.3 Hz, 1H), 7.48–7.41 (m, 2H), 7.41–7.31 (m, 3H), 7.17 (dd, J = 
8.3, 2.1 Hz, 1H), 7.06 (d, J = 2.1 Hz, 1H), 2.77–2.66 (m, 2H), 2.42–2.33 (m, 2H), 2.34 (s, 3H), 
2.27–2.16 (m, 2H), 1.78–1.52 (m, 7H) ppm. 13C-NMR (101 MHz, CDCl3) δ = 175.74, 139.00, 
133.30, 132.89, 132.56, 130.47, 129.43, 128.97, 128.62, 127.53, 120.22, 78.56, 55.47, 37.11, 
26.74, 21.01 ppm. FTIR (neat) ν = 3208, 2963, 2868, 1681, 1514, 1467 cm-1. HR-MS (ESI) 
C21H25N2O+ [M+H]+ calculated: 321.1961 found: 321.1960. M.p. = 89–91 °C. 
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N-(2-Morpholinoethyl)tetrahydro-1H-pyrrolizine-7a(5H)-carboxamide (3.64) 
Purification by column chromatography on basic Al2O3 using EtOAc 
(Rf = 0.17). The product was obtained as a colorless oil in 32 % yield 
(41 mg, 0.15 mmol). 1H-NMR (250 MHz, CDCl3) δ = 8.17 (s, 1H), 
3.68 (d, J = 4.5 Hz, 4H), 3.31 (q, J = 6.2 Hz, 2H), 3.07 (ddd, J = 9.8, 6.5, 4.2 Hz, 2H), 2.62–2.52 
(m, 2H), 2.44 (dd, J = 6.3, 3.4 Hz, 6H), 2.22–2.11 (m, 2H), 1.84–1.60 (m, 6H) ppm. 13C-NMR 
(101 MHz, CDCl3) δ = 177.74, 161.24, 77.89, 67.18, 57.68, 55.88, 53.55, 37.17, 35.84, 26.37 
ppm. FTIR (neat) ν = 3326, 2956, 2856, 2811, 1657, 1512, 1118 cm-1. HR-MS (ESI) 
C14H26N3O2+ [M+H]+ calculated: 268.2020 found: 268.2023. 
 
N-(4-Hydroxyphenethyl)tetrahydro-1H-pyrrolizine-7a(5H)-carboxamide (3.65) 
The reaction was performed using GP 2 on a 0.145 mmol scale. 
Purification by column chromatography on silica gel using 
CH2Cl2:MeOH = 20:1 (Rf = 0.05). The product was obtained as a 
white solid in 51 % yield (16 mg, 74 µmol). 1H-NMR (400 MHz, 
CDCl3) δ = 8.11 (s, 1H), 7.04–6.96 (m, 2H), 6.78 (dd, J = 8.4, 1.6 Hz, 2H), 3.48 (q, J = 6.6 Hz, 
2H), 2.96 (dt, J = 10.3, 5.8 Hz, 2H), 2.72 (t, J = 6.8 Hz, 2H), 2.51 (ddd, J = 9.8, 7.8, 5.6 Hz, 2H), 
2.11–2.01 (m, 2H), 1.70 (m, 4H), 1.59–1.44 (m, 2H) ppm. 13C-NMR (101 MHz, CDCl3) δ = 
178.12, 155.40, 129.80, 115.56, 77.80, 55.81, 40.27, 37.07, 35.10, 29.84, 26.12 ppm. FTIR 
(neat) ν = 3279, 2922, 2867, 1640, 1513, 1451, 1241 cm-1. HR-MS (ESI) C16H23N2O2+ [M+H]+ 
calculated: 275.1754 found: 275.1755. M.p. = 109–111 °C. 
 
N-Benzyltetrahydro-1H-pyrrolizine-7a(5H)-carboxamide (3.66) 
Purification by column chromatography on basic Al2O3 using 
EtOAc:pentane = 1:3 (Rf  = 0.4). The product was obtained as a yellow oil 
in 71 % yield (82 mg, 0.34 mmol). 1H-NMR (400 MHz, CDCl3) δ = 8.32 
(s, 1H), 7.38–7.23 (m, 5H), 4.42 (d, J = 6.0 Hz, 2H), 3.10–3.00 (m, 2H), 2.63–2.52 (m, 2H), 
2.29–2.20 (m, 2H), 1.86–1.72 (m, 4H), 1.73–1.64 (m, 2H) ppm. 13C-NMR (101 MHz, CDCl3) δ 
= 177.72, 139.15, 128.74, 127.50, 127.31, 77.96, 55.94, 43.15, 37.35, 26.41 ppm. FTIR (neat) ν 
= 3322, 2961, 2868, 2362, 1667, 1508 cm-1. HR-MS (ESI) C15H21N2O+ [M+H]+ calculated: 
245.1648 found: 245.1651. 
(S)-N-(1-Phenylethyl)tetrahydro-1H-pyrrolizine-7a(5H)-carboxamide (3.67) 
Purification by column chromatography on silica gel using CH2Cl2:MeOH 
= 20:1 (Rf = 0.07). The product was obtained as a yellow oil in 69 % yield 
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(69 mg, 0.33 mmol, e.r. 99:1 by HPLC). 1H-NMR (400 MHz, CDCl3) δ = 8.30 (d, J = 6.7 Hz, 
1H), 7.37–7.20 (m, 5H), 5.06 (dq, J = 13.9, 6.9 Hz, 1H), 3.14–3.01 (m, 2H), 2.64–2.53 (m, 2H), 
2.28–2.20 (m, 1H), 2.19–2.11 (m, 1H), 1.85–1.63 (m, 6H), 1.47 (t, J = 6.3 Hz, 3H) ppm. 13C-
NMR (101 MHz, CDCl3) δ = 176.69, 144.08, 128.67, 127.10, 126.04, 77.88, 55.95, 47.98, 
37.21, 37.19, 26.40, 22.47 ppm. FTIR (neat) ν = 3313, 2965, 2868, 2361, 1669, 1497 cm-1. HR-
MS (ESI) C16H23N2O+ [M+H]+ calculated: 259.1805 found: 259.1805. [α]24D = -39.3° (c = 1.12, 
CHCl3). Enantiomeric purity was determined by HPLC using a Chiracel 1A column (1 mLmin-1, 
iPrOH:n-hexane 3:97, UV 225 nm): major enantiomer: Rt = 19.66 min, minor enantiomer Rt = 
26.93 min. 
 
Methyl-(hexahydro-1H-pyrrolizine-7a-carbonyl)-tryptophanate (3.68) 
The reaction was performed using GP 2 on a 0.3 mmol scale. Puri-
fication by column chromatography on silica gel using 
EtOAc:pentane = 3:1 (Rf = 0.04). The product was obtained as a 
colorless oil in 76 % yield (21 mg, 60 μmol, e.r. 53:47 by HPLC). 
1H-NMR (500 MHz, CDCl3) δ = 8.46 (d, J = 8.6 Hz, 1H), 8.31 (s, 1H), 7.57 (d, J = 7.8 Hz, 1H), 
7.34 (d, J = 8.1 Hz, 1H), 7.20–7.14 (m, 1H), 7.12–7.08 (m, 1H), 6.99 (d, J = 2.3 Hz, 1H), 4.87 
(dt, J = 8.8, 6.1 Hz, 1H), 3.68 (s, 3H), 3.31–3.27 (m, 2H), 3.01–2.95 (m, 1H), 2.82–2.76 (m, 1H), 
2.50–2.40 (m, 2H), 2.20–2.12 (m, 1H), 2.05–1.97 (m, 1H), 1.75–1.69 (m, 1H), 1.69–1.62 (m, 
4H), 1.40 (m, 1H) ppm. 13C-NMR (126 MHz, CDCl3) δ = 197.26, 182.60, 177.84, 172.79, 
136.20, 127.83, 122.62, 122.19, 119.57, 118.75, 111.26, 110.69, 77.73, 55.82, 55.64, 52.77, 
52.32, 37.27, 36.89, 27.87, 26.28, 26.21 ppm. FTIR (neat) ν = 3261, 2957, 2923, 2852, 1744, 
1646, 1506 cm–1. HR-MS (ESI) C7H14NO+ [M+H]+ calculated: 356.1969 found: 356.1972. The 
e.r. was determined of the Boc-protected derivative by HPLC using a Chiracel OD-H column 
(0.5 mLmin-1, iPrOH:n-hexane 3:97, UV 225 nm): first enantiomer: Rt = 41.83 min, second en-
antiomer Rt = 61.73 min.  
 
Methyl-(hexahydro-1H-pyrrolizine-7a-carbonyl)-valinate (3.69) 
Purification by column chromatography on silica gel using EtOAc:pentane 
= 1:1 (Rf = 0.05). The product was obtained as a colorless oil in 69 % yield 
(55 mg, 0.26 mmol, e.r. 50:50 by HPLC). 1H-NMR (400 MHz, CDCl3) δ = 
8.48 (d, J = 8.9 Hz, 1H), 4.45 (dd, J = 9.6, 4.9 Hz, 1H), 3.71 (s, 3H), 3.19–
3.08 (m, 2H), 2.65–2.56 (m, 2H), 2.23–2.13 (m, 3H), 1.83–1.69 (m, 6H), 0.92 (d, J = 6.8 Hz, 
3H), 0.88 (d, J = 6.9 Hz, 3H) ppm. 13C-NMR (126 MHz, CDCl3) δ = 177.80, 172.78, 77.95, 
56.76, 55.88, 55.86, 52.11, 37.33, 37.14, 31.21, 26.57, 26.42, 19.38, 17.75 ppm. FTIR (neat) ν = 
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3322, 2961, 2932, 2870, 1741, 1673, 1499 cm-1. HR-MS (ESI) C15H25N2O5+ [M+H]+ calculated: 
269.1860 found: 269.1861. The e.r. was determined by HPLC using a Chiracel AD-H column 
(0.5 mL min-1, iPrOH:n-hexane 5:95, UV 225 nm): first enantiomer: Rt = 16.73 min, second en-
antiomer Rt = 20.13 min. 
 
 Methyl-(hexahydro-1H-pyrrolizine-7a-carbonyl)-phenylalaninate (3.70) 
Purification by column chromatography on silica gel using 
CH2Cl2:MeOH = 40:1 (Rf = 0.48). The product was obtained as a yel-
low oil in 63 % yield (94 mg, 0.3 mmol, e.r. 53:47 by HPLC). 1H-NMR 
(400 MHz, CDCl3) δ = 8.38 (d, J = 7.6 Hz, 1H), 7.35–7.18 (m, 3H), 
7.17–7.08 (m, 2H), 4.85–4.75 (m, 1H), 3.72 (s, 3H), 3.18 (dd, J = 13.9, 5.5 Hz, 1H), 3.10–3.04 
(m, 1H), 3.03 (dd, J = 13.9, 7.6 Hz, 1H), 2.98–2.88 (m, 1H), 2.57–2.46 (m, 2H), 2.19–2.13 (m, 
1H), 2.01–1.93 (m, 1H), 1.76–1.71 (m, 1H), 1.70–1.63 (m, 4H), 1.51–1.40 (m, 1H) ppm. 13C-
NMR (101 MHz, CDCl3) δ = 172.40, 136.49, 129.35, 128.54, 127.07, 77.81, 55.85, 55.73, 
52.73, 52.33, 38.19, 37.12, 36.97, 26.33, 26.23 ppm. FTIR (neat) ν = 3310, 2955, 2869, 1744, 
1669, 1502 cm-1. HR-MS (ESI) C18H25N2O3+ [M+H]+ calculated: 317.1860 found: 317.1865. 
The e.r. was determined by HPLC using a Chiracel OD-H column (0.5 mL min-1, iPrOH:n-
hexane 3:97, UV 225 nm): first enantiomer: Rt = 48.25 min, second enantiomer Rt = 58.35 min. 
 
 Methyl-(hexahydro-1H-pyrrolizine-7a-carbonyl)-methioninate (3.71) 
Purification by column chromatography on silica gel using 
CH2Cl2:MeOH = 20:1 (Rf = 0.38). The product was obtained as a yel-
low oil in 63 % yield (89 mg, 0.3 mmol, e.r. 52:48 by HPLC). 1H-
NMR (400 MHz, CDCl3) δ = 8.49 (d, J = 9.1 Hz, 1H), 4.63 (td, J = 8.3, 5.0 Hz, 1H), 3.73 (s, 
3H), 3.19–3.06 (m, 2H), 2.65–2.56 (m, 2H), 2.52–2.46 (m, 2H), 2.24–2.12 (m, 3H), 2.10 (s, 3H), 
2.02–1.91 (m, 1H), 1.88–1.78 (m, 2H), 1.78–1.63 (m, 4H) ppm. 13C-NMR (101 MHz, CDCl3) δ 
= 177.80, 172.53, 77.70, 55.77, 55.76, 52.34, 51.09, 37.07, 31.98, 30.24, 26.41, 26.24, 15.56 
ppm. FTIR (neat) ν = 3305, 2960, 2868, 1743, 1670, 1502, 1442, 1224, 1175 cm-1. HR-MS 
(ESI) C14H25N2O3S+ [M+H]+ calculated: 301.1580 found: 301.1585. The e.r. was determined by 
HPLC using a Chiracel AD-H column (0.5 mL min-1, iPrOH:n-hexane 5:95, UV 225 nm): first 
enantiomer: Rt = 37.20 min, second enantiomer Rt = 42.95 min. 
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Dimethyl-(hexahydro-1H-pyrrolizine-7a-carbonyl)-glutamate (3.72) 
The reaction was performed using GP 2 on a 0.3 mmol scale. Purifi-
cation by column chromatography on silica gel using 
EtOAc:pentane = 2:1 (Rf = 0.05). The product was obtained as a 
yellow oil in 51 % yield (47 mg, 0.15 mmol, e.r. 57:43 by HPLC). 
1H-NMR (500 MHz, CDCl3) δ = 8.44 (d, J = 8.7 Hz, 1H), 4.53 (td, J = 8.8, 5.2 Hz, 1H), 3.72 (s, 
3H), 3.67 (s, 3H), 3.17–3.07 (m, 2H), 2.63–2.55 (m, 2H), 2.43–2.29 (m, 2H), 2.27–2.20 (m, 1H), 
2.20–2.11 (m, 2H), 2.01–1.92 (m, 1H), 1.81–1.64 (m, 6H) ppm. 13C-NMR (126 MHz, CDCl3) δ 
= 178.14, 173.14, 172.56, 77.80, 55.89, 55.84, 52.48, 51.92, 51.25, 37.22, 37.18, 30.36, 27.58, 
26.46, 26.33 ppm. FTIR (neat) ν = 3261, 2957, 2923, 2852, 1744, 1646, 1506, 1439 cm-1. HR-
MS (ESI) C15H25N2O5+ [M+H]+ calculated: 313.1758 found: 313.1762. The e.r. was determined 
by HPLC using a Chiracel AD-H column (0.5 mL min-1, iPrOH:n-hexane 5:95, UV 225 nm): 
first enantiomer: Rt = 63.66 min, second enantiomer Rt = 67.22 min. 
 
4-(3,4-Dihydro-2H-pyrrol-5-yl)-2-methylbutan-2-ol (3.90) 
Diisopropylamine (0.97 mL, 6.86 mmol, 1.2 equiv.) was dissolved in anhy-
drous THF (6.3 mL) and cooled to -78 °C. n-BuLi (3.93 mL of 1.6 M solution 
in hexane, 6.29 mmol, 1.1 equiv.) was added dropwise and stirred for 40 min 
at -78 °C. A solution of 2-methyl-1-pyrroline (0.57 mL, 5.71 mmol, 1.0 equiv.) in THF (0.6 mL) 
was added dropwise at -78 °C and it was stirred for 1 h. Isobutylene epoxide (0.51 mL, 5.71 
mmol, 1.0 equiv.) was added at -78 °C and it was stirred for further 60 min. The reaction mixture 
was allowed to warm to room temperature and stirred overnight.   
The reaction was quenched with 10% NaOH, (6 mL) and the aqueous layer was extracted with 
CH2Cl2 (3x). The combined organic layers were dried over MgSO4 followed by evaporation 
gave the product as a yellow oil in 91% yield (0.803 g, 5.17 mmol). The product was of suffi-
cient purity to be used for the next step. 
1H-NMR (CDCl3, 400 MHz) δ = 4.92 (bs, 1H), 3.78 (ddq, J = 9.4, 5.9, 2.0 Hz, 2H), 2.48 (m, 
4H), 1.91-1.86 (m, 2H), 1.83 (t, J = 6.8 Hz, 2H), 1.21 (s, 6H) ppm. 13C-NMR (101 MHz, CDCl3) 
δ = 179.6, 69.4, 60.4, 38.9, 38.2, 29.7, 29.0, 22.6 ppm. FTIR (neat) ν = 3373, 2928, 2968, 2928, 
2869, 2366, 1642 cm-1. HR-MS (ESI) C9H18NO+ [M+H]+ calculated: 156.1383 found: 156.1382. 
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 2-(3-Methylbut-2-en-1-yl)-N-phenylpyrrolidine-2-carboxamide (Δ2,3) and 2-(3-methylbut-
3-en-1-yl)-N-phenylpyrrolidine-2-carboxamide (Δ3,4 ) (3.92 and 3.93) 
Imine (44 mg, 0.28 mmol, 1.0 equiv.) and isonitrile (29 mg, 
0.28 mmol, 1.0 equiv.) were dissolved in dry toluene (2 mL) 
and Et3N·HCl (77 mg, 0.56 mmol, 2.0 equiv.) was added. The 
suspension was heated under reflux for 17 h and the reaction 
was monitored by TLC. The reaction mixture was diluted 
with water, the layers were separated and the aqueous layer was extracted using EtOAc (2x). The 
combined organic layers were dried over MgSO4. The solvents were removed in vacuo and the 
residue was purified by flash column chromatography on silica gel using CH2Cl2:MeOH 40:1, 
0.1% Et3N (Rf = 0.24). A mixture of two products (Δ2,3:Δ3,4 = 2.1:1) was obtained as a yellow oil 
in 57% yield (41 mg, 0.16 mmol). 
Δ2,3: 1H-NMR (400 MHz, CDCl3) δ = 10.06 (bs, J = 12.0 Hz, 1H), 7.66-7.58 (m, 2H), 7.37-7.27 
(m, 2H), 7.12-7.04 (m, 1H), 5.09 (tdt, J = 6.8, 2.9, 1.4 Hz, 1H), 3.16-3.03 (m, 1H), 2.99-2.89 (m, 
1H), 2.79-2.67 (m, 1H), 2.44-2.32 (m, 1H), 2.28-2.20 (m, 1H), 1.86 – 1.73 (m, 3H), 1.68 (d, J = 
27.2 Hz, 6H) ppm. 13C-NMR (101 MHz, CDCl3) δ = 175.51, 138.28, 136.37, 129.04, 123.85, 
119.29, 118.78, 70.12, 47.34, 36.73, 36.14, 26.56, 26.18, 18.14 ppm. 
Δ3,4: 1H-NMR (400 MHz, CDCl3) δ = 10.06 (bs, J = 12.0 Hz, 1H), 7.66-7.58 (m, 2H), 7.37-7.27 
(m, 2H), 7.12-7.04 (m, 1H), 4.73-4.65 (m, 2H), 3.16-3.03 (m, 1H), 2.99-2.89 (m, 1H), 2.44-2.32 
(m, 1H), 2.28-2.20 (m, 1H), 2.02 (td, J = 9.8, 5.4 Hz, 2H), 1.86 – 1.73 (m, 4H), 1.72 – 1.70 (m, 
3H) ppm. 13C-NMR (101 MHz, CDCl3) δ = 175.01, 145.29, 138.15, 129.07, 123.96, 119.32, 
110.33, 70.50, 47.34, 37.39, 37.21, 33.20, 26.33, 22.75 ppm. FTIR (neat) ν = 3244, 2967, 2872, 
1681, 1600, 1516, 1441, 1310, 755 cm-1. HR-MS (ESI) C16H23N2O+ [M+H]+ calculated: 
259.1805 found: 259.1809. 
 
4-(3,4-Dihydro-2H-pyrrol-5-yl)butan-1-ol (3.103) 
Freshly distilled diisopropylamine (0.2 mL, 1.4 mmol, 1.2 equiv.) was dis-
solved in THF (4.4 mL) and cooled to -78 °C. n-butyllithium (0.83 mL, 1.3 
mmol, 1.1 equiv.) was added and it was stirred for 45 min at -78 °C. Fresh-
ly distilled 2-methyl pyrroline was added and it was stirred for 1 h at -78 °C. Freshly distilled 
trimethyleneoxide (0.081 mL, 1.2 mmol, 1.0 equiv.) was added followed by boron trifluoride 
diethyl etherate (0.18 mL, 1.4 mmol, 1.2 equiv.) at -78 °C. The reaction stirred for 22h slowly 
warming to room temperature, before it was quenched with NaOH (10%). The reaction mixture 
was extracted with EtOAc (3x) and the combined organic layers were dried with MgSO4. The 
solvents were evaporated and the crude product was purified by column chromatography on 
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Al2O3 using EtOAc:pentane 7:1 (Rf = 0.1). The product was isolated as a brown oil in 16% yield 
(27 mg, 0.19 mmol). 
1H-NMR (500 MHz, CDCl3) δ = 3.97 (s, 1H), 3.78–3.71 (m, 2H), 3.55 (t, J = 6.2 Hz, 2H), 2.44 
(t, J = 8.2 Hz, 2H), 2.32 (t, J = 7.1 Hz, 2H), 1.83 (p, J = 7.7 Hz, 2H), 1.69 (p, J = 7.2 Hz, 2H), 
1.55 (p, J = 6.4 Hz, 2H) ppm. 13C-NMR (126 MHz, CDCl3) δ = 179.22, 61.33, 60.41, 37.57, 
33.06, 32.47, 22.48, 21.82 ppm. FTIR (neat) ν = 3364, 33270, 2924, 2868, 1643, 1430, 1060 
cm-1. HR-MS (ESI) C8H16NO+ [M+H]+ calculated: 142.1227 found: 142.1226. 
 
3-Oxo-N-phenyltetrahydro-1H-pyrrolizine-7a(5H)-carboxamide (3.105) 
Oxidation of pyrrolizidine-7a-carboxamide 3.32.[138] Pyrrolizidine 3.32 (15 
mg, 65 µmol, 1.0 equiv.) was dissolved in anhydrous CH2Cl2 (1.0 mL) under 
argon atmosphere. Benzyl(triethyl)ammonium permanganate[171] (61 mg, 
0.195 mmol, 3.0 equiv.) was added and the suspension was stirred for 24 h 
at room temperature. Conversion was monitored by GC-MS. The suspension was filtered over 
cotton and the filtrate was transferred to a separation funnel. The solution was washed with wa-
ter, the layers were separated and the aqueous layer was extracted with CH2Cl2 (2x 2 mL). The 
combined organic layers were dried over MgSO4 and the solvent was evaporated. The crude ex-
tracts were purified by column chromatography on silica gel using CH2Cl2:MeOH = 30:1 (Rf = 
0.2). The product was obtained as a white solid in 73% yield (11.6 mg, 47 μmol). 1H-NMR (400 
MHz, CDCl3) δ = 8.15 (s, 1H), 7.62 –7.54 (m, 2H), 7.40–7.31 (m, 2H), 7.19–7.12 (m, 1H), 3.86–
3.75 (m, 1H), 3.21 (ddt, J = 12.3, 8.3, 4.5 Hz, 1H), 2.82 (dt, J = 17.1, 10.2 Hz, 1H), 2.68–2.57 
(m, 2H), 2.50 (ddd, J = 17.1, 9.5, 2.4 Hz, 1H), 2.30–2.16 (m, 1H), 2.12–1.94 (m, 2H), 1.82–1.70 
(m, 1H) ppm. 13C-NMR (101 MHz, CDCl3) δ = 179.17, 172.36, 137.18, 129.27, 125.11, 120.05, 
75.23, 43.92, 36.60, 33.58, 32.23, 26.02 ppm. FTIR (neat) ν = 3293, 2953, 1676, 1598, 1532, 
1441 cm-1. HR-MS (ESI) C14H17N2O2+ [M+H]+ calculated: 245.1285 found: 245.1281. M.p. = 
172 °C.  
 
7a-(Phenylcarbamoyl)hexahydropyrrolizine-4(1H)-oxide (3.106) 
 
N-Oxide formation of pyrrolizidine-7a-carboxamide 3.32: To a solution 
of pyrrolizidine 3.32 (10 mg, 43 μmol, 1.0 equiv.) in anhydrous CH2Cl2 
(0.22 mL) at 0 °C was added a solution of m-CPBA (12 mg, 43 μmol, 1.0 
equiv.) in anhydrous CH2Cl2 (0.22 mL). The solution was stirred at 0 °C and completion was 
monitored on TLC (CH2Cl2:MeOH = 40:1). After 5 h, the reaction mixture was quenched with 
sat. aqueous Na2CO3 solution (1 mL). The mixture was diluted with Et2O (1 mL) and transferred 
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to a separation funnel. The organic layer was washed with Na2CO3 solution, the layers were sep-
arated and the organic layer was dried over MgSO4. The crude extracts were purified by column 
chromatography on basic Al2O3 using CH2Cl2:MeOH 100:1 as an eluent (Rf = 0.16). The product 
was obtained as a colorless oil in 82% yield (8.8 mg, 36 μmol). 1H-NMR (400 MHz, CDCl3) δ = 
14.60 (s, 1H), 7.62 (dd, J = 8.2, 1.1 Hz, 3H), 7.35–7.25 (m, 2H), 7.07 (td, J = 7.3, 1.2 Hz, 1H), 
3.87–3.76 (m, 2H), 3.76–3.66 (m, 2H), 2.97–2.86 (m, 2H), 2.38–2.25 (m, 2H), 2.18–2.00 (m, 
4H) ppm. 13C-NMR (101 MHz, CDCl3) δ = 167.96, 138.52, 128.98, 124.09, 120.43, 83.53, 
68.40, 32.97, 19.87 ppm. FTIR (neat) ν = 3386, 3270, 2922, 1661, 1596, 1556, 1495, 1449 cm-1. 
HR-MS (ESI) C14H19N2O2+ [M+H]+ calculated: 247.1441 found: 247.1444. 
 
N-((Tetrahydro-1H-pyrrolizin-7a(5H)-yl)methyl)aniline (3.107) 
 
Reduction of pyrrolizidine-7a-carboxamide 3.32: In a two-neck round-
bottom flask equipped with a reflux condenser under argon was dissolved 
pyrrolizidine 3.32 (65 mg, 0.28 mmol, 1.0 equiv.) in toluene (3 mL) and the 
solution was cooled to 0 °C. Red-Al®-solution (0.73 mL, 2.26 mmol, 60% in toluene) was added 
dropwise. The cooling bath was removed after addition and the reaction mixture was heated to 
reflux for 15 h. The reaction mixture was cooled to 0 °C and aqueous NaOH (c = 3 mol·L-1, 6.5 
mL) was added carefully. The reaction mixture was stirred at room temperature overnight. The 
reaction mixture was transferred into a separation funnel and diluted with ether. The aqueous 
layer was separated and the organic layer was washed with 10% NaOH solution and brine. The 
organic layer was dried over MgSO4 and the solvent was evaporated to give the product as a pale 
yellow oil in 99% yield (60.7 mg, 0.28 mmol). 1H-NMR (400 MHz, Methanol-d4) δ = 7.12–7.05 
(m, 2H), 6.67–6.62 (m, 2H), 6.62–6.57 (m, 1H), 3.07–3.00 (m, 2H), 3.03 (s, 2H), 2.74–2.66 (m, 
2H), 2.00–1.93 (m, 2H), 1.92–1.85 (m, 2H), 1.82–1.74 (m, 2H), 1.72–1.66 (m, 2H) ppm. 13C-
NMR (101 MHz, Methanol-d4) δ = 150.68, 130.03, 117.94, 113.83, 56.41, 53.52, 37.32, 25.77 
ppm. FTIR (neat) ν = 3360, 2953, 2865, 2357, 1604, 1504, 1315, 1260 cm-1. HR-MS (ESI) 
C14H21N2+ [M+H]+ calculated: 217.1699 found 217.1703. 
 
7a-((Phenylamino)methyl)octahydropyrrolizin-4-ium hydrogen carbonate (3.109) 
Pyrrolizidine 3.107 (19 mg, 88 µmol) was dissolved in 0.6 mL CD3OD. A 
CO2 stream generated from dry ice was bubbled through the solution for 5 
min. The sample was submitted for NMR analysis. Mass analysis resulted 
in the same mass as 3.107.  
1H-NMR (500 MHz, CD3OD) δ = 7.19–7.11 (m, 2H), 6.78–6.74 (m, 2H), 6.70 (tt, J = 7.3, 1.1 
Hz, 1H), 3.56 (dt, J = 11.8, 7.0 Hz, 2H), 3.43 (s, 2H), 3.19 (dt, J = 12.4, 6.3 Hz, 2H), 2.27–2.17 
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(m, 2H), 2.21–2.10 (m, 2H), 2.11–2.04 (m, 2H), 2.03–1.97 (m, 2H) ppm. 13C-NMR (126 MHz, 
CD3OD) δ = 161.56, 149.86, 130.19, 118.98, 114.25, 83.15, 56.61, 49.92, 35.97, 25.12 ppm. 
FTIR (neat) ν = 2952, 2863, 1605, 1504, 1313, 1259 cm-1. 
 
7.3.2 H218O-labeling experiment 
 
 
Incorporation of 18O-labeled (97%) water was investigated as follows: 
(S)-(−)-α-Methylbenzyl isocyanide (5.12 mg, 0.039 mmol, 1.0 equiv.) and imine 3.21 (5 mg, 
0.039 mmol, 1.0 equiv.) were dissolved in toluene (0.18 mL) and suspended with triethylamine 
hydrochloride (10.7 mg, 0.078 mmol, 2.0 equiv.). 18O-labeled water (7.00 μL, 0.39 mmol, 10 
equiv.) was added and the reaction mixture was heated to 100 °C overnight. The reaction mix-
ture was diluted with Et2O and water and the aqueous layer was extracted using Et2O (3x). The 
combined organic layers were dried over MgSO4 and the solvent was evaporated. The residue 
was purified by column chromatography using CH2Cl2:MeOH = 20:1 (Rf = 0.07). The product 
was analyzed by HR-MS (ESI).  
Table 9 shows the natural isotope distribution of 3.67 measured by HR-MS (ESI). The spectrum 
of the reaction in presence of 18O-labeled is shown in Table 10. A clear enhancement of the iso-
tope 261.18 is observed. The isotope corresponds to 14.2% of the main isotope 259.18 whereas 
the natural distribution includes only 1.4% of isotope 261.18. We therefore obtain 12.8% incor-
poration. 
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Table 9: HR-MS (ESI) report of 3.67. 
 
 
  
Analysis Info 05.03.2014 17:39:39Acquisition Date
Analysis Name N:\new acq data\IK-254 001.d
hnhn Direct_Infusion_pos mode_75-1500 mid 4eV.m OperatorMethod
Isabel Kerschgens, IK-254 maXis 4G 21243Sample Name Instrument / Ser#
IK-254, 10 ug / ml ACNComment
Acquisition Parameter
0.4 BarSet NebulizerPositive Ion PolarityESI Source Type
180 °CSet Dry HeaterNot active Set Capillary 4500 VFocus
Set Dry Gas 4.0 l/minSet End Plate Offset -500 V75 m/zScan Begin
Scan End 500.0 VppSet Collision Cell RF1500 m/z Set Divert Valve Waste 
259.1805 +MS, 0.37-0.58min #(22-34)
0
1
2
3
5x10
Intens.
200 400 600 800 1000 1200 1400 m/z
259.1805
+MS, 0.37-0.58min #(22-34)
0
2
4
5x10
Intens.
240 260 280 300 320 340 360 m/z
# m/z I % I
  1 152.6281 0.0 168
  2 155.1175 0.1 225
  3 159.6094 0.0 178
  4 160.6166 0.3 938
  5 161.1184 0.1 213
  6 161.6066 0.0 171
  7 168.6141 0.1 280
  8 169.6221 0.2 657
  9 173.1418 0.0 168
 10 178.6272 0.1 442
 11 181.1302 0.0 178
 12 182.1462 0.0 182
 13 186.9228 0.1 209
 14 187.0940 0.1 416
 15 190.1355 0.0 167
 16 201.1017 0.0 166
 17 205.0599 0.1 235
 18 217.1048 0.2 661
 19 223.0968 0.0 181
 20 227.0952 0.0 174
 21 229.1407 0.1 225
 22 231.1199 0.2 807
 23 239.0887 0.1 316
 24 251.1616 0.1 214
 25 254.2477 0.0 172
 26 256.2630 0.1 258
 27 259.0422 0.1 200
 28 259.0819 0.1 236
 29 259.1805 100.0 366197
 30 260.1836 15.7 57658
 31 261.1303 0.1 368
 32 261.1865 1.4 5002
 33 262.1894 0.1 365
 34 265.1428 0.0 174
 35 265.2142 0.1 210
 36 267.1616 0.1 251
 37 269.1654 0.1 201
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Table 10: HR-MS (ESI) report of 3.86. 
 
  
Analysis Info 09.10.2014 09:22:22Acquisition Date
Analysis Name N:\new acq data\IK-317-rep 002.d
hnhn Direct_Infusion_pos mode_75-1700 mid 4eV.m OperatorMethod
Isabel Kerschgens, IK-317-rep maXis 4G 21243Sample Name Instrument / Ser#
IK-317-rep, ca. 10 ug/ml MeCNComment
Acquisition Parameter
0.4 BarSet NebulizerPositive Ion PolarityESI Source Type
180 °CSet Dry HeaterNot active Set Capillary 3600 VFocus
Set Dry Gas 4.0 l/minSet End Plate Offset -500 V75 m/zScan Begin
Scan End 500.0 VppSet Collision Cell RF1700 m/z Set Ion Energy ( MS only ) 4.0 eV
259.1808
528.5102
+MS, 0.09-0.21min #(5-12)
0
1
2
5x10
Intens.
200 400 600 800 1000 1200 1400 1600 m/z
259.1808
260.1837 261.1848
262.1879
+MS, 0.09-0.21min #(5-12)
0
1
2
5x10
Intens.
259.0 259.5 260.0 260.5 261.0 261.5 262.0 262.5 263.0 m/z
# m/z I % I
  1 120.9870 0.3 797
  2 136.9611 0.3 938
  3 147.0084 0.2 538
  4 152.9349 0.5 1304
  5 160.9796 0.2 488
  6 161.0239 2.3 6413
  7 162.0247 0.2 502
  8 163.0386 0.2 489
  9 170.1175 0.3 926
 10 170.9613 0.2 592
 11 172.0945 0.3 828
 12 197.0783 4.2 11497
 13 198.0816 0.4 1217
 14 200.9721 0.3 747
 15 217.0470 4.4 12165
 16 217.1046 0.3 794
 17 218.0505 0.5 1499
 18 218.9851 0.2 674
 19 228.9667 0.2 674
 20 230.2475 0.2 482
 21 233.0210 0.2 491
 22 253.0170 1.0 2627
 23 256.9623 0.2 593
 24 258.9776 0.3 869
 25 259.0712 0.2 494
 26 259.1808 100.0 274958
 27 260.1837 16.6 45553
 28 261.1848 14.2 38931
 29 262.1879 2.4 6504
 30 263.1916 0.3 688
 31 267.0323 2.0 5590
 32 268.0337 0.3 822
 33 269.0304 0.2 509
 34 274.2735 0.9 2593
 35 275.1246 0.3 781
 36 275.2767 0.2 523
 37 276.2295 0.8 2258
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7.4 Application of pyrrolizidines in carbon dioxide capture  
7.4.1 Synthesis 
(Tetrahydro-1H-pyrrolizin-7a(5H)-yl)methanamine (4.13) 
An oven-dried flask was charged with LiAlH4 (8.40 g, 220 mmol, 4.0 equiv.) and 
was evacuated and backfilled with argon three times. Anhydrous THF (100 mL) 
was added and the reaction mixture was cooled to 0 °C. The crude mixture of nitrile 
4.21 (7.69 g) was slowly added to the reaction mixture. The suspension was allowed to warm to 
room temperature and stirred for 15 h. The mixture was cooled to 0 °C and quenched with water 
(1 mL/g LiAlH4), aqueous sodium hydroxide (15%, 1 mL/g LiAlH4) and water (3 mL/g LiAlH4). 
The suspension was stirred for 15 min and was diluted with diethyl ether (50 mL). Na2SO4 was 
added and the suspension was stirred for another 30 min. The mixture was filtered over a pad of 
Celite® and the solvent was removed under reduced pressure. The residue was treated with 
HCl·iPrOH (21%, 10 mL) and filtered. The resulting solid was refluxed in EtOH/iPrOH (7:1) to 
yield the dihydrochloride salt of the free amine. The salt was resuspended in diethyl ether and 
gaseous NH3 was bubbled through the suspension to release the free amine. Filtration and subse-
quent removal of the solvent afforded the desired product (2.07 g, 14.8 mmol, 27% from 4.19) as 
colorless oil. The analytical data are in agreement with the literature.[120,172] 
1H-NMR (400 MHz, CD3OD): δ = 2.98–2.92 (m, 2H), 2.68–2.63 (m, 2H), 2.52 (s, 2H), 1.89–
1.82 (m, 4H), 1.76–1.68 (m, 2H), 1.64–1.57 (m, 2H) ppm. 13C-NMR (101 MHz, CD3OD): 
δ = 76.1, 55.4, 51.3, 36.9, 25.6 ppm. 
 
2-(Tetrahydro-1H-pyrrolizin-7a(5H)-yl)ethan-1-amine (4.15) 
Crude (1-azabicyclo[3.3.0]octane-5-yl)acetonitrile (9.79 g) was dissolved in metha-
nol (60 mL) and sodium hydroxide (5.26 g, 130 mmol, 2.0 equiv.) was added. 
Raney-Ni (50% in water, 4.12 g) was added and the reaction mixture was charged 
with hydrogen atmosphere (1 atm). The reaction mixture was stirred under hydro-
gen atmosphere for 24h until full conversion of the starting material was observed in the 1H-
NMR. The mixture was filtered over a pad of Celite® and the solvent was removed under re-
duced pressure. The resulting residue was resuspended in Et2O and stirred for 30 min at room 
temperature. The precipitate was filtered off and the organic layer was concentrated under re-
duced pressure. The resulting crude amine (8.82 g, 88%) was treated with a HCl·iPrOH solution 
(21%) to precipitate the free amine. The resulting dihydrochloride salt (determined by EA) was 
recrystallized from EtOH/iPrOH (4:1) and resuspended in diethyl ether. NH3 gas was bubbled 
through the suspension for 30 min and the mixture was stirred for 5h at room temperature. Filtra-
N
NH2
N
NH2
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tion and subsequent removal of the solvent afforded the desired product as light yellowish oil in 
42% yield (4.25 g, 27.6 mmol). The analytical data were in agreement with the literature.[120]  
1H-NMR (400 MHz, CD3OD) δ = 3.02–2.91 (m, 2H), 2.68–2.54 (m, 2H), 2.60–2.52 (m, 2H), 
2.36 (s, 2H), 1.90–1.67 (m, 6H), 1.70–1.56 (m, 4H) ppm. 13C-NMR (101 MHz, CD3OD) δ = 
74.0, 56.0, 49.0, 41.9, 38.2, 36.1, 25.5 ppm. 
 
N-Methyl-1-(tetrahydro-1H-pyrrolizin-7a(5H)-yl)methanamine (4.14) 
An oven-dried two-neck flask was charged with LiAlH4 (195 mg, 5.14 mmol, 
2.0 equiv.) and was three times evacuated and backfilled with argon. After cooling 
to 0 °C THF (5.0 mL) was added followed by 4.22 (428 mg, 2.54 mmol, 1.0 equiv.) 
in THF (10 mL) was added dropwise. The reaction mixture was heated to reflux for 
2h. After cooling to 0 °C, remaining LiAlH4 was quenched by the addition of water (1 mL/g 
LiAlH4), NaOH (15%, 1 mL/g LiAlH4) and water (3 mL/g LiAlH4). The resulting slurry was 
diluted with diethyl ether (10 mL) and stirred for 5 min., treated with Na2SO4 and the suspension 
was stirred for 15 min. Filtration over Celite® and removal of the solvent afforded the desired 
product as a colorless oil in 84% yield (330 mg, 2.14 mmol). 
1H-NMR (400 MHz, CDCl3): δ = 2.99–2.93 (m, 2H), 2.62 (m, 2H), 2.43 (s, 2H), 2.43 (s, 3H), 
1.88–1.80 (m, 2H), 1.79–1.67 (m, 4H), 1.56–1.50 (m, 2H), 1.26 (br. s, 1H) ppm. 13C-NMR (101 
MHz, CDCl3): δ = 73.1, 62.7, 55.9, 37.4, 37.2, 25.3 ppm. FTIR (neat) v = 3320, 2949, 2865, 
2785, 2687, 1685, 1457, 1319, 1262, 1136, 1095, 1024, 904, 794, 700, 633 cm-1. 
HR-MS (ESI) C9H19N2+ [M+H]+ calculated: 155.1543 found: 155.1544. 
 
N-Methyl-2-(tetrahydro-1H-pyrrolizin-7a(5H)-yl)ethan-1-amine (4.16) 
An oven-dried two-neck flask was charged with LiAlH4 (154mg, 4.06 mmol, 
2.0 equiv.) and was three times evacuated and backfilled with argon. After cool-
ing to 0 °C THF (5 mL) was added followed by solution of 4.25 (370 mg, 
2.03 mmol, 1.0 equiv.) in THF (14 mL) was added dropwise. The reaction mix-
ture was heated to reflux for 2h. After cooling to 0 °C, remaining LiAlH4 was quenched by the 
addition of water (1 mL/g LiAlH4), NaOH (15%, 1 mL/g LiAlH4) and water (3 mL/g LiAlH4). 
The resulting slurry was diluted with Et2O (15 mL), Na2SO4 was added and the mixture was 
stirred for 15 min. Filtration over Celite® and removal of the solvent afforded the crude product 
(348 mg, quant.) as a yellowish oil. The oil was treated with HCl·Et2O (18%, 5-10 mL) under 
formation of a white solid which was identified as the dihydrochloride salt of the product (de-
termined by EA). The solid was recrystallized from iPrOH/EtOH (1:4, 11 mL) and precipitated 
N
NH
Me
N
HN
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with Et2O leading to the HCl-salt of the desired product (413 mg, 84%). The HCl-salt was sus-
pended in Et2O and NH3 gas was introduced for 1h. Filtration and subsequent removal of the 
solvent afforded the product colorless oil in 74% yield (254 mg, 1.51 mmol). 
1H-NMR (400 MHz, CDCl3): δ = 3.00–2.95 (m, 2H), 2.61–2.53 (m, 4H), 2.42 (s, 3H), 1.78–1.67 
(m, 6H), 1.62–1.58 (m, 2H), 1.55–1.49 (m, 2H) ppm. 13C-NMR (101 MHz, CDCl3): δ = 77.4, 
55.5, 49.3, 42.3, 37.8, 36.9, 25.1 ppm. FTIR (neat) v = 3287, 2950, 2865, 1550, 1478, 1382, 
1308, 1261, 1163, 1059, 929, 814, 706 cm-1. HR-MS (ESI) C10H21N2+ [M+H]+ calculated: 
169.1700 found: 169.1702. 
 
N-(2-(Tetrahydro-1H-pyrrolizin-7a(5H)-yl)ethyl)aniline (4.17) 
An oven dried Schlenk tube was charged with BrettPhos precatalyst (35.0 mg, 
43.8 µmol, 1 mol%, Sigma Aldrich: 718750), BrettPhos ligand (24.0 mg, 
44.7 µmol, 1 mol%) and NaOtBu (838 mg, 8.72 mmol, 2.0 equiv.) and it was 
three times evacuated and backfilled with argon. Then amine 4.15 (803 mg, 
5.21 mmol, 1.2 equiv.) was added as a solution in dioxane (15 mL). Chloroben-
zene (0.45 mL, 4.44 mmol, 1.0 equiv.) was added and the mixture was heated to 80 °C for 1.5h 
until GC-MS showed full conversion. After cooling to room temperature ethyl acetate (10 mL) 
was added and the mixture was transferred into a separation funnel and washed with water 
(15 mL). The aqueous layer was extracted with ethyl acetate (2x) and the combined organic lay-
ers were dried over Na2SO4 giving the crude product. The mixture was treated with HCl·Et2O 
(18%, 15 mL) and washed with Et2O. The resulting solid was recrystallized in iPrOH/EtOH (1:3, 
15 mL) and after cooling to room temperature treated with Et2O. The resulting solid was washed 
with Et2O, leading to the HCl-salt of the desired product. This was suspended in Et2O and NH3 
gas was introduced for 1h. After stirring for 4h the solid was removed by filtration. Subsequent 
removing of the solvent afforded the desired product as a yellow oil in 96% yield (951 mg, 
4.13 mmol). 
1H-NMR (400 MHz, CD3OD): δ = 7.12–7.08 (m, 2H), 6.64–6.59 (m, 3H), 3.12–3.08 (m, 2H), 
3.00–2.94 (m, 2H), 2.65–2.60 (m, 2H), 1.88–1.81 (m, 4H), 1.77–1.72 (m, 4H), 1.68–1.63 (m, 
2H) ppm. 13C-NMR (101 MHz, CD3OD): δ = 150.3, 130.0, 118.1, 114.2, 74.0, 56.0, 42.2, 41.7, 
38.3, 25.6 ppm. FTIR (neat) v = 3255, 3021, 2951, 2864, 1601, 1506, 1319, 1289, 1179, 1122, 
864, 746, 690 cm-1. HR-MS (ESI) C15H23N2+ [M+H]+ calculated: 231.1856 found: 231.1859. 
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2,4-Dinitro-N-((tetrahydro-1H-pyrrolizin-7a(5H)-yl)methyl)aniline (4.18) 
Amine 4.13 (480 mg, 3.42 mmol, 1.0 equiv.) was dissolved in acetone (39 mL) 
and water (16 mL) and treated with NaHCO3 (439 mg, 5.23 mmol, 1.5 equiv.). 
The reaction mixture was cooled to 0 °C and 2,4-dinitrofluorobenzene 
(0.53 mL, 4.21 mmol, 1.2 equiv.) was added. The mixture was stirred at 0 °C 
for 3 h until TLC showed full conversion of amine 4.13. Acetone was removed 
under reduced pressure and the aqueous layer was extracted with ethyl acetate 
(3x 35 mL). The combined organic layers were dried over MgSO4 and the solvent was removed 
under reduced pressure. Purification by column chromatography (SiO2, MeOH/CH2Cl2 1:10 with 
NEt3 (1%), Rf = 0.47) afforded the desired product as yellow crystals in 61% yield (661 mg, 
2.16 mmol).  
1H-NMR (400 MHz, CD3OD): δ = 9.04 (d, J= 4.4 Hz, 1H), 8.28 (dd, J = 15.6 Hz, J = 4.4 Hz, 
1H), 7.19 (d, J = 15.6 Hz, 1H), 3.39 (s, 2H), 3.15–3.07 (m, 2H), 2.80–2.71 (m, 2H), 1.96–1.75 
(m, 8H) ppm. 13C-NMR (101 MHz, CD3OD) δ = 150.1, 137.0, 131.6, 131.1, 124.8, 116.2, 74.3, 
56.8, 52.5, 37.7, 25.9 ppm. FTIR (neat) v = 3314, 3106, 2956, 2867, 2342, 2171, 2027, 1620, 
1525, 1417, 1334, 1137, 1097, 922, 817, 744 cm-1. HR-MS (ESI) C14H19N4O4+ [M+H]+ calcu-
lated: 307.1401 found: 307.1401. M.p. = 111–114 °C. 
 
1,7-Dichloroheptan-4-one (4.19) 
Methanol (180 mL) was cooled to 0 °C and sodium (14.8 g, 0.64 mol, 
1.1 equiv.) was added in small portions. After the sodium was dis-
solved, γ-butyrolactone (90.0 mL, 1.17 mol, 2.0 equiv.) was added. The reaction mixture was 
heated to 100 °C and methanol was removed from the reaction mixture with a Dean-Stark appa-
ratus. Towards the end of the reaction methanol was removed under reduced pressure to yield the 
desired product as a high viscous yellowish oil, which turned solid after cooling to room temper-
ature. 
The crude 4.20 was heated to 100 °C. Hydrochloric acid (32%, 270 mL) was slowly added via a 
dropping funnel with CO2 being released from the mixture. After the addition was complete, the 
mixture was refluxed for another 30 min at 100 °C and then cooled to room temperature. The 
crude mixture was diluted with water (250 mL) until the solid had dissolved, transferred into a 
separation funnel and the aqueous layer was extracted with diethyl ether (3x 150 mL). The com-
bined organic layers were washed with water (200 mL) and sat. aqueous NaHCO3 (3x 150 mL). 
The combined aqueous layers were extracted with ether (100 mL) and the combined organic 
O
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layers were dried over MgSO4. Removal of the solvent afforded the desired product as a brown 
oil in 68% yield (71.8 g, 392 mmol). 
1H-NMR (400 MHz, CDCl3): δ = 3.58 (t, J = 6.4 Hz, 2H), 2.64 (t, J = 7.2 Hz, 2H), 2.05 (p, J = 
6.8 Hz, 2H) ppm. 13C-NMR (101 MHz, CDCl3): δ = 208.6, 44.5, 39.6, 26.4 ppm. 
 
Tetrahydro-1H-pyrrolizine-7a(5H)-carbonitrile1,7-Dichloroheptan-4-one (4.21) 
 (30.1 g, 164 mmol, 1.0 equiv.) was dissolved in methanol (150 mL) and gaseous NH3 
was bubbled through the solution for 1.5 hours. The reaction mixture was stirred at 
room temperature for 3h until GC-MS showed full consumption of the starting material. After-
wards potassium cyanide (32.0 g, 492 mmol, 3.0 equiv.) was added and the mixture was stirred 
overnight at room temperature until GC-MS showed full conversion. Aqueous sodium hydroxide 
solution (20%, 200 mL) was added and the aqueous layer was extracted with CH2Cl2 
(3x 150 mL). The combined organic layers were dried over Na2SO4 and the solvent was removed 
under reduced pressure to afford a crude mixture (16.1 g) of the desired product and 5-
cyclopropyl-3,4-dihydro-2H-pyrrole in a 70:30 ratio as a brown oil. This mixture was used with-
out further purification. The analytical data matches the literature. The analytical data are in 
agreement with the literature.[26][30] 
1H-NMR (250 MHz, CDCl3): δ = 3.25–3.17 (m, 2H), 2.62–2.53 (m, 2H), 2.39–2.30 (m, 2H), 
2.12–1.86 (m, 6H) ppm. 
 
N-((Tetrahydro-1H-pyrrolizin-7a(5H)-yl)methyl)formamide (4.22) 
To a solution of 5-aminomethyl-1-azabicyclo[3.3.0]octane (377 mg, 2.69 mmol, 
1.0 equiv.) and sodium hydroxide (244 mg, 6.10 mmol, 2.0 equiv.) in methanol 
(3.5 mL) was added ethylformate (1.10 mL, 13.5 mmol, 10 equiv.) was added and 
the mixture was stirred at room temperature for 30 min, until GC-MS showed full 
conversion. The solvent was removed under reduced pressure and diethyl ether (15 mL) was 
added to the residue and stirred for 10 min. Filtration and subsequent removal of the solvent af-
ford the desired product as a mixture of cis- and trans-isomers as colorless oil in 95% yield 
(428 mg, 2.54 mmol). 
1H-NMR (400 MHz, CDCl3): δ = 8.22 (m, 0.8H), 8.06 (d, J = 12.2 Hz, 0.2H), 6.15 (br. s, 0.8H), 
5.95 (br. s, 0.2H), 3.20 (d, J = 6.6 Hz, 1.6H), 3.02 (d, J = 6.5 Hz, 0.4H), 2.99–2.93 (m, 2H), 
2.65–2.58 (m, 2H), 1.84–1.77 (m, 2H), 1.75–1.65 (m, 4H), 1.63–1.58 (m, 2H) ppm. 13C-NMR 
(101 MHz, CDCl3): δ = 161.5, 72.8, 55.8, 45.8, 36.4, 25.2 ppm. FTIR (neat) v = 3291, 3058, 
2955, 2867, 2361, 1669, 1539, 1455, 1384, 1239, 1091, 758, 698 cm-1. 
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HR-MS (ESI) C9H17N2O+ [M+H]+ calculated: 169.1335 found: 169.1338. 
 
2-(Tetrahydro-1H-pyrrolizin-7a(5H)-yl)acetonitrile (4.24) 
1,7-Dichloroheptan-4-one (20.1 g, 110 mmol, 1.0 equiv.) was dissolved in aqueous 
NH3 (25%, 65 mL) and cyanoacetic acid (46.7 g, 549 mmol, 5.0 equiv.) was slowly 
added. NH3 gas was bubbled through the reaction mixture for 1h. Hexane (20 mL) 
was added and the mixture was stirred for 48h at room temperature. After GC-MS showed full 
conversion, the aqueous NH3 was removed under reduced pressure and sodium hydroxide (20%, 
160 mL) was added to the residue. The aqueous layer was extracted with ethyl acetate 
(3x 150 mL) and the combined organic layers were dried over Na2SO4. Removal of the solvent 
afforded the crude product (9.79 g, 59 %) as brown oil. This crude product was used in the next 
step without further purification. The analytical data were in agreement with the literature.[120] 
1H-NMR (400 MHz, CDCl3): δ = 3.13–3.08 (m, 2H), 2.63–2.57 (m, 2H), 2.41 (s, 2H), 1.94–1.80 
(m, 6H), 1.75–1.71 (m, 2H) ppm. 
 
N-(2-(Tetrahydro-1H-pyrrolizin-7a(5H)-yl)ethyl)formamide (4.25) 
To a solution of amine 4.15 (741 mg, 4.80 mmol, 1.0 equiv.) and sodium hydrox-
ide (401 mg, 10.0 mmol, 2.0 equiv.) in methanol (5.0 mL), ethylformate 
(1.90 mL, 23.5 mmol, 5.0 equiv.) was added and stirred for 30 min until GC-MS 
showed full conversion. The solvent was removed under reduced pressure and the 
resulting residue was resuspended in diethyl ether and stirred for 1h. Filtration 
and subsequent removal of the solvent afforded the crude product (764 mg, 93 %) as colorless 
oil. The purity was sufficiently high, so that no further purification was necessary. 
1H-NMR (400 MHz, CDCl3): δ = 8.43 (br. s, 1H), 8.11 (s, 1H), 3.42–3.38 (m, 2H),  
3.00–2.94 (m, 2H), 2.62–2.56 (m, 2H), 1.82–1.67 (m, 6H), 1.64–1.58 (m, 4H) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 161.1, 73.4, 55.4, 38.3, 37.9, 35.6, 25.0 ppm. 
FTIR (neat) v = 3463, 3276, 3058, 2953, 2867, 2137, 1667, 1540, 1457, 1384, 1244, 1088, 926, 
833, 717 cm-1. HR-MS (ESI) C10H19N2O+ [M+H]+ calculated: 183.1492 found: 183.1491. 
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N-((Tetrahydro-1H-pyrrolizin-7a(5H)-yl)-methyl)aniline through Buchwald-Hartwig cou-
pling (3.107) 
An oven-dried flask was charged with NaOtBu (13.3 mg, 139 µmol, 2.0 equiv.), 
BrettPhos precatalyst (2.60 mg,, 3.25 µmol, 5 mol%, Sigma Aldrich: 718750), 
BrettPhos ligand (1.99 mg, 3.71 µmol, 6 mol%) and three times evacuated and back-
filled with argon. Amine 4.13 (10.8 g, 76.0 µmol, 1.2 equiv.), dioxane (0.7 mL) and 
chlorobenzene (0.6 µL, 63.0 µmol, 1.0 equiv.) were added successively. The reac-
tion mixture was heated to 80 °C for 2h until GC-MS showed full consumption of the chloro-
benzene. After cooling to room temperature the reaction mixture was diluted with ethyl acetate 
(1.5 mL), washed with water (0.5 mL) and the aqueous layer was extracted with ethyl acetate 
(3x 1.5 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated 
under reduced pressure. The crude residue was treated with HCl·iPrOH (21%, 1.0 mL) and the 
resulting dihydrochloride salt was recrystallized in EtOH/iPrOH (7:1, 0.1 mL) and treated with 
diethyl ether (0.5 mL). The resulting crystals were filtered off and resuspended in diethyl ether. 
NH3 gas was bubbled through the reaction mixture until saturation occurred and the suspension 
was stirred for five hours at room temperature. Filtration and removal of the solvent afforded the 
desired product as colorless oil in 34% yield (4.3 mg, 0.02 mmol). 
1H-NMR (400 MHz, CDCl3): δ = 7.18–7.14 (m, 2H), 6.69–6.65 (m, 1H), 6.64–6.62 (m, 2H), 
4.15 (br. s, 1H), 3.06–3.00 (m, 2H), 2.55 (d, J = 5.6 Hz, 2H), 2.68–2.62 (m, 2H), 1.90–1.71 (m, 
8H), 1.65–1.60 (m, 2H) ppm. 13C-NMR (101 MHz, CDCl3): δ = 149.4, 129.3, 117.1, 113.1, 
73.2, 55.8, 52.4, 36.9, 25.3 ppm. 
 
7.4.2 CO2 Uptake experiments 
The carbon dioxide was purchased from PanGas Switzerland, with a purity of 5.3 
(>99.9993%). Flow-controllers F-201CV-020-AGD-33-V were delivered from Bronkhorst Swit-
zerland with a flow rate area of 0.18-9.0 mL/min. The inlet pressure was 2-6 bar and the outlet 
pressure was 1 bar. Gravimetric measurements were performed using Mettler-Toledo ME204 
balance with a readability of 0.01/0.1 mg. 
N
NH
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Figure 58: Apparatus for CO2 experiments.  
 
For the CO2 uptake experiments we dissolved 3 mmol of amine absorbent and 12 mmol of 
PEG200 in a glastube and sealed it with a septum. A long needle was plunged through the septum 
and placed above the solution. A second but shorter needle served as an exit. The atmosphere in 
the tube was replaced by charging the container with CO2 through the longer needle (no CO2 was 
allowed to enter the solution at this point). After changing the atmosphere to CO2, the weight of 
the glastube including septum and needles was determined. Placing the longer needle in the solu-
tion and the introducing a CO2 stream through this needle started the measurement. The needle 
was disconnected every 5 min from the CO2 stream and weight increase measured on an analyti-
cal balance. The absorption curves for the amine absorbents are depicted below.45  
                                                
45 Due to difficulties with the initial experimental setup described in section 4.4.3 we have no suitable absorption 
curve for compound 4.17. 
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(Tetrahydro-1H-pyrrolizin-7a(5H)-yl)methanamine (4.13) 
 
 
N-Methyl-1-(tetrahydro-1H-pyrrolizin-7a(5H)-yl)methanamine (4.14) 
 
 
2-(Tetrahydro-1H-pyrrolizin-7a(5H)-yl)ethan-1-amine (4.15) 
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N-Methyl-2-(tetrahydro-1H-pyrrolizin-7a(5H)-yl)ethan-1-amine (4.16) 
 
 
N-((Tetrahydro-1H-pyrrolizin-7a(5H)-yl)methyl)aniline (3.107) 
 
N1,N1,N2-Trimethylethane-1,2-diamine 
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N1,N1,N3-Trimethylpropane-1,3-diamine 
 
 
PEG200 
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7.4.3 Titration of pyrrolizidine derivatives 
A 0.01 M aqueous solution of diamine was prepared by dissolving 0.1 mmol diamine in 10 mL 
of water and filled in a flask equipped with a stirring bar. A pH-electrode (calibrated before each 
experiment) was placed in the flask. The amine solution was titrated using an aqueous 0.01 M 
HCl solution (0.2 mL portions) and the corresponding pH values were recorded. 
 
(Tetrahydro-1H-pyrrolizin-7a(5H)-yl)methanamine (4.13) 
 
 
N-Methyl-1-(tetrahydro-1H-pyrrolizin-7a(5H)-yl)methanamine (4.14) 
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N-((Tetrahydro-1H-pyrrolizin-7a(5H)-yl)-methyl)aniline (3.107) 
 
 
 
2-(Tetrahydro-1H-pyrrolizin-7a(5H)-yl)ethan-1-amine (4.15) 
 
N-Methyl-2-(tetrahydro-1H-pyrrolizin-7a(5H)-yl)ethan-1-amine (4.16) 
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N-(2-(Tetrahydro-1H-pyrrolizin-7a(5H)-yl)ethyl)aniline (4.17) 
 
 
7.4.4 pKa-value correction for water-insoluble derivatives  
The phenyl-substituted diamines 3.107 and 4.17 were not soluble in water. Instead, the sample 
was dissolved in MeOH (10 mL) and titrated with 0.1 M aqueous HCl. The pKa obtained with 
the solvent mixture was corrected to the corresponding pKa to water using the following equa-
tions[168] 
 
4.5 mL H2O, 10 mL MeOH, ! = 0.69 
 !"! =!! 10.01 
 !"!!! = ! !"#!! − !! − !!!  
 ! = ! 0.09! !"#$ − 0.11!!"#$!1− 3.15!!"#$ + 3.15!!"#$! − 1.35!!"#$!  !! = ! 1+ !!!!!"#$ + !!!!!"#$!1+ !!!!!!"#$ + !!!!!"#$!  
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!! = ! !!!!!"#$ + !!!!!"#$!1+ !!!!!!"#$ + !!!!!"#$!  
 ! = ! 0.09 ∙ 0.69− 0.11 ∙ 0.69!1− 3.15 ∙ 0.69+ 3.15 ∙ 0.69! − 1.35 ∙ 0.69! = 0.062− 0.05231− 2.17+ 1.50− 0.44 = 0.0097−0.11  
 = −0.088 
 !! = !1+ (−0.476 ∙ 0.69)+ (0.209 ∙ 0.69!)1+ −0.4 ∙ 0.69 + (0.158 ∙ 0.69!) = 1− 0.33+ 0.09951− 0.276+ 0.075 = 0.7690.799 = 0.962 
 !! = ! (−0.458 ∙ 0.69)+ (0.477 ∙ 0.69!)1+ −1.674 ∙ 0.69 + (0.69 ∙ 0.69!) = −0.32+ 0.2271− 1.15+ 0.33 = −0.0930.18 = −0.52 
 !"! = 10.01+ 0.52+ 0.0880.962!! = 10.620.962 = 11.04 
 
 
4.75 mL H2O, 10 mL MeOH, ! = 0.68 
 !"! =!! 9.55 
 ! = ! 0.09 ∙ 0.68− 0.11 ∙ 0.68!1− 3.15 ∙ 0.68+ 3.15 ∙ 0.68! − 1.35 ∙ 0.68! = 0.061− 0.0511− 2.14+ 1.46− 0.424 = 0.01−0.104 
 = −0.096 
 !! = !1+ (−0.476 ∙ 0.68)+ (0.209 ∙ 0.68!)1+ −0.4 ∙ 0.68 + (0.158 ∙ 0.68!) = 1− 0.324+ 0.0971− 0.272+ 0.073 = 0.7730.801 = 0.965 
 !! = ! (−0.458 ∙ 0.68)+ (0.477 ∙ 0.68!)1+ −1.674 ∙ 0.68 + (0.69 ∙ 0.68!) = −0.311+ 0.2211− 1.14+ 0.319 = −0.090.179 = −0.503 
N
HN
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 !"! = 9.55+ 0.503+ 0.0960.965!! = 10.120.965 = 10.49 
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8 Appendices 
8.1 Image processing parameters 
Images were processed using Fiji (ImageJ) by adjusting the brightness and contrast. In the ta-
ble below the adjusted values for each image are listed. All images acquired are 8-bit images 
with a full display range of 0–255. Overlay images have not been corrected after merging the 
partial images and thus are not listed here. 
Location Image Range Location Image Range 
Scheme 7, a 
 
 
0–255 Scheme 12, e 
 
0–92 
Scheme 7, b 
 
0–255 Scheme 13, a 
 
0–140 
Scheme 7, c 
 
0–255 Scheme 13, b 
 
0–255 
Scheme 7, d 
 
0–255 Scheme 15, a 
 
24–163 
Scheme 12, a 
 
0–255 Scheme 15, b 
 
16–154 
Scheme 12, b 
 
0–129 Scheme 15, d 
 
0–140 
Scheme 12, d 
 
0–255 Scheme 15, e 
 
16–185 
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Scheme 15, f 
 
59–244 Scheme 15, q 
 
5–241 
Scheme 15, g 
 
5–171 Scheme 15, s 
 
0–107 
Scheme 15, i 
 
0–107 Scheme 15, t 
 
18–198 
Scheme 15, j 
 
12–181 Figure 27 
 
0–255 
Scheme 15, k 
 
24–163 Figure 27 
 
1–153 
Scheme 15, l 
 
6–124 Scheme 18, BF 
 
41–148 
Scheme 15, n 
 
0–107 Scheme 18, 
chloroplast 
 
0–255 
Scheme 15, o 
 
0–188 Scheme 18, 
fluorescein 
 
0–255 
Scheme 15, p 
 
0–119 Scheme 18, 
vancomycin 
antibody 
 
0–73 
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Location Image Range 
Figure 29, a 
 
0–255 
Figure 29, a 
 
0–255 
Figure 29, d 
 
0–255 
Figure 29, c 
 
0–255 
Scheme 27, a 
 
0–255 
Scheme 27, b 
 
0–255 
Scheme 27, c 
 
0–255 
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8.2 Imaging conditions 
General:  
Argon Laser: 20% 
Temperature: room temperature 
Resolution: 8 bits 
Objective: HCX PL APO lambda blue 63.0x1.40 OIL UV 
Aquisition software: Leica AF 
Image Resolution (xyz) Imaging  
medium 
Laser Detector 1 Detector 2 
Scheme 7,  
a, b 
1024x1024x91 
139.08x139.08x15.11 µm 
step size: 0.17 µm 
Kuhl  
medium 
λex = 488 nm 
8% 
 
HyD 
500-530 nm 
20% gain 
 
HyD 
600-700 nm 
10% gain 
Scheme 7, c, 
d 
1024x1024x92 
90.35x90.35x15.27 µm 
step size: 0.17 µm 
Kuhl  
medium 
λex = 488 nm 
8% 
 
HyD 
500-530 nm 
20% gain 
 
HyD 
600-700 nm 
10% gain 
Scheme 12, 
a, b 
1024x1024x1 
129.17x129.17x0 µm 
 
Kuhl  
medium 
λex = 488 nm 
8% 
 
HyD 
500-530 nm 
20% gain 
 
HyD 
600-700 nm 
10% gain 
Scheme 12,  
c, d 
1024x1024x1 
90.35x90.35x0 µm 
Kuhl  
medium 
λex = 488 nm 
 
8% 
 
HyD 
500-530 nm 
20% gain 
 
HyD 
600-700 nm 
10% gain 
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Scheme 13, 
a, b 
1024x1024x1 
72.63x71.63x0 µm 
 
Kuhl  
medium 
λex = 488 nm 
18% 
 
PMT 
493.8-530 nm 
60% gain 
 
HyD 
555-727 nm 
28% gain 
Scheme 15,  
a-e 
1024x1024x63 pixel 
82.01x82.01x7.8 µm 
step size: 0.13 µm 
 
ProLong λex = 488 nm 
5% 
 
HyD 
500-530 nm 
12% gain 
 
HyD 
600-700 nm 
10% gain 
Scheme 15,   
f-j 
1024x1024x64 
82.01x82.01x7.93 µm 
step size: 0.13 µm 
 
ProLong λex = 488 nm 
8% 
 
HyD 
500-530 nm 
34% gain 
 
HyD 
600-700 nm 
10% gain 
Scheme 15,   
k-o 
1024x1024x42  
89.64x89.64x5.16 µm 
step size: 0.13 µm 
 
 
ProLong λex = 488 nm 
5% 
 
 
HyD 
500-530 nm 
15% gain 
 
HyD 
600-700 nm 
10% gain 
Scheme 15,   
p-t 
1024x1024x42  
49.21x49.21x5.16 µm 
step size: 0.13 µm 
 
ProLong λex = 488 nm 
8% 
 
HyD 
500-530 nm 
34% gain 
 
HyD 
600-700 nm 
10% gain 
Figure 27 1024x1024x44 
49.21x49.21x5.41 µm 
step size: 0.13 µm 
ProLong λex = 488 nm 
11% 
 
HyD 
500-530 nm 
39% gain 
 
HyD 
600-700 nm 
57% gain 
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Figure 29,  
a 
1024x1024x48 
82.01x82.1x5.92 µm 
step size: 0.13 µm 
Agarose 
patch 
λex = 488 nm 
10% 
 
HyD 
500-530 nm 
37% gain 
 
HyD 
605-644 nm 
104% gain 
Figure 29,  
c, d 
1024x1024x35 
82.01x82.1x4.28µm 
step size: 0.13 µm 
Agarose 
patch 
λex = 488 nm 
10% 
 
HyD 
500-530 nm 
37% gain 
 
HyD 
605-644 nm 
104% gain 
Scheme 27, 
a 
1024x1024x39 
49.21x49.21x4.78 µm 
step size: 0.13 µm 
ProLong λex = 488 nm 
5% 
 
HyD 
500-530 nm 
41% gain 
 
HyD 
600-700 nm 
12% gain 
Scheme 27, 
b 
1024x1024x1 
49.21x49.21x0 µm 
ProLong λex = 488 nm 
5% 
 
HyD 
500-530 nm 
41% gain 
 
HyD 
600-700 nm 
18% gain 
Scheme 27, 
c 
1024x1024x1 
49.21x49.21x0 µm 
ProLong λex = 488 nm 
5% 
 
HyD 
500-530 nm 
41% gain 
 
HyD 
600-700 nm 
18% gain 
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Immunolabeling: 
Same conditions have been applied to all images in Scheme 18. 
 
Resolution (xyz) Imaging 
medium 
Laser 1 Detector 1  
512x512x1 
49.21x49.21x0 µm 
ProLong λex = 355 nm 
65% 
HyD 
428-465 nm 
PhotonCount-
ing 
 
   
 
 
! ! Laser 2! Detector 2! Detector 3!
! ! λex = 488 nm 
8%!
HyD 
506-535 nm 
PhotonCount-
ing!
HyD 
600-700 nm 
PhotonCounting!
! ! !
! !
 
 
 
 
 
 8.3 Single crystal X-ray structures 
    
Table 11: Crystal data for pyrrolizidine 3.32. 
Formula C14H18N2O 
Formula weight 230.31 g·mol-1 
Z, calculated density 8, 1.256 Mg · m-3 
F (000) 992 
Description and size of crystal colorless needle, 0.060 · 0.100 · 0.280 mm3 
Absorption coefficient 0.631 mm-1 
Min/max transmission 0.94 / 0.96 
Temperature 123K 
Radiation (wavelength) Cu Kα (λ = 1.54178 Å) 
Crystal system, space group monoclinic, P 21/c 
a 6.2225(4) Å 
b 27.8281(16) Å 
c 14.2974(8) Å 
α 90° 
β 100.432(2)° 
γ 90° 
V 2434.8(3) Å3 
Min/max Θ 3.176° / 68.386° 
Number of collected reflections 23143 
Number of independent reflections 4420 (merging r = 0.028) 
Number of observed reflections 4369 (I>2.0σ(I)) 
Number of refined parameters 307 
R 0.0346 
rW 0.0391 
Goodness of fit 1.1196 
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Table 12: Crystal data for carbamate 4.29. 
Formula C18H38N4O7 
formula weight 422.52 
Z, calculated density 4, 1.343 Mg · m-3 
F(000) 919.991 
description and size of crystal colorless plate, 0.020 · 0.110 · 0.180 mm3 
absorption coefficient  0.854 mm-1 
min/max transmission  0.91 / 0.98 
temperature 123K 
radiation(wavelength)  Cu Kα (λ = 1.54178 Å) 
Crystal system, space group monoclinic, P n 
a 7.8954(8) Å 
b 22.637(2) Å 
c 11.6950(11) Å 
α 90° 
β 90.952(7)° 
γ 90° 
V 2089.9(2) Å3 
min/max Θ 3.905° / 68.901° 
number of collected reflections 15770 
number of independent reflections 6655 (merging r = 0.070) 
number of observed reflections 5647 (I>2.0σ(I)) 
number of refined parameters  584 
r 0.0453 
rW 0.0773 
goodness of fit 1.1157 
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Table 13: Crystal data for carbamate 4.30. 
Formula C11H28N2O6 
formula weight 284.35 
Z, calculated density 4, 1.273 Mg · m-3 
F(000) 624 
description and size of crystal  colorless block, 0.040 · 0.110 · 0.230 mm3 
absorption coefficient 0.856 mm-1 
min/max transmission  0.91 / 0.97 
temperature 123K 
radiation (wavelength)  Cu Kα (λ = 1.54178 Å) 
Crystal system, space group monoclinic, P 21/n 
a 7.0751(5) Å 
b 16.6440(12) Å 
c 13.0818(9) Å 
α 90° 
β 105.578(2)° 
γ 90° 
V 1483.89(10) Å3 
min/max Θ 4.401° / 69.119° 
number of collected reflections 9721 
number of independent reflections 2692 (merging r = 0.022) 
number of observed reflections 2629 (I>2.0σ(I)) 
r 0.0319 
rW 0.0360 
goodness of fit 1.1204 
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8.4 1H and 13C-NMR spectra 
Synthesis of 3-(3,4-dihydro-2H-pyrrol-5-yl)propan-1-ol (3.21) 
 
250 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3  
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1-Isocyano-4-methoxybenzene (3.35) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3  
 Appendices 
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1-Fluoro-4-isocyanobenzene (3.36) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3  
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2-Isocyano-1,3-dimethoxybenzene (3.40) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3  
 Appendices 
195  
4-(2-Isocyanoethyl)phenol (3.54) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3  
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N-Phenyltetrahydro-1H-pyrrolizine-7a(5H)-carboxamide (3.32) 
 
500 MHz 1H-NMR in CDCl3 
 
126 MHz 13C-NMR in CDCl3  
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N-(4-Methoxyphenyl)tetrahydro-1H-pyrrolizine-7a(5H)-carboxamide (3.55) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
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N-(4-(Methylthio)phenyl)tetrahydro-1H-pyrrolizine-7a(5H)-carboxamide (3.56) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
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N-(2,6-Dimethoxyphenyl)tetrahydro-1H-pyrrolizine-7a(5H)-carboxamide (3.57) 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3  
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N-(Benzo[d][1,3]dioxol-5-yl)tetrahydro-1H-pyrrolizine-7a(5H)-carboxamide (3.58) 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
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N-(Naphthalen-2-yl)tetrahydro-1H-pyrrolizine-7a(5H)-carboxamide (3.59) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3  
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N-(4-Bromophenyl)tetrahydro-1H-pyrrolizine-7a(5H)-carboxamide (3.60) 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
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N-(4-Fluorophenyl)tetrahydro-1H-pyrrolizine-7a(5H)-carboxamide (3.61) 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
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N-(4-Ethynylphenyl)tetrahydro-1H-pyrrolizine-7a(5H)-carboxamide (3.62) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3  
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N-(5-Methyl-[1,1'-biphenyl]-2-yl)tetrahydro-1H-pyrrolizine-7a(5H)-carboxamide (3.63) 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3  
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N-(2-Morpholinoethyl)tetrahydro-1H-pyrrolizine-7a(5H)-carboxamide (3.64) 
250 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3  
 Appendices 
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N-(4-Hydroxyphenethyl)tetrahydro-1H-pyrrolizine-7a(5H)-carboxamide (3.65) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3  
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N-Benzyltetrahydro-1H-pyrrolizine-7a(5H)-carboxamide (3.66) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3  
 Appendices 
209  
(S)-N-(1-Phenylethyl)tetrahydro-1H-pyrrolizine-7a(5H)-carboxamide (3.67) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3  
CHAPTER 8 
 
210 
Methyl-(hexahydro-1H-pyrrolizine-7a-carbonyl)-tryptophanate (3.68) 
 
500 MHz 1H-NMR in CDCl3 
 
126 MHz 13C-NMR in CDCl3  
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Methyl-(hexahydro-1H-pyrrolizine-7a-carbonyl)-valinate (3.69) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3  
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Methyl-(hexahydro-1H-pyrrolizine-7a-carbonyl)-phenylalaninate (3.70) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3  
 Appendices 
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Methyl-(hexahydro-1H-pyrrolizine-7a-carbonyl)-methioninate (3.71) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3  
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Dimethyl-(hexahydro-1H-pyrrolizine-7a-carbonyl)-glutamate (3.72) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3  
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4-(3,4-Dihydro-2H-pyrrol-5-yl)-2-methylbutan-2-ol (3.90) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3  
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2-(3-Methylbut-2-en-1-yl)-N-phenylpyrrolidine-2-carboxamide (3.92 and 3.93) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3  
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4-(3,4-Dihydro-2H-pyrrol-5-yl)butan-1-ol (3.103) 
 
500 MHz 1H-NMR in CDCl3 
 
126 MHz 13C-NMR in CDCl3  
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3-Oxo-N-phenyltetrahydro-1H-pyrrolizine-7a(5H)-carboxamide (3.105) 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
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7a-(Phenylcarbamoyl)hexahydropyrrolizine-4(1H)-oxide (3.106) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3  
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N-((Tetrahydro-1H-pyrrolizin-7a(5H)-yl)methyl)aniline (3.107) 
 
400 MHz 1H-NMR in CD3OD 
 
101 MHz 13C-NMR in CD3OD  
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7a-((phenylamino)methyl)octahydropyrrolizin-4-ium hydrogen carbonate (3.109) 
 
500 MHz 1H-NMR in CD3OD 
 
126 MHz 13C-NMR in CD3OD  
CHAPTER 8 
 
222 
(Tetrahydro-1H-pyrrolizin-7a(5H)-yl)methanamine (4.13) 
 
400 MHz 1H-NMR in CD3OD 
 
101 MHz 13C-NMR in CD3OD  
 Appendices 
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((Hexahydropyrrolizin-4-ium-7a(1H)-yl)methyl)carbamate (4.29) 
 
400 MHz 1H-NMR in CD3OD 
 
101 MHz 13C-NMR in CD3OD  
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2-(Tetrahydro-1H-pyrrolizin-7a(5H)-yl)ethan-1-amine (4.15) 
 
400 MHz 1H-NMR in CD3OD 
 
101 MHz 13C-NMR in CD3OD  
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N-Methyl-1-(tetrahydro-1H-pyrrolizin-7a(5H)-yl)methanamine (4.14) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
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2,4-Dinitro-N-((tetrahydro-1H-pyrrolizin-7a(5H)-yl)methyl)aniline (4.18) 
 
400 MHz 1H-NMR in CD3OD 
 
101 MHz 13C-NMR in CD3OD 
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N-Methyl-2-(tetrahydro-1H-pyrrolizin-7a(5H)-yl)ethan-1-amine (4.16) 
 
400 MHz 1H-NMR in CDCl3 
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